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  Thesis Summary 
Objectives: In the present project, I attempted to uncover novel and clinically 
important drug-gene interactions (DGIs) and drug-drug-gene interactions 
(DDGIs) among 50 commonly used chronic drugs and 50 commonly used 
chronic drug combinations in the UK. 
Methods: Using the UK Biobank (cross-sectional) cohort and 3 other Scottish 
cohorts (longitudinal), I have studied the association of 162 genetic variants in 
important genes with three drug response phenotypes for the 50 selected 
drugs/combinations. This has generated a total of 48,600 findings divided equally 
between the two studies (DGIs and DDGIs), which I have made accessible via two 
online databases. I then undertook further replication for our top findings utilizing 
the UK Biobank primary care data. 
Results: We identify 8 novel associations after Bonferroni correction, 3 of which are 
replicated or validated in the UK biobank or have other supporting results:  The C-
allele at rs4918758 in CYP2C9 was associated with a 25% (15-44%) lower odds of 
dose reduction of quinine, p=1.6×10-5;  the A-allele at rs9895420 in ABCC3 was 
associated with a 46% (24-62%) reduction in odds of dose reduction with doxazosin, 
p=1.2×10-4,  and altered blood pressure response in the UK Biobank;  the 
CYP2D6*2 variant was associated with a 30% (18 %- 40%) reduction in odds of 
stopping ramipril treatment, p=1.01×10-5, with similar results seen for enalapril and 
lisinopril and with other CYP2D6 variants.
I have also detected two other novel findings with directionally consistent results 
in the replication cohort with p-values close to significance levels (amlodipine- 
rs868853 (ABCC4)-lower odds for daily dose reduction and clopidogrel-
rs12353214 (PTGS1)-decreased drug stopping risk)). 
19  
In addition, out of 3 novel DDGIs, one association was validated using an alternative 
phenotype in UK Biobank. In the discovery cohort, carrying the G allele at rs9516519 
(T>G) variant in ABCC4 transporter was linked with a 4.72 (2.44-9.13) times 
increased risk of stopping bisoprolol or atorvastatin treatments when they were used 
concomitantly (p=1.48 × 10-5). In the replication cohort, this drug combination was 
associated with a great SBP reduction (~ 8 mmHg drop in mean SBP (p < 2 × 10-16)) 
and the presence of the rs9516519 (T>G) variant increased this effect. 
 
 
Finally, 19 DG associations were identified that replicated previous study findings 
including but not limited to the association of CYP2C9*3 with increased gliclazide 
side effects and the association of CYP2C8*3 with reduced pioglitazone efficacy. 
We also report some other novel and potentially important associations from both 
the DG and DDG interaction studies.  
 
 
Conclusion: The work in this thesis highlights the value of using large population 
datasets for pharmacogenomic discovery and has identified novel findings that may 

























































Chapter I (literature review): 
 
Drug-Gene/Drug-Drug-Gene Interactions and 




The work related to drug-drug-gene interactions in this chapter has been published 
( Malki M, Pearson E. Drug–drug–gene interactions and adverse drug reactions. The 




The economic and health burden caused by adverse drug reactions has increased 
dramatically in the last few years. This is likely to be mediated by increasing 
polypharmacy, which increases the likelihood of drug-drug interactions. Tools 
utilized by health care practitioners to flag potential adverse drug reactions secondary 
to drug-drug interactions ignore individual genetic variation, which has the potential 
to markedly alter the severity of these interactions. To date, there have been limited 
published studies on the impact of genetic variation on drug interactions. In this 
introduction, I establish a detailed classification for pharmacokinetic drug-gene 
/drug-drug-gene interactions and give examples from the literature that support this 
approach. The increasing availability of real-world drug outcome data linked to 
genetic bioresources is likely to enable the discovery of previously unrecognized, 




It was previously and alarmingly reported that adverse drug reactions (ADRs) 
represent the fourth leading cause of death in the USA [1]. A recent review (2015) 
showed that 3.6% of patients were admitted to hospitals in Europe due to ADRs, and 
10% of patients developed side effects during their in-patient stay [2]. The latest 
report issued by MiDatabank in cooperation with the Medicines and Healthcare 
Products Regulatory Agency (MHRA), shows an increasing trend in the number of 
reported ADRs in the period between 2011 and 2016 across the UK [3]. It has also 
been estimated that ADRs alone cost the NHS £770M annually [4]. Non-steroidal 
anti-inflammatory drugs (NSAIDs), diuretics, anticoagulants, and antiplatelets have 
been recognized to be the major culprits, with prescribing errors being major 
contributors to medication-related adverse events [5]. The chance of prescribing 
errors increases when patients undergo multiple treatments; a situation that is highly 
prevalent in elderly patients [6]. There are a number of factors that influence the 
occurrence of ADRs secondary to drug interactions, such as age, renal function and 
other comorbidities. In addition, genetic variation is likely to play a crucial role in the 
development of ADRs. In his publication "Inborn errors of metabolism" (1909/1923), 
the British scientist Archibald Garrod was the first to describe the individual 
differences between people in metabolizing different substances [7]. This concept had 
then received more attention in 1956 when some patients with pseudocholinesterase 
deficiency died after succinylcholine injections [8]. In the following year (1957), 
Motulsky (USA) has re-defined the concept of Garrod that defects in metabolism may 
be responsible for variability in drug response [9]. In 1959, the term 
"pharmacogenetics" was first suggested by Friedrich Vogel (Germany) to describe 
this concept [10].  
 
24  
This term has been then replaced by a broader term "pharmacogenomics" to describe 
the influence of genetic variants in any gene, rather than only metabolizing enzymes 
genes, to change drug responses between individuals. 
The importance of considering genetic variants when evaluating drug outcomes can 
be observed from one study in which the authors noted that when only considering 
genetic polymorphisms in three drug-metabolizing enzymes (cytochrome P450 2C9 
(CYP2C9), CYP2C19, and CYP2D6), 15% of the ADRs were due to drug-gene 
interactions (DGIs), and 19% were due to drug-drug-gene interactions (DDGIs) 
[11]. Incorporation of these gene variants increased the number of predicted 
clinically critical drug interactions by ~51% [11]. Given the large number of genes 
involved in drug metabolism and transport, we cannot underestimate the importance 
of genetic variation in contributing to the potential for clinically critical ADRs. 
Following the recent advances in pharmacogenomics, the traditional view of drug-
drug interactions needs to be modified to include genetic variation. To date, the 
literature on drug-gene interactions is still limited although it has been growing 
rapidly recently while the literature on drug-drug-gene interactions remains very 
limited, with only one previous review evaluating the impact of CYP2C9, C19 and 
2D6 variants [12]. In this introduction, we attempt to provide an in-depth framework 
for the classification of pharmacokinetic DG/DDG interactions caused by different 
mechanisms, and their potential impact on increasing clinically critical drug 
interactions in the context of the polypharmacy seen in modern medicine today. 
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2. Drug-gene/drug-drug-gene interactions classification 
 
 
Drug interactions can be divided into three main categories: inhibitory interactions, 
induction interactions, and phenoconversion interactions. Inhibitory and induction 
interactions can be defined as any interactions that affect the victim drug's 
pharmacokinetics (PK) to increase or reduce concentrations of the drug, respectively. 
Induction or inhibition can occur either with the administration of a perpetrator drug 
that alters the victim drug metabolism or transport (drug-drug interactions (DDIs)), or 
with the presence of loss- or gain-of-function (LOF or GOF) genetic variants that alter 
the function of enzymes that alter metabolism or transport of the victim drug (DGI), 
or the combination of both (DDGI). A DDGI can be thought of as a double hit – 
whereby the genetic variant and the perpetrator drug combine to act on transporter or 
metabolism pathways to greatly alter drug concentrations. It is also possible to see 
phenoconversion - where the interacting drug effect and the genotype have opposing 
effects, resulting in a temporary phenotype shift, e.g., neutralizing/reversing the effect 
of a gain-of-function genotype when an inhibitory drug is prescribed. In this 
introduction I describe, with examples, different cases of interactions under each of 
the above three categories, focusing initially on metabolizing enzymes, before 
considering drug transporters covering examples from both DG and DDG interaction 
studies. 
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3. Drug-Metabolizing Enzyme Gene Interactions (DMEGIs) 
 
 
                   3.1 Inhibitory Interactions 
 
 
One of the well-established pharmacogenomic associations is the correlation between 
warfarin (a CYP2C9 substrate) reduced dosage requirements and carriage of the 
CYP2C9*2/*3 reduced activity variants. Carriers of these variant alleles are at increased 
risk for warfarin-induced bleeding due to decreased warfarin metabolism. In 2007, the 
Food and Drug Administration (FDA) issued a label informing practitioners about this 
genotype-phenotype correlation which was updated later in 2010 by providing a specific 
dosage ranges recommendation [13,14]. In addition, a couple of genotype-guided 
warfarin dosage estimation tools (http://warfarindosing.org/Source/Home.aspx and 
http://www.warfarindoserevision.com/the-dose-revision-tool ) have been developed to help 
 
health care providers to select the most suitable dose based on individual patients' 
parameters. However, findings from clinical trials regarding the clinical utility of this 
genotype-phenotype association have been contradictory [15,16]. 
 
Another key example for the clinical application of pharmacogenomics is the use of 
CYP2D6 genotype data to examine suitability for tamoxifen therapy. Tamoxifen is a 
prodrug activated by CYP2D6 into its active metabolite endoxifen. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) recommends that individuals 
carrying the CYP2D6 poor metabolizer phenotypes avoid tamoxifen and use alternative 
breast cancer therapies due to the strong evidence showing lack of efficacy as indicated 
by the increased risk of breast cancer relapse [17]. In this DG inhibitory interaction, 
loss of CYP2D6 enzyme function could have resulted in inhibiting the activation of 
tamoxifen into its active metabolite endoxifen resulting in reducing the therapeutic 
efficacy of the treatment.    
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There are different mechanisms by which loss of enzyme function can occur at the 
molecular (genetic) level. In the coding region of the gene, nonsynonymous single-
nucleotide polymorphisms (SNPs) result in changing the sequence of amino acids to 
produce a malfunctioning protein. This change could occur as a result of replacement 
of one nucleotide in the codon by another one resulting in a different codon coding for 
a different amino acid (i.e., missense mutations). Alternatively, nonsynonymous SNPs 
could also result in producing stop codons, early during the translation process, which 
prevents the translation of the remaining codons into their corresponding amino 
proteins (i.e., non-sense mutations). In the non-coding region of the gene, SNPs could 
affect regions, such as promotors and enhancers, which control transcription processes 
or could affect non-coding RNAs which could affect gene expression as well.  
Poor CYP2D6 metabolizers could represent those who carry one or more variants 
linked with loss of CYP2D6 function or reduced gene expression, as outlined above. 
These patients are at increased risk of tamoxifen treatment resistance and, therefore, 
CYP2D6 variant testing would be recommended before treatment initiation to avoid 
exacerbation of the disease.          
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                    3.2 Induction Interactions 
 
 In general, gain-of-function mutations are less common than loss-of-function 
mutations. These rare kinds of mutations could result in increasing the expression 
of the gene via activating its transcription. This could result in increased gene 
products (RNA/proteins) leading to increased enzyme metabolic activity. Induction 
interactions occur when increased activity of the enzyme could reduce the efficacy 
of active drugs (as a result of increased deactivation of the drug) or increase the 
toxicity of prodrugs (as a result of increased production of active metabolites). 
Below, I present two examples explaining these two different scenarios. 
 
The proton pump inhibitors (PPIs) lansoprazole, omeprazole, and pantoprazole are 
mainly metabolized by CYP2C19. Due to the convincing evidence from the literature 
that the increased activity variant CYP2C19*17 is associated with decreased PPI 
plasma concentration and, in turn, increased chance for therapeutic failure, it is 
recommended by the CPIC to increase the daily dose of these agents for carriers of 
this variant allele [18]. 
The prodrug codeine, which is activated into morphine by CYP2D6 enzyme, has 
also received genotype-guided CPIC recommendations. They recommend avoiding 
codeine therapy and using an alternative analgesic agent for those with rapid and 
ultra-rapid CYP2D6 metabolism status due to the strong evidence of increased 







 4. Drug-Drug-Metabolizing Enzyme Gene Interactions (DDMEGIs) 
 
 
                    4.1 Inhibitory Interactions 
 
Inhibitory effects of drugs and genotype can alter substrate metabolism by both drug 
and genotype impacting on the same metabolizing enzyme, or on two distinct routes 
of metabolism.  
In general, poor metabolizers are expected to experience the highest substrate drug 
plasma concentration, compared to other genotypes, when co-treated with inhibitors. 
For example, co-administration of simvastatin (a CYP2C9 inhibitor) with warfarin 
(a CYP2C9 substrate) has been shown to reduce warfarin dosage requirements in 
CYP2C9*3 carriers by a greater percentage as compared to non-carriers (29% vs 5% 
respectively) [20].  
A similar conclusion has been reported with celecoxib (Table 1, [21]). The inhibitory 
effect of drug and genotype is not always additive – genetically poor metabolizers 
may have only limited further enzyme inhibition by the administration of an 
inhibitory drug. For instance, a statistically significant elevation in rabeprazole (a 
CYP2C19 substrate) plasma levels was observed in both normal metabolizers and 
heterozygous genotype carriers after treatment with fluvoxamine (a CYP2C19 
inhibitor) while no additional clinically significant elevation was detected with poor 
metabolizers who have already experienced the highest rabeprazole plasma levels 
[22]. A similar scenario is seen in other examples (Table 1, [23-26]). 
Where a drug is metabolized by two or more CYP enzymes, then inhibition of one of 
these enzymes alone (by drug or genotype) may have minimal effect, due to 
redundancy of the pathways. However, if a genotype and interacting drug affect these 
different routes of metabolism, then the interaction may be very large.  For example,  
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it has been observed that for voriconazole (a CYP2C19 & CYP3A4 substrate) 
bioavailability is increased markedly (~ 5.6-fold) in patients who have reduced 
CYP2C19 activity and are administered with atazanavir or ritonavir (potent CYP3A4 
inhibitors) [27]. A similar scenario can be noted with other examples (Table 1, [28- 
30]). 
Prodrugs, on the other hand, require the function of certain CYPs to be therapeutically 
active, and in these cases, the effect is the opposite to that described above. 
Clopidogrel, for example, is activated by CYP1A2, CYP2B6, CYP3A4, CYP2C9, 
and CYP2C19 [31]. Carriers of LOF variants in one or more of these genes and co-
administered with their inhibitors are at increased risk for treatment resistance. For 
instance, carriers of CYP2C19*2 and/or *3 alleles who are treated with clopidogrel 
and proton pump inhibitors (CYP2C19 inhibitors) were observed to be more likely to 
have reduced clopidogrel efficacy; the addition of a third risk factor (e.g., calcium 
channel blockers (CYP3A4 inhibitors)) was also correlated with a greater reduction 
in the efficacy of clopidogrel [32,33].
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                    4.2 Induction Interactions 
 
Increased-metabolism of active drugs by an enzyme inducer or gain-of-function 
variant will result in reduced efficacy of the victim drug. For example, when 
voriconazole (a CYP2C19 substrate) is co-prescribed with carbamazepine                  
(a CYP2C19 inducer), the voriconazole dose is usually increased to overcome this 
increased metabolism. In a case report, therapeutic concentrations of voriconazole 
were not achieved, as the patient carried two gain-of-function CYP2C19 *17 variants 
[34]. 
The opposite effect is seen with prodrugs. Increased metabolism by an enzyme-
inducing drug or gain-of-function variant, will result in high plasma levels of active 
metabolites leading to increased side effects and/or efficacy. Thus, patients carrying 
CYP2C19*17 gain-of-function variants have increased conversion of clopidogrel to 
active metabolites resulting in reduced cardiovascular events and/or increased 
bleeding episodes [35-44]. Co-administration of an inducer of CYP1A2, CYP2C9, 
and/or CYP3A4 would be expected to result in greater efficacy of clopidogrel, with 
increased risk of bleeding. However, no studies have been published to establish 
this. 
                   4.3 Phenoconversion Interactions 
 
As described above, a temporary phenotype shift can be seen when the perpetrator 
drug and genetic effect are opposed. For example, the presence of reduced function 
CYP2C9 variants results in reduced tolbutamide (a CYP2C9 substrate) metabolism, 
yet co-treatment with rifampicin (a CYP2C9 inducer) in these patients reverses this 
genetic effect resulting in a two-fold increase in tolbutamide clearance [45]. 
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Conversely, proton pump inhibitors (CYP2C19 inhibitors) treatment with 
clopidogrel results in phenoconversion in genetically determined ultra-rapid 
phenotype to a poor metabolizer status indicated by loss of clopidogrel efficacy 
[46]. 
The beneficial side of phenoconversion interactions is that genetically determined 
phenotypes can be normalized by the addition of medications of opposite effects on 
metabolism. For example, resistance to nortriptyline (a CYP2D6 substrate) due to 
abnormally rapid metabolism has been successfully reversed and normalized with the 
addition of paroxetine (a CYP2D6 inhibitor), which produces a recovery of 
nortriptyline therapeutic plasma levels [47]. 
 
 
The three figures below show the predicted changes of plasma levels of active drugs 
and active metabolites of prodrugs with and without the presence of inhibitors and/or 
LOF variants (Figure 1) and with and without the presence of inducers and/or GOF 
variants (Figure 2) and presents different scenarios of phenoconversion interactions 
(Figure 3). 
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Figure 1: The predicted active drug /active metabolites of prodrugs plasma levels and biliary 
excretion changes without or with the presence of inhibitors or LOF variants or both on metabolizing 
enzymes. The predicted active drug / active metabolites of prodrugs plasma levels and biliary 
excretion changes without (a-1/a-2) or with the presence of inhibitors or LOF variants (b-1/b-2) or 
both (c-1/c-2) on metabolizing enzymes. (a-1/a-2) represent the normal scenario with no interacting 
drug or genetic variant. In b-1/b-2) either an inhibitory drug or loss of function variant (LOF) in the 
metabolizing enzyme, results in reduced metabolism to inactive metabolites , and increased 
(b-1)/decreased(b-2) active drug in the systemic circulation. In c-1/c-2) the presence of inhibitory 
drug and the LOF genetic variant combine to produce greater increase(c-1)/decrease(c-2) in the 





Figure 2: The predicted active drug / active metabolites of prodrugs plasma levels and biliary 
excretion changes without or with the presence of inducers or GOF variants or both on metabolizing 
enzymes. The predicted active drug / active metabolites of prodrugs plasma levels and biliary 
excretion changes without (a-1/a-2) or with the presence of inducers or GOF variants (b-1/b-2) or 
both (c-1/c-2) on metabolizing enzymes. (a-1/a-2) represent the normal scenario with no interacting 
drug or genetic variant. In b-1/b-2) either an inducer drug or gain of function variant (GOF) in the 
metabolizing enzyme, results in increased metabolism to inactive metabolites , and decreased(b- 
1)/increased(b-2) active drug in the systemic circulation. In c-1/c-2) the presence of inducer drug and 
the GOF genetic variant combine to produce greater decrease(c-1)/increase(c-2) in the systemic 












































Figure 3 : Different scenarios of phenoconversion interactions where genetic effects may be reversed or shifted in 
the opposite direction . (a) represents the normal scenario with no interacting drug or genetic variant. In b) the 
effect of loss of function variant (LOF) or gain of function variant (GOF) is reversed with the presence of a 
moderate inducer drug or a moderate inhibitor drug respectively and results in a clinical outcome similar to the 
normal situation (a). In c) the presence of a strong inducer drug has temporarily shifted a poor metabolism status 
into a rapid metabolism status and results in decreased active drug in the systemic circulation. In d) the presence of 
a strong inhibitor drug has temporarily shifted a rapid metabolism status into a poor metabolism status and results 
in increased active drug in the systemic circulation. 
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5. Transporter-related interactions 
 
 
Drug transporters govern the movement of pharmaceutical compounds from and into 
different body tissues. The liver, kidney, blood-brain barrier (BBB), and intestine are 
the key sites of transporters that influence drug pharmacokinetics. In addition to 
summarizing the distribution and localization of transporters, Figure 4 below (which 
has been formulated with the aid of reference [48]) also classifies transporters into 
three categories according to the similarity of transport directions in different tissue 
types: Group I efflux transporters, Group II efflux transporters, and Group III (uptake) 
transporters. The following paragraphs discuss these three categories of transporters 
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Figure 4: Drug transporters as classified into three categories according to the similarity of the transport 
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    5.1 Group I efflux transporters 
 
P-glycoprotein 1 (P-gp, ABCB1), multidrug resistance-associated protein 2 (MRP2, 
ABCC2), and breast cancer resistant protein (BCRP, ABCG2) transporters are 
expressed in the intestine, liver, kidney, and blood-brain barrier (BBB), sharing 
similar transport pathways. They efflux substrates back to the intestinal lumen, 
facilitate hepatic and renal excretion (excluding BCRP), and work inversely in the 
BBB where they protect the brain from the entry of xenobiotics and return them back 
to the systemic circulation. Blocking their function in the intestine, liver, or kidney is 
expected to elevate a substrate's systemic exposure (although opposite effects would 
be predicted if inhibiting transport across the BBB). In the sections below, I show 
examples of DGIs and DDGIs related to group I transporters. 
5.1.1 Drug-Transporter Gene Interactions (DTGIs) 
 
The rs1045642 (C>T) variant is the most common studied SNP in ABCB1 
transporter. Pharmacogenomic studies report opposing effects of this SNP with 
different drugs. For example, carriers of this variant experienced low methotrexate 
plasma levels and toxicity [49], while this variant shows increased hepatotoxicity 
among nevirapine users [50]. Both of these two findings have been classified under 
the same category of high evidence findings (level 2A) according to the 
Pharmacogenomics Knowledge Base (PharmGKB) which has also reported many 
other similar examples with other drugs [51]. 
According to PharmGKB, one of the best evidence available to date for ABCG2 
transporter is the correlation between rs2231142 (G>T) variant and rosuvastatin 
efficacy. Carriage of the T allele has been associated with increased rosuvastatin 
lipid-lowering efficacy [52]. This is believed to occur as a result of increased 
40  
rosuvastatin accumulation in the liver, the site of rosuvastatin action, due to 
decreased hepatic ABCG2 efflux activity. 
To date, there are no published genotype-based clinical guidelines for any drug 
regarding genetic variants under this group of transporters. 
        5.1.2 Drug-Drug-Transporter Gene Interactions (DDTGIs) 
 
In this group, the most evidence for DDTGI comes from drugs altering ABCB1 (P- 
gp) transport and genetic variants in the gene encoding this transporter. For example, 
cyclosporine is an ABCB1 substrate. Diltiazem (a moderate ABCB1 inhibitor [53]) 
has been shown to increase cyclosporin trough concentrations in Chinese patients who 
carry the TT genotype (low P-gp activity) at rs1045642(C>T) in ABCB1; yet no 
effect was seen in other ABCB1 genotypes (e.g., CC at rs1045642) [54]. Methadone is 
also a P-gp substrate, acting in the brain and effluxed across the BBB via P-gp. 
Patients with the TT genotype at rs1045642 and treated with quetiapine (an ABCB1 
inhibitor) experienced the lowest increase in methadone plasma levels compared to 
those with CT or CC genotypes (3% vs 23% vs 33% respectively) [55]. Low 
methadone plasma levels in this study would be explained by loss of the ABCB1 
protective function in the BBB, which results in an increased intracerebral 
concentration of this central nervous system (CNS) drug. As a result of a similar 
DDTGI mechanism, the CNS drug granisetron was associated with increased efficacy 
in Japanese subjects (Table 1, [56]) 
In some cases, it seems that adding strong inhibitors abolishes the effect of genotype. 
For example, no additional inhibitory effects were detected in carriers of different 
genotypes of the rs1045642 (C>T) ABCB1 variant who were either on 
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dabigatran/rivaroxaban-clarithromycin combination or tacrolimus-itraconazole 
combination (ABCB1 substrates-ABCB1 strong inhibitors [53])[57,58]. 
     5.2 Group II efflux transporters 
 
MRP1 (ABCC1), MRP3 (ABCC3), and MRP4 (ABCC4) share the similar transport 
direction in the kidney and BBB as the Group 1 transporters. However, in the liver, 
they are expressed in the basolateral membrane working to pump drugs back into the 
systemic circulation. Unlike group 1 transporters, there are no published studies 
describing DDTGIs for group II transporters. So here I report DGTIs to highlight the 
potential mechanisms whereby genes and drugs that alter these transporters may 
influence drug outcomes. 
MRP1, for example, transports the active metabolite of irinotecan (SN-38) out of 
hepatocytes into the blood contributing to the well-known side effect of irinotecan 
induced neutropenia [59]. The reduced function variant, rs17501331, in the ABCC1 
gene is associated with a low incidence of neutropenia; the reverse effect was detected 
with the gain-of-function variant rs6498588 in the same gene [60]. In some cases, 
reduced ABCC1 activity could be disadvantageous. For instance, carriers of the AA 
genotype (suggested to be linked with reduced ABCC1 activity) at rs246240 (A>G) 
ABCC1 variant are at higher risk for developing methotrexate gastrointestinal and 
hepatic toxicity as a result of increased methotrexate intracellular accumulation [61]. 
Of note, MRP1 is also expressed in the myocardium protecting the heart from the 
entry of xenobiotics [62]. For example, the reduced transport associated with the 
rs45511401 (G>T) variant in ABCC1 gene increases the chance of developing 
cardiotoxicity due to intracellular accumulation of doxorubicin [63].  
ABCC1 and ABCC3, in contrast to ABCB1, ABCC2 and ABCG2, are expressed in 
the basolateral membrane of the intestine effluxing substrates into the portal  
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circulation. As orally administered drugs are first exposed to intestinal transporters, 
any modification of their role might affect drug concentration in the other tissues 
(liver, kidney, or BBB). C.1037C>T and c.1820G>A ABCC3 variants, for example, 
have low transport activity [64] suggesting their potential to diminish the 
bioavailability of oral ABCC3 substrates irrespective of subsequent alteration in 
transport into other tissues, or subsequent metabolism. 
     5.3 Group III (uptake) transporters 
 
In the liver, kidney, and BBB, all important uptake transporters (organic cation 
transporters (OCTs)1/2/3, organic anion-transporting polypeptide (OATP) 
1B1/1B3/2B1, and multidrug and toxic compound extrusion proteins (MATE) 1/2), 
follow an identical primary route for transporting their substrates: from the systemic 
circulation into different tissues or urine/bile in case of MATEs. Consequently, 
reducing or increasing these transport capacities would result in increased or reduced 
systemic drug concentrations, respectively. The reverse effects are seen with the 
uptake transporters expressed in the intestinal apical membrane such as OATPs and 
OCT1 since the transportation pathway is in the opposite direction. In the sections 
below, I show examples of DGIs and DDGIs related to group III transporters. 
       5.3.1 Drug-Transporter Gene Interactions (DTGIs) 
 
In many situations, the efficacy of a drug relies upon the ability of that drug to access 
certain tissues. Statins are taken up into the liver by OATP1B1(SLCO1B1), and this 
is crucial for their lipid-lowering effect. Reducing this uptake pathway reduces statin 
efficacy and raises plasma concentrations, resulting in myopathy and, rarely, 
rhabdomyolysis. The rs4149056 (T>C) (SLCO1B1*15) variant has been widely 
studied, and in 23 studies [65-87], this variant has been persistently connected to 
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increased statin plasma exposure, muscle aches, dose reduction, and/or treatment-
resistant phenotypes. The strongest evidence to date is available between simvastatin 
and rs4149056 (T>C) SLCO1B1 variant in term of increased myopathy risk. 
Therefore, CPIC guidelines recommend to reduce the dose or use an alternative statin 
not significantly affected by SLCO1B1 for carriers of this variant allele [88]. Of note, 
this is the only genotype-phenotype association which has received CPIC 
recommendations at the level of drug transporters available to date. 
      5.3.2 Drug-Drug-Transporter Gene Interactions (DDTGIs) 
 
In some circumstances, altering the uptake transporter function can increase ADRs. 
For example, it has been observed that carriers of two OCT1 (SLC22A1) reduced 
function alleles who were treated with OCT1-inhibitors were over four times more 
likely to develop gastrointestinal side effects with metformin (an OCT1 substrate) 
treatment, which would be attributable to metformin accumulation in the intestinal 
lumen (assuming apical OCT1 localization) [89]. This finding was supported by a 
previous study [90]. At the level of renal uptake transporters, other DDTGIs have 
been reported in which carrying the mutant alleles, and the co-administration of 
inhibitors was linked to increased metformin plasma levels/toxicity or reduced 
clearance (see Table 1, [91,92]). By contrast, reducing transport in some cases may 
reduce certain side effects. For instance, cisplatin (an OCT2 (SLC22A2) substrate) is 
both a nephrotoxic and an ototoxic agent. People carrying the rs316019 (C>A) OCT2 
mutation were protected from these adverse reactions as the variant resulted in a 
reduced transport of cisplatin into the kidney and the inner ear (cochlea) (where 
OCT2 is expressed as well) [93-95]. 
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A number of other DDGIs have been described for the SLCO1B1 transporter. For 
example, although the increase in pravastatin (a SLCO1B1 substrate) AUC after 
treatment with ritonavir (a SLCO1B1 inhibitor) was not statistically significant (21% 
increase vs pravastatin alone), a large interaction was seen in those carrying the 
SLCO1B1*15 or *17 haplotypes, with a resulting 113% elevation in pravastatin AUC 
[96]. Other DDTGIs with a similar mechanism have also been published (see Table 
1, [97-99]). Interestingly, unlike the ritonavir example just outlined, in some 
situations reduced function variants do not show any significant PK change until after 
the addition of inhibitors. For example, patients with AG or AA genotypes at 
rs2289669 (G>A) of the MATE1 transporter only had significantly lower metformin 
(a MATE1 substrate) clearance compared to carriers of GG genotype after treatment 
with ranitidine (a MATE1 inhibitor) [100].
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   6. DGIs/DDGIs and challenges in clinical practice 
 
 
Metabolizing enzyme and transporter substrates, inducers, or inhibitors are not fully 
documented in many popular drug interaction databases, leaving physicians 
unaware of potentially important interactions. In addition, most of the resources 
commonly used by prescribers (e.g., Stockley's, Micromedex, Drug.com, RxList, or 
other drug interaction checkers) do not consider genetic variation when classifying 
drug interactions into minor, moderate, or major classes. Genetic variation may 
markedly increase or ameliorate the severity of potential drug interactions and do 
need to be considered when considering real-world use of drugs. 
In this introduction, I have discussed the different mechanisms of interactions in their 
simplest forms with the assumption that the patient is free of transporter 
polymorphisms or inhibitors/inducers in the case of discussing DMEGIs/DDMEGIs 
and vice versa with DTGIs/DDTGIs. However, in real-world clinical practice, 
achieving precisely tailored drug therapy requires a detailed examination of all 
mutations in the candidate enzyme or transporter genes with a good awareness of all 
prescribed medications and possible pathways of interaction. Thus, the clinical 
scenario ranges from a relatively simple picture where the effect of genotype and 
interacting drug(s) can be approximated and treatment altered accordingly, to a far 
more complex scenario where physiologically-based PK (PBPK) modelling may be 
helpful and where the evaluation of large-scale clinical data linked to genotypes is 
required to evaluate the clinical impact of multiple interacting drugs/multiple 
genotypes on drug outcomes. 
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Consider a relatively simple scenario: a patient with type 2 diabetes treated with 
metformin (has no effect on CYPs) who carries reduced function variants in CYP2C9 
(*2 or *3 variants) and who is started on gliclazide (a CYP2C9/19 substrate). 
Reduced metabolism of gliclazide will result in increased efficacy [101] and 
increased risk of hypoglycemia [102]. The metformin use will not alter this DGI. 
However, if this patient were also treated with pioglitazone and/or atorvastatin (both 
are CYP2C9/19 inhibitors), they would be at potentially even greater risk of 
gliclazide-induced hypoglycemia and should be treated with a reduced dose of 
gliclazide. However, even for this simple scenario, such DDGI studies have not been 
reported; nor have dosing algorithms been developed to date for patients with 
CYP2C9 variants prescribed sulphonylureas and as such it is difficult to implement 
this into drug interaction calculators. 
There are many more complex scenarios where, for example, a combination of both 
metabolizing enzyme and transporter LOF/GOF variants, as well as 
inhibitors/inducers are included. This kind of interaction may be only initially 
predictable when all their sub-interactions result in the same clinical effect. For 
instance, reduced CYP3A4 and SLCO1B1 activities can both result in increased AUC 
of the substrate drug, and greater harm would be anticipated. Carriers of the TC 
genotype of SLCO1B1 rs4149056 (T>C) variant who are treated with amlodipine     
(a CYP3A4 inhibitor) experienced a 90% increased simvastatin AUC compared to 
subjects not treated with amlodipine and wild-type for rs4149056 [103]. A similar 
scenario was reported with other two case reports (see Table 1, [104,105]). 
In other situations, sub-interactions do not share a similar clinical effect. Here, 
predicting the overall clinical outcome is challenging. As an illustration, oral 
rosuvastatin is mainly eliminated via biliary excretion with a minor contribution of 
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CYP2C9 to its metabolism [106]. This implies that its transporters (e.g., ABCC2, 
ABCG2, ABCC1, and SLCO1B1) are the core players in its elimination. The 
concomitant administration of verapamil (an ABCC1/2 inhibitor) and venlafaxine (an 
ABCG2 inducer) in those who have inherited CYP2C9*3 and/or SLCO1B1 rs4149056 
(T>C) LOF variants results in unpredictable clinical consequences. CYP2C9, 
SLCO1B1, and ABCC2 impairment would boost rosuvastatin AUC, inducing 
ABCG2 would lower rosuvastatin AUC, and inhibition of ABCC1 could result in 
both increase or decrease in AUC (high AUC if the site of interaction is in the kidney 
and low AUC if it is in the intestine or liver). 
The exact estimation of the predicted net AUC following a certain drug interaction 
relies on calculating the contribution of each metabolizing enzyme and transporter to 
the elimination process (i.e., the degree of sensitivity of substrates), 
inhibition/induction potency of the perpetrator agent or the net effect of multiple 
inhibitors, inducers, or both, and the net percentage of reduction/elevation in the 
enzyme/s and/or transporter/s activity caused by a single or more SNPs. The outcome 
of such a hugely complex scenario is impossible to predict by the clinician and 
requires a clinical support tool based upon a PK DDGI prediction algorithm. Most of 
the current work concentrates on generating DD interaction predictors rather than the 
combined effect of both drugs and variants. However, using PBPK models, one 
predictor tool (https://www.ddi-predictor.org/) has recently been successfully 
generated to estimate drug exposure and the recommended dose following the dual 
action of both the perpetrator drug and mutations in certain CYPs (CYP2D6, 
CYP2C9, and CYP2C19) [107]. Other PBPK models do attempt to incorporate 
genotype and drug-drug interactions, but these do not model transporter variants well 
and have yet to translate through into clinically useful tools [108]. 
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An alternative method to evaluate the impact of DGIs/DDGIs is via measurement of 
 
endogenous biomarkers of metabolizing enzymes and transporters function rather 
 
than plasma concentrations of substrate drugs. Multiple enzymes/transporters-related 
 
biomarkers have been identified and are summarized in a published review [109] from 
 
which I highlight some examples in this paragraph. For instance, it has been shown 
 
that the cholesterol, cortisone, and cortisol metabolites: 4β-hydroxycholesterol, 6β- 
 
hydroxycortisone, and 6β-hydroxycortisol respectively, which are catalyzed by 
 
CYP3A4 activity, are increased under the effect of inducers and decreased with 
 
inhibitors of CYP3A4. It was also recognized that bufotenine is a major metabolite 
 
resulting from the metabolizing activity of CYP2D6. With regard to transporters, 
 
several studies have observed the association between increased bilirubin plasma 
 
levels and reduced hepatic OATP1B1/1B3 uptake function. The similar scenario was 
noted recently with the novel biomarkers coproporphyrins I and III (CPs I and III) 
where plasma CPs levels elevated with the inhibition of these transporters to a similar 
 
extent as with rosuvastatin. In DGIs/DDGIs studies, endogenous biomarkers can be 
utilized to predict the effect of genetic variants and/or inhibitors/inducers on the 
substrate drugs plasma levels. 
It is worth noting that potential DDIs do not necessarily reflect actual interactions. It 
has been observed that clinically significant interactions are consistently lower than 
theoretically predictable interactions [110]. However, the authors noted that 20% of 
ADRs are linked with DDIs; most of them are serious, with a high percentage of 
fatal cases. They also concluded that therapeutic failure secondary to DDIs, which is 
usually underestimated, represents a considerable part of total DDIs-related 
undesirable effects. The degree of clinical significance can be judged by observing 
other risk factors associated with a potential DDI such as polypharmacy and genetic 
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variants. Polypharmacy is commonly seen with elderly and hospitalized patients 
making them the most vulnerable patient's sub-groups to clinically significant 
interactions besides carriers of risky genetic variants. In addition, not all types of 
DGIs/DDGIs are expected to be common. Induction and phenoconversion interactions 
are predicted to be seen with lower incidence compared to inhibitory interactions as 
the majority of perpetrator drugs are inhibitors rather than inducers and most of the 
functional genetic variants are loss rather than gain-of-function mutations. 
The increasing availability of 'big data' linking health data and genomics has the 
potential to evaluate the real-world clinical impact of multiple drugs/multiple variant 
interactions. A number of data sets are now available or about to become available for 
study. In Scotland national prescribing and linked outcomes are available for the 
entire population enabling evaluation of real-world DDIs, and with an increasing 
bioresource (https://www.registerforshare.org) it should be possible to evaluate 
 
DGIs/DDGIs in ~500K people over the next few years. In addition, other resources 
such as UK biobank including genetic information on 500K individuals (with primary 
care data available on 200K during 2019) and other national bioresources (such as the 
Danish biorepository) and US bioresources linked to EHRs (EMERGE network) will 
enable the evaluation of n-way DDG interactions to identify clinically important 
interactions that can be incorporated into clinical decision support tools in the future.
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7. Conclusion and the aim of this PhD project 
 
 
Dozens of new pharmaceutical compounds enter the market each year, and a 
considerable number of patients are prescribed multiple drugs that necessitate the 
utilization of drug interaction databases for better management. One of the major 
limitations of these drug interaction checkers is the omission of the genetic effect on 
drug interactions. This reflects both the lack of clinical studies that quantify potential 
DGIs/DDGIs and the fact that genetic information is rarely available on patients at the 
point of prescribing. In this introduction, I have illustrated, with some examples, 
various mechanisms by which DGIs/DDGIs can occur at the level of metabolizing 
enzymes, drug transporters, or both. As DDGIs are a relatively new topic in 
pharmacogenomics with very limited publications, I have established a detailed 
classification framework of these interactions based on clinical studies or case reports. 
I have also shown the different degrees of complexity clinicians may face in judging 
the predicted clinical outcome following a certain DDGI. The more factors that are 
included, the more challenging it becomes to evaluate the outcome. There is a need 
for PBPK models, clinical studies and real-world evaluation of drug outcomes linked 
to genetic information to develop clinical useful DDGI models, to reduce adverse 
DDIs and improve drug outcomes in the setting of increasing multi-morbidity and 
polypharmacy. 
Due to the lack of DG and DDG interactions studies, my aim in this PhD project is to 
investigate a large variety of drugs and drug combinations and study the impact of 
different genetic variants in genes known to affect drug pharmacokinetics on different 
drug response phenotypes with the aim of uncovering novel DG/DDG associations. I 
will begin by describing the general methodology in the next chapter before 
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presenting our findings from DG and DDG interaction studies in chapters III, IV, and 
V. 
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 Table 1: classification of drug-drug-gene interactions according to their different 
mechanisms as observed from findings of clinical studies or case reports. 
 
 
Metabolizing enzymes interactions 
Inhibitory interactions-the victim drug as an active drug 
Interaction type Interaction model Example/s Clinical outcome 
Single enzyme interactions 
(Both the inhibitor and the genotype 
affect the same enzyme) 
 
 
Substrate + inhibitor +LOF 
variants in the same 
enzyme inhibited by the 
inhibitor 
Warfarin+simvastatin+CYP2C9*3 in CYP2C9 gene CYP2C9*3 carriers require lower warfarin 
dose compared to non-carriers [20]. 
Lansoprazole/rabeprazole+ fluvoxamine+ poor 
metabolism genotype in CYP2C19 gene. 
 
Although the greater increase in the substrate 
drug plasma level is always seen with poor 
metabolizers, the effect of adding inhibitors is 
observed more clearly in normal metabolizers 
followed by heterozygous genotype carriers 
with the lowest effect being with poor 
metabolizers as they already carry reduced 
activity metabolizing enzymes [22-26]. 
Omeprazole+ moclobemide+ poor metabolism genotype 
in CYP2C19 gene. 
Metoprolol+ diphenhydramine+ poor metabolism 
genotype in CYP2D6 gene. 
Metoprolol+ dronedarone+ poor metabolism genotype in 
CYP2D6 gene. 
 Substrate +2nd substrate 
(competitive inhibitor) 
+LOF variants in the same 
enzyme inhibited by the 
inhibitor 
Warfarin + celecoxib+ CYP2C9*2/*3 in CYP2C9 gene Increased bleeding risk with warfarin in those 
carrying the variant CYP2C9 alleles [21]. 
Multiple enzymes interactions 
(The inhibitor and the genotype 
affect different enzymes) 
Substrate +inhibitor +LOF 
variants in an enzyme 
differ from the one 
inhibited by the inhibitor 
Voriconazole + atazanavir/ritonavir (CYP3A4 inhibitors) 
+ poor metabolism genotype in CYP2C19 gene. 
 
 
Poor metabolizers experienced marked AUC 
increase from the substrate drugs compared to 
normal metabolizers [27-30]. 
Tacrolimus + voriconazole (a CYP3A4 inhibitor) + 
poor/intermediate metabolism genotype in CYP2C19 
gene. 
Voriconazole + erythromycin (a CYP3A4 inhibitor) + 
poor metabolism genotype in CYP2C19 gene. 
Lansoprazole + clarithromycin (a CYP3A4 






Inhibitory interactions-the victim drug as a prodrug 
Single enzyme interactions Substrate +inhibitor +LOF 
variants in the same 
enzyme inhibited by the 
inhibitor 
Clopidogrel + proton pump inhibitors 
(CYP2C19 inhibitors) + CYP2C19*2/*3 in 
CYP2C19 gene 
Poor metabolizers were more likely to develop 
clopidogrel resistance compared to normal 
metabolizers [32]. 
Multiple enzymes interactions Substrate + 2 inhibitors of 
2 different enzymes +LOF 
variants in one of the 
enzymes inhibited by one 
of the two inhibitors. 
Clopidogrel + proton pump inhibitors (CYP2C19 
inhibitors) + calcium channel blockers (CYP3A4 
inhibitors) + CYP2C19*2/*3 in CYP2C19 gene   
Poor metabolizers developed a marked 
reduction in clopidogrel efficacy compared to 
normal metabolizers [33]. 
Induction Interactions 
Single enzyme interactions Substrate +inducer +GOF 
variant in the same enzyme 
induced by the inducer 
Voriconazole + carbamazepine+ CYP2C19*17/17 
in CYP2C19 gene 
Major loss of voriconazole efficacy was seen 
in one patient [34]. 
Phenoconversion Interactions    
Single enzyme interactions  
 
Substrate +inhibitor+ GOF 
variant in the same enzyme 
inhibited by the inhibitor 
a) Ultra-rapid metabolism > poor metabolism 
 
Clopidogrel+ proton pump inhibitors+ CYP2C19*17 
in CYP2C19 gene 
Loss of clopidogrel efficacy [46]. 
b) Ultra-rapid metabolism > normal metabolism 
 
Nortriptyline + paroxetine + ultra-rapid metabolism 
genotypes in CYP2D6 gene. 
Normal nortriptyline therapeutic plasma levels 
[47]. 
Substrate +inducer+ LOF 
variant in the same enzyme 
induced by the inducer 
c) Poor metabolism> ultra-rapid metabolism 
 
Tolbutamide + rifampin+ intermediate or poor 
metabolism genotypes in CYP2C9 gene 







Inhibitory interactions-efflux transporters 





+LOF variant in the same 
transporter inhibited by the 
inhibitor 
Cyclosporine + diltiazem + rs1045642(C>T) in ABCB1 
gene 
TT genotype carriers at rs1045642 variant 
show increased cyclosporin trough 
concentration (no effect was detected with 
other genotypes) [54] and the lowest increase 
in methadone plasma level compared to other 
genotypes [55]. 
Methadone + quetiapine + rs1045642(C>T) in ABCB1 
gene 
[Granisetron + dexamethasone] + [doxorubicin+ 
cyclophosphamide] + rs2032582(G>T)* in ABCB1 gene 
 
*G, but not T, allele was linked to reduced ABCB1 activity in 
this study with Japanese population. 
GG carriers show the highest response from 
the substrates compared to other genotypes 
[56]. 
Dabigatran/rivaroxaban + clarithromycin or 
Tacrolimus + itraconazole 
+ rs1045642 (C>T) in ABCB1 gene 
No effect was seen with any genotype 
[57,58]. 
Inhibitory interactions-uptake transporters 
Single transporter interactions  
 
 
Substrate +inhibitor +LOF 
variant in the same 
transporter inhibited by the 
inhibitor 
Metformin + OCT1 inhibitors (tricyclic antidepressants, 
citalopram, proton pump inhibitors, verapamil, diltiazem, 
doxazosin, spironolactone , clopidogrel , rosiglitazone , 
quinine , tramadol ,and codeine) +  R61C, C88R , 
G401S, M420del, and G465R in OCT1 gene. 
Carriers of two LOF alleles were over four 
times more likely to develop metformin 
intolerance [89]. 
Metformin + trimethoprim (a MATE1/OCT2 inhibitor) + 
rs2289669 in MATE1 gene or 
rs316019 in OCT2 gene 
Increased metformin plasma concentrations 
[91]. 
Metformin + cimetidine + c.808G>T in OCT2 gene. TT genotype carriers show the lowest rate of 






  Pravastatin + ritonavir + SLCO1B1*15 or *17 haplotypes 
in SLCO1B1 gene. 
Carrying the variant alleles has elevated 
pravastatin AUC by 113%. No significant 
interaction was seen with normal genotypes. 
[96]. 
Olmesartan + pravastatin or 
Repaglinide + gemfibrozil 
+ rs4149056 (T>C) in SLCO1B1 gene. 
CC genotype carriers displayed higher plasma 
concentrations from the substrate drugs 
compared to other genotypes [97,98]. 
Atorvastatin + rifampicin + rs4149056 (T>C) in 
SLCO1B1 gene. 
Although no significant difference in 
atorvastatin plasma concentration between the 
three genotypes was detected, a clear increase 
can be observed with CC genotype carriers 
and on the drug combination compared to 
those on atorvastatin only [99]. 
Metformin + ranitidine + rs2289669(G>A) in MATE1 
gene 
AG and AA genotype carriers experienced 
lower metformin clearance compared to GG 
genotype carriers [100]. 
Enzyme/s + transporter/s interactions 
Multiple enzyme/s and 
transporter/s interactions 
(The perpetrator drug and the 
genotype affect both enzyme/s 
and transporter/s of the same 
substrate) 
Substrate + transporter/s 
and/or enzyme/s inhibitor/s 
and/ or inducers and/or 
2nd substrate + LOF/GOF 
variants in one enzyme or 
more and/or in one 
transporter or more 
  
Simple (predictable) interactions (sub-interactions result in the same clinical outcome) 
 Simvastatin + amlodipine (a CYP3A4 
inhibitor) + rs4149056 (T>C, LOF) in 
SLCO1B1 gene. 
Subjects with TC genotype experienced a 90% 
increase in simvastatin AUC compared to 
those not treated with amlodipine and carry 





 Fluvastatin + telmisartan (an ABCC2 inhibitor) + 
CYP2C9*3 and -24C > T (LOF variants) in CYP2C9 and 
ABCC2 genes respectively. 
An elevation in creatine kinase level was 
observed in a patient on this drug-drug- 
genotypes combination [104]. 
Atorvastatin + pantoprazole (a SLCO1B1 and an 
ABCB1 inhibitor, and a CYP3A4 substrate) + CC 
genotype* at rs4149056 (T>C) in SLCO1B1 gene + TT 
genotype* at rs1045642 (C>T) in ABCB1 gene. 
 
* CC and TT genotypes are associated with reduced activity. 
A patient on this drug-drug-genotypes 
combination has developed rhabdomyolysis 
and acute renal failure [105]. 
Complex (unpredictable) interactions (sub-interactions result in different clinical outcomes) 
 Rosuvastatin + verapamil (an ABCC1/2 inhibitor) 
and venlafaxine (an ABCG2 inducer) + 
CYP2C9*3 and/or rs4149056 (T>C) LOF variants 
in CYP2C9 and/or SLCO1B1 genes respectively. 
 
This example has been used for illustration purpose only (no 
studies were reported). 
Advanced PBPK prediction tools are required 
to be developed with conducting real-world 
clinical studies to address and understand this 











































      1. Introduction 
 
 
This chapter will provide a general overview of databases and statistical methods 
utilized throughout this project as well as presenting the different methods used to 
define drug response/intolerance phenotypes. 
 
     2. The clinical databases 
 
We have used four databases to produce the main findings in this project which are 
each described in brief. 
                      2.1 The UK biobank (UKBB) database 
 
The information below has been summarized from references 111 and 112. 
 
 
              2.1.1 Participants and data collection 
 
The UKBB is a dataset of ~ half a million participants. They were recruited in the 
period between 2006 and 2010 when their age range was between 40 and 69 years. 
Participants were assessed in 22 centres across the UK, including a mix of different 
ethnicities. A large variety of phenotypic data was collected during these assessment 
visits. Sociodemographic, environmental, lifestyle, physical, medical history, and 
treatments information were collected via questionnaire and interviews. At the time of 
starting this PhD in March 2017, the available data were cross-sectional until 
September 2019 when longitudinal primary care data became available for ~ 230,000 
participants. All participants provided consent to use their anonymized medical data 
for relevant research. Researchers are not required to submit a separate ethics 
approval to use the data as the UKBB has its own independent Ethics and Governance 
Framework which formulates its policies and access arrangements. 
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           2.1.2 Genotype data 
 
Genotype data for ~150,000 participants were first released in 2015 before the 
availability of genotype data for most of the cohort (n~ 488,377) in 2017 at the time 
of starting this project. Two novel closely-related genotyping arrays were specifically 
developed for the UKBB genotyping project: Applied Biosystems™ UK BiLEVE 
Axiom™ Array by Affymetrix and Applied Biosystems™ UK Biobank Axiom™ 
Array. The former was used to genotype 49,950 individuals participating in the UK 
Biobank Lung Exome Variant Evaluation (UK BiLEVE) study, and the latter was 
used for genotyping the remaining 438,427 subjects with a total of ~825K markers 
included. Coding markers of all different MAF categories were included (i.e. MAF < 
1% [rare], MAF =1-5% [low frequency], or MAF > 5% [common]). Most 
importantly, around 45K variants associated with different chronic diseases and 
pharmacogenomics were also included on the genotyping array. 
Affymetrix used a GeneTitan® MultiChannel (MC) Instrument to analyze DNA 
samples, and a number of quality checks were performed. Samples that failed to meet 
these checks were excluded. Some markers were not previously assayed by 
Affymetrix and required the development of new assay methods. As these new 
attempts were not successful, this group of markers were excluded. This resulted in 
genotyping of 812,428 different variants. 
A number of approaches were taken into account to examine the quality of 
genotyping by the UKB research team such as checking HWE deviation, sex effects, 
plate effects, array effects, batch effects, and the DNA sample quality. To reduce the 
effect of population stratification (as the UKBB population consists of 94.23% White, 
1.94% Asian, 1.57% Black, 0.31 % Chinese, 0.58 % mixed, and 1.38% unknown 
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ethnicity), principal component analysis (PCA) was undertaken to control for 
population stratification effect. White British participants represent the majority of the 
UKBB cohort and can be used by researchers interested in a homogenous ethnicity to 
avoid the risk of ethnic diversity on HWE deviation. Markers are excluded when there 
is sufficient evidence of poor genotyping quality. The final number of variants 
becomes 805,426 for 488,377 participants. 
For the purpose of increasing the number of tested markers, genotype imputation was 
carried out by the UKBB research team. Imputation is the process of predicting 
indirectly assayed genotypes for a sample of subjects. The imputation process 
includes pre-phasing the directly genotyped markers first before imputation. In the 
first step, markers which failed quality control for more than 1 batch, had > 5% 
missing data, or had a minor allele frequency of < 0.0001 were removed. Some 
samples which were recognized as outliers were also removed. This reduced the 
number of markers into 670,739 and reduced the number of samples into 487,442. 
As the accuracy of imputation increases with the increased number of haplotypes in 
the reference panel and if there is a good match between the ancestries of the sample 
haplotypes and the reference panel haplotypes, the Haplotype Reference Consortium 
(HRC) panel was utilized. This panel consists of many more haplotypes with the 
European (including the British) ancestry representing the majority of individuals as 
the UKBB cohort. The HRC panel also consists the 1000 Genomes Phase 3 reference 
panels which consist of a diverse set of haplotypes from different ethnicities 
matching the other ethnicities in the UKBB cohort. 
The imputation has been performed in groups of ~50,000 markers on 5000 samples 




The mechanism of genotype imputation relies on the concept of linkage 
disequilibrium (LD, see section 3.2 below). LD occurs when adjacent loci are 
inherited together non-randomly. This could result in observing groups (blocks) of 
shared alleles between individuals who inherited them from the same ancestor (i.e., 
haplotypes). This concept facilitates the process of genotype prediction for 
indirectly assayed genotypes. In the imputation process, information from the 
directly assayed markers in the study sample is first compared to a reference panel 
of haplotypes which consists of information on a much larger number of markers. 
Then, shared haplotypes are recognised and missing data in the study sample are 
filled using information from the matching reference haplotype. Figure 5 below 
visually illustrates imputation process.   
 
 
   
Figure 5: The imputation process and predicting missing data for the study sample. 
 
* Using data from reference haplotypes (1), the missing data in the study sample (2) 
can be predicted (3) from the matching reference haplotype in the reference panel (1).    
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            2.1.3 Funding bodies 
 
The UKBB study is mainly funded by the UK Medical Research Council and 
Wellcome Trust. Other contributors include Scottish and Welsh Governments, 
British Heart Foundation, North West Development Agency, and Diabetes UK. 
                      2.2 Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTs) database 
 
The information below has been summarized from reference 113. 
 
 
           2.2.1 Data collection and participants 
 
 
The study started in 1996 as a collaboration between the University of Dundee's 
medical department, Ninewells Hospital, Perth Royal Infirmary, Stracathro Hospital 
and a group of Tayside general practitioners. The study focused on recruiting diabetic 
patients in the Tayside area. In 1998, patients were invited to provide clinical 
information and samples for the benefit of genetic research in diabetes mellitus (DM) 
and its treatments. 
Data were collected in three stages in the periods 1998-2004, 2004-2009, and 2009- 
2015 until it reached to a total of 18306 participants (10149 type 2 diabetic patients 
and 8157 controls). All participants provided permission to use their medical data 
anonymously for research-related purposes. The GoDARTs database now consists of 




           2.2.2 Genotype data 
 
Out of 10149 cases and 8157 controls, genotype data are available for 8564 and 4586 
patients, respectively. Five assay methods were used to genotype participants. 
Affymetrix Genome-Wide Human SNP Array 6.0 (932,979 SNPs) and the Illumina 
HumanOmniExpress (731,296 SNPs) were used to produce genome-wide data for 
7857 cases and 1108 controls. Further customized genotyping for 707 cases and 3478 
controls was performed using the Immunochip (196,524 variants, focused on immune 
diseases), the Cardio-Metabochip (Metabochip) (196,725 markers, focused on 
cardiometabolic diseases) and the Human Exome array (247,870 markers). 
              2.2.3 Funding bodies 
 
The study is funded by the Scottish Home and Health Department, the Wellcome 




                   2.3 Generation Scotland: Scottish Family Health Study (GS: SFHS) database 
 
The information below has been summarized from references 114-116. 
 
 
        2.3.1 Data collection and participants 
 
The Generation Scotland (GS) study started in 2003 as a collaboration between 
Scottish medical schools and the National Health Service (NHS). In 2004, GS was 
funded by the Scottish government to start the Scottish Family Health Study (SFHS) . 
SFHS collected participants as families rather than individuals to facilitate genetic 
epidemiological studies and uncover rare variants associated with diseases and drug 
response. In the period from 2006 to 2010, a total of 126,000 potential candidates 
were invited to participate, of whom 6665 responded and met the study  
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criteria (aged >= 18 – 65 and able to bring at least one family member to participate). 
An additional 1288 individuals participated without invitation with 16,007 family 
members (some participants aged above 65 (up to 100 years) and some with no 
relatives were allowed to participate). This gives a final of 23,960 participants in the 
study. 99 % of the sample were of White ethnicity, and 74.2 % shared their 
medication history. All participants provided consent to use their medical records for 
research purposes. The NHS Tayside committee on research ethics provided ethical 
approval for this study. The data collection started cross-sectionally with subsequent 
longitudinal medical data as a result of linkage to NHS data. 
             2.3.2 Genotype data 
 
98% of the cohort have had their DNA extracted. Over than 20,000 participants were 
genotyped using high-density genome-wide chips: Illumina OmniExpress (~700,000 
variants) and the human exome chip (~250,000 variants). Genotype quality checks for 
32 SNPs on a test sample of ~ 10,000 subjects showed high quality genotyping with 
call rates of 97% or more for the majority of SNPs. The prescribing data were 
available for ~ 10K participants at the time of our study. 
          2.3.3 Funding bodies 
 
GS was mainly funded by the Chief Scientist Office of the Scottish Government and 
the Scottish Funding Council. 
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                   2.4 Scottish Health Research Register (SHARE) and Genetics of SHARE (GoSHARE) database 
 
The information below has been summarized from references 117-119. 
 
 
        2.4.1 Data collection and participants. 
 
The SHARE project has established an approach to ask the public to share their data 
stored in NHS databases for research purposes. Any individual from Scotland aged >= 
16 years can join the project. The recruitment process started in 2011 and is still 
ongoing with the hope of reaching 1,000,000 individuals. To date (2020), 277,082 
individuals have participated in paper forms or online. The GoSHARE project, which 
initiated in Tayside but is now national, asks SHARE participants to consent to use of 
leftover blood samples collected as part of routine clinical care. From SHARE, 70,790 
participants were resident in Tayside and Fife, and have linkage to medical record 
data; of these genotype data were available for 4,819 participants. 
          2.4.2 Funding bodies 
 
The project is mainly funded by NHS Research Scotland (NRS), which is a 
cooperation between the Scottish Health Boards and the Scottish Government Chief 
Scientists Office (CSO). 
                       2.5 Utilization of the four cohorts in our project. 
 
The 3 Scottish cohorts have been combined in a single cohort, and then this single 
cohort was utilized in chapters III and IV in order to generate our initial (discovery) 
findings. The UKBB cross-sectional cohort was also used as a separate discovery 
cohort in these two chapters to generate findings using a different phenotype than the 
ones used in the combined Scottish cohort. 
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Figure 6: The process of utilizing the four cohorts (GoDARTs, 
GS, GoSHARE, and UKBB) in order to generate the discovery and 
the replication/validation results in our project. 
 
Then, in chapter V, the UKBB primary care data was used as a replication/validation 
cohort for the top results from the combined Scottish cohort. 





































3. Statistical Genetics 
 
Given the role of genetics within this thesis, here I outline statistical genetic principles 
in general and how these were applied during the PhD. 
Information in sections 3.1-3.7 below has been summarized from the reference number 120. 
 
                      3.1 Alleles and genotypes 
 
Each individual inherits a group of different genotypes. An individual's genotype 
consists of two alleles inherited from the parents. One is usually known as the major 
allele, and the other one is the minor allele based on their frequencies in a certain 
population. In general, the minor allele is responsible for presenting the uncommon 
phenotype, which is the subject of many genetic studies. The minor allele is 
considered common if its distribution in a specific population is over than 1% even 
though a frequency of >= 5% is more desirable for some researchers. 
 
 
                         3.2 Linkage Disequilibrium (LD) 
 
Linkage equilibrium occurs when there is a high chance for two DNA segments to 
separate from each other, by a process called recombination, as a result of the large 
distance between them. In contrast, linkage disequilibrium occurs when adjacent loci 
are inherited together non-randomly due to their physical proximity. LD tends to 
decay throughout generations. 
Two statistical measures can be used to quantify the extent of occurrence of a 
recombination event between two variants: the absolute value of deviation from the 
equilibrium status (D′) and more commonly the absolute value for the correlation 
coefficient (r2). If we have two linked variants with alleles Aa and Bb, then four 
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Allele A count = (genotype AA count * 2) + genotype Aa count 
Allele a count = (genotype aa count * 2) + genotype Aa count 
Allele A frequency = Allele A count / total alleles' counts (A+a) 
Allele a frequency = Allele a count / total alleles' counts (A+a) 
 
possible haplotypes are expected: AB, Ab, aB, and ab. D and r2 between the two 
 
variants are given by the below equations: 
 
D = AB frequency – A frequency * B frequency. 
 
r2 =D2 / A frequency * a frequency * B frequency * b frequency 
 
If the absolute value of D or r2 = 1, then the two genetic variants are in complete correlation 
 
(LD) with each other and allele frequency of the two is similar. The higher the deviation from 
1, the higher chance that the two variants are independent of each other. 
                         3.3 Allele frequency calculations 
 
Given that the major allele and the minor allele are denoted by "A" and "a" symbol 
respectively, three probabilities are expected to represent an individual's genotype: 
'AA' (dominant homozygous), 'Aa' (heterozygous), or 'aa' (recessive homozygous). 
When at equilibrium, the frequency of each allele can be calculated from known 
genotype counts after calculating allele counts by utilizing the below equations: 
 
 
For example, if the number of subjects with 'AA', 'Aa', and 'aa' genotypes are 
1400,500, and 40 respectively, the minor allele (a) frequency (MAF) would be: - 
[(40*2) + 500] / [ (1400*2) + 500] + [ (40*2) + 500] = 580 / (3300 + 580) = 0.14 
 
As the total proportion of both alleles always equals 1, the major allele (A) frequency 




                        3.4 Genotype frequency calculations 
 
The frequency of a specific genotype can be calculated by dividing the genotype 
count by the total sample size. For instance, the 'aa' and 'Aa' genotype frequencies 
from the aforementioned example are 40 / (1400+500+40) = 0.02 and 0.25 
respectively which implies that 'AA' genotype frequency is 1 – (0.02 + 0.25) = 0.73. 
Understanding the above principles is helpful in understanding what is known as 
Hardy-Weinberg equilibrium law and its associated calculations. 
                       3.5 Hardy-Weinberg equilibrium (HWE) law and its assumptions 
 
HWE law shows to what extent allele and genotype frequencies would change from 
one generation to another generation. It concludes that no change in the allele 
frequencies is expected to be seen in the next generation as long as five assumptions 
have been met. These assumptions are: 
a) Random selection: carrying risky genotypes which affect survival rate 
would result in changing allele frequency in the next generations. 
b) Absence of new mutations: frequency rates of alleles may change if new 
alleles appeared by certain mutations. 
c) No migration: leaving one population to another population can change 
allele and genotype frequencies. 
d) No chance events: occurrence of genetic drift by chance when, 
unexpectedly, some individuals started to contribute higher alleles than 
others. 
e) Random mating: If mating occurs in a way depending on the genetic 
constitution between couples, genotype frequency but not allele frequency 
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would change. This can be seen in communities where there is a preference 
of mating between the same racial group for example. 
A population is said not to be at HWE if any of the above assumptions has been 
violated. 
                         3.6 HWE calculations and testing 
 
HWE calculates genotype frequencies of the next generation using observed allele 
frequencies of the current population. Using the example in section 3.3 above, for an 
'AA' genotype to be produced, both parents should provide an 'A' allele to their child. 
So, the expected 'AA' genotype frequency is expressed as the probability of a sperm 
containing an 'A' allele (0.86) multiplied by the probability that an egg provides an 'A' 
allele as well (0.86) = 0.7396. Similarly, the expected 'aa' genotype frequency would 
be expressed as a (0.14) * a (0.14) = 0.0196. For the 'Aa' genotype, there are two 
possibilities for the sperm and the egg to be fertilized, the sperm may carry either 'A' 
or 'a' allele, and the egg may carry either of the two alleles as well. Therefore, the 
expected 'Aa' genotype frequency can be calculated as follows: 2 * A (0.86) * a (0.14) 
= 0.2408. Adding the 3 probabilities together (0.7396 + 0.0196 + 0.2408) = 1. The net 
of the 3 genotype frequencies always equals 1. Accordingly, the HWE equation has 
been formulated to generalize the above concept. 
HWE equation is expressed as follows: 
 
p2 + 2*(p*q) + q2 = 1 
 
Where p = 'A' and q = 'a' in our example. 
 
The expected genotype frequencies calculated above can then be converted into the 
number of individuals carrying the genotypes by multiplying these frequencies by the 
72  
Table 2: an example for the observed number carrying the 3 
different genotypes and the calculated expected number of 
individuals carrying these genotypes in the next generation. Any 
significant difference would indicate violating HWE principle. 
 
total sample size. 'AA', 'Aa', and 'aa' genotype counts = (1400+500+40 =1940) * 
0.73 = 1416.2, 1940 * 0.24 = 465.6, and 1940 * 0.019 = 36.86. Then, a table with 
the observed and expected genotype counts can be created with Chi-square test used 
to test whether there is a significant deviation away from HWE. The table, in our 











AA 1400 1416.2 
Aa 500 465.6 
aa 40 36.86 
 
 
If the p-value of the Chi-square test >= 0.05, it can be concluded that the population is 
at HWE. On the other hand, if the p-value is < 0.05, this indicates a deviation from 
HWE as there is a significant difference in the genotype frequencies between the 
observed population and the next generation. Visual, but not statistical, inspection of 
the above table would tell us that there is no significant difference between the 
observed and the expected genotype counts and therefore the population seems to be 
on HWE. It is worth noting that the HWE p-value threshold can be more relaxed with 
large sample sizes, as even very minor deviation away from HWE will be statistically 
significant but not represent clinically relevant deviation or genotyping error. 
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Some researchers consider p-values >= 1*10-4 or 1*10-8 as the cut-off points. In 
fact, this is a debatable subject among researchers. 
                          3.7 Types of genetic models and their uses. 
 
In genetic studies, the three genotypes can be grouped by different methods to study 
the genotype-phenotype association. There are four main genetic models which can be 
used which are explained below. 
a) Dominant model: used when one or two copies of the variant allele (a) 
 
is/are needed for an x-fold increase/decrease in the risk linked to the 
phenotype. Here both 'Aa' and 'aa' genotypes are combined and 
compared to the reference 'AA' genotype (('Aa' + 'aa') vs 'AA'). 
b) Recessive model: used when two copies of the variant allele (a) are 
 
needed for x-fold increase/decrease in the risk linked to the phenotype. 
Here the 'aa' genotype is compared to the reference genotype, which 
represents both 'AA and 'Aa' genotypes ('aa' vs ('AA' + 'Aa')). 
c) Codominant (or genotypic) model: used to identify the individual 
genotypic effect on the phenotype of interest. Here, the 'Aa' genotype 
alone is compared to the reference 'AA' genotype and the 'aa' genotype 
is compared to the reference 'AA' genotype ( ('Aa' vs 'AA') and ('aa' 
vs. 'AA') ). 
d) Log-additive model: used when one copy of the variant allele (a) is 
 
needed for an x-fold increase/decrease in the risk linked to the 
 
phenotype and two copies (aa) are required for a 2x-fold 
 
                        increase/decrease in the risk. The model tests whether log  
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ratio (cases counts/total sample size) changes linearly with 'AA', 
'Aa', and 'aa' genotypes. 
 
 
As the mode of effect is usually unknown when studying drug-gene associations, the 
log-additive model is commonly used in these studies. If the model returns a 
significant result, the researcher may be interested in knowing the individual 
genotypic effect, which is the function of the codominant model. This model shows 
the effect of either 'Aa' or 'aa' genotype compared to the wild-type genotype (AA). 
If there are a very limited number of individuals with a recessive homozygous 
genotype (aa), some researchers prefer to convert the model into the dominant model 
where both 'Aa' and 'aa' genotypes are combined together and compared to the normal 
genotype. In other situations, the effect of the 'Aa' genotype would be negligible and 
close to the normal genotype (AA) carriers, converting the model into recessive by 
combing 'AA' and 'Aa' carriers in the same category would show the effect of 'aa' 
genotype more clearly. 
                         3.8 Utilization of statistical genetics principles in our project 
 
In chapter III, MAF, LD, and HWE tests have been utilized to facilitate the selection 
of candidate genetic variants. 
In our project, we were interested in common genetic variants with MAF of 5 % or 
more. After calculating the number of individuals carrying each of the 3 genotypes, I 
then calculated MAFs for SNPs of interest using "maf ()" function under 
"HardyWeinberg'' R package in R software and including SNPs with MAF >= 5%. 
Another helpful tool to select SNPs is the LD test. Among a large list of genetic 
variants, many of these can be correlated to each other, and therefore it is 
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unnecessarily to study all of them. The LD test provides an estimation for the degree 
of correlation between all possible SNP pairs so it can be used to condense the initial 
list of SNPs into a smaller list. I performed the LD test by using "genotype()" and 
"LD.data.frame()" functions under the "genetics" package in R for all of the SNPs of 
interest. This helped to identify correlated SNP pairs (defined as SNP pairs with r2 
>=0.5) so we only keep uncorrelated SNPs in our analysis considering r2 criteria. 
 
The third useful test facilitating SNP selection is HWE. It can be used to check the 
validity of genotyping or the correctness of sample selection. Genetic variants which 
deviate from HWE would indicate that either the genotype data are unreliable due to 
technical error or that the sample contains different ethnic subgroups. The 
"HardyWeinberg" R package was used to calculate p-values of the HWE using 
"HWChisq()" function for SNPs of interest. SNPs were included if their p-values were 
>= 1*10-8. SNPs with p-values less than this threshold were considered significantly 
deviated from HWE and regarded as unreliable. 
The HWE principle and their underlying assumptions were also utilized in order to 
explore drug response phenotypes in the cross-sectional databases. This will be 
discussed in more details later in this chapter under section 5.1. 
Regarding genetic models, using 'SNPassoc' R package', I have mainly used the log- 
additive model for all of our genotype-phenotype associations in chapters III, IV, and 




  4. General statistics 
 
 
After discussing methods related to the genotype data and before discussing our drug 
response phenotype definitions, in this section, I highlight methods used to study the 
association between the genotype and the phenotype. By knowing these methods, we 
can understand how I have utilized them to study the associations between genotypes 
(explanatory variables) and different drug response phenotypes (outcome variables) 
which I will discuss in section 5 following this section. 
Information in sections 4.1-4.3 below has been summarized from references 121-123. 
 
                        4.1 Regression model types 
 
Regression tests examine the association between dependent (outcome/response/Y) 
variable and independent (explanatory/predictor/X) variable/s. There are four main 
types of regression models, and the type of variables on the Y- and X-axis 
determines the type of the regression model, which are as follows: 
a) Simple linear regression: study the relationship between a single continuous 
 
(numerical) outcome variable and a single continuous explanatory variable 
 
such as the correlation between cholesterol level and weight. 
 
b) Multiple regression: study the relationship between a single continuous 
 
(numerical) outcome variable and multiple continuous or categorical 
 
explanatory variables such as the correlation between cholesterol level and 
 
age, sex, and weight. 
 
c) Mixed (multilevel) regression: study the relationship between a single 
 
continuous (numerical) outcome variable with multiple levels (e.g., multiple 
 
cholesterol measurements per patient) and multiple continuous or categorical 
 
explanatory variables such as sex and weight. 
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Figure 7: visual presentation of differences between simple (a), 
multiple (b), multilevel (c), and logistic (d) regression models. 
 
d) Logistic regression: study the relationship between a binary categorical 
 
outcome variable and multiple continuous or categorical explanatory variables 
 
such as studying whether or not (yes/no) hypertension is associated with age 
and/or diabetes mellitus. 







4.2 Checking regression model assumptions 
 
            4.2.1 Simple, multiple, and multilevel regression models 
 
 
Simple, multiple, and multilevel regression models assume: 
 
a) Constant variance: the spread of the outcome variable about its average value 
(i.e., residuals) is the same for all X variables (homogeneity of variance). 
b) Linearity: the average value of the outcome variable is a linear function of the 
explanatory variables. 
c) Normality: normal distribution of residuals. 
 
d) No multicollinearity (i.e., no high correlation between explanatory variables): 
variance inflation factor (VIF) for each explanatory variable has to be < 5 to 
exclude multicollinearity. 
e) There are no outliers (extreme values) in the continuous explanatory variables: 
 
an observation is said to be an outlier if the absolute value of 
 
standardized residual is >3 (> +3 or > -3).  
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(a) (b) 
Figure 8: The difference between non-normally (a) and normally (b) distributed 




Using statistical software such as R, normal probability plot (normal Q-Q plot) can be 
used to check for the normality assumption. In Figure 8 below, the right-hand plot 
below shows that residuals are normally distributed while the left-hand plot displays 





Regarding constant variance and linearity assumptions, this can be checked via 
residuals versus fit plots. In Figure 9 below, the right-hand plot below violates the 
linearity assumption since the data points are distributed in a curved line. The plot in 
the middle violates the constant variance assumption as the data points show a clear 
triangle pattern. The left-hand plot meets both constant variance and linearity 
assumption as the data points are equally distributed in the graph without any pattern 
can be observed. 
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Figure 9: The differences between data meeting both constant variance and 
linearity assumptions (a) and data violating the constant variant assumption (b) or 










          4.2.2 Logistic regression 
 
Logistic regression assumes that: 
 
a) There is a linear correlation between the log of the response variable and each 
 
continuous predictor variable: can be checked the same way as above after creating 
 
scatter plots for each explanatory plot against the log of the response variable. 
 
b) There are no outliers (extreme values) in the continuous explanatory variables: 
 
an observation is said to be an outlier if the absolute value of standardized residual is 
 
>3 (> +3 or > -3). Standardized residual values are calculated by statistical software. 
 
c) There is no high correlation between explanatory variables: variance inflation 
factor (VIF) for each explanatory variable has to be < 5 to exclude multicollinearity. 
(a) (b) (c) 
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                       4.3 Interpretation of the main elements in regression model outputs  
 
                        The simple regression is expressed in the equation: 
 
Y variable = α + β*X variable. 
 
The output calculates both the intercept (α) and the slop (β) of the population 
regression line. This enables the prediction of Y for a known X value, such as 
predicting drug clearance (Y) for a patient weighing 75 Kgs (X). 
The main elements of a regression model outputs are: 
 
a) P-value of the explanatory (X) variable: this tests the null hypothesis that the 
explanatory variable is not associated with the phenotype of interest in        
Y-axis (H=0). For a single test analysis (e.g. 1 SNP vs. 1 phenotype), the p-
value significance level is <= 0.05. In case of testing multiple hypotheses 
(e.g., 50 independent SNPs for 1 phenotype), the p-value significance level is 
modified by Bonferroni correction to be: 0.05/number of tests (e.g., 0.05/50 = 
0.001 for the above example). If the p-value is below the significance 
threshold, then we have sufficient evidence to reject the null hypothesis that 
there is no association and accept the alternative hypothesis that there is an 
association between the studied variable and the phenotype (H≠0). 
 
 
b) β (coefficient/estimate) value: this represents the size of the effect associated 
with each explanatory variable. The 95% confidence interval (CI) range    
[y1-y2] of the value is also usually calculated. If the β = 0.34 and 95% CI = 
[0.15-0.60], Y = drug clearance, X = patients' weight, p=0.003, then this 
could be interpreted by mentioning that we are 95% confident that average 





between 0.15-0.60 with our best estimate of 0.34 litre/hour for every 1 kg 
increase in weight. This can be generalized into: we are 95% confident that 
average "Y'' of the sample increases/decreases by "β" units for every one 
unit increase in "X". This interpretation applies for the simple, multiple, and 
multilevel regression models whilst noting that the other explanatory 
variables in multiple or multilevel models are constant. In the logistic 
regression model, the β value represents the odds ratio (OR) which is 
usually calculated with its CI. The OR can also be converted into a 
percentage to deliver another way of interpretation by using the absolute 
result of the equation: (OR * 100)-100. If the explanatory variable is 
continuous, then this could be interpreted as one unit increase in the 
explanatory variable is expected to increase/decrease the odds of the risk 
factor in the Y-axis by OR times or percentage. If the explanatory variable is 
categorical, then one or more of the categories would be OR times more/less 
likely to experience the risk factor in the research question. 
 
c) R-square (coefficient of determination): this value shows the percentage of 
the variability in "Y" which can be explained by variation in "X". If R-square 
= 90% for the above example; this implies that 90% of the variability in 
clearance is explained by the variability in weight. As R-square increases 
with adding multiple variables in the model, the adjusted R-square value is 




                        4.4 Utilization of regression models in this thesis. 
 
In this thesis, particularly in chapters III and IV, I have utilized the logistic regression 
model for most analyses since our main outcome variables were categorical (On the 
drug/drug combination (Yes/No), drug-stop (Yes/No), dose-decrease (Yes/No)). In 
chapter V, I have used a continuous outcome variable (systolic blood pressure (SBP)) 
in two different ways: one time as a single measurement per patient (e.g., mean SBP) 
and once as two measurements per patient (e.g., mean SBP pre-and post-treatment). 
Therefore, a multiple regression model was used for the first case, and the mixed 
effect model was used in the second case. "Lm ()" and "glm ()" functions in the 
"stats" package in R are usually used for multiple and logistic regression analysis 
respectively. However, I have utilized more sophisticated functions 
("WGassociation()" and "association()" ) under "SNPassoc" R package, which are 
specially designed for genetic analysis. The analysis for both categorical (e.g., 
cases/controls) or quantitative (e.g., SBP) outcome variables can be run using these 
functions to provide the results under any genetic model of interest (which have been 
explained previously in sub-section 3.7 of this chapter). Beside p-values, the results 
given are "ORs" (for categorical outcome variables) or "mean difference" (for 
quantitative outcome variables) with their 95% CI. Regarding the multilevel (mixed) 
regression model, it can be fitted using "Lme()" or "Lmer()" functions under "nlme" 
or "lme4" packages respectively. While these packages do not compute p-values, 
"Lmer()" function under "LmerTest" package provides p-values in the model and is 
the package used in chapter IV.
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5. Defining drug response phenotypes. 
 
                    5.1 In a cross-sectional cohort (the UKBB) 
 
I started this PhD project in March 2017 when the prescribing data for the UKBB 
cohort were cross-sectional. As certain drug response phenotypes such as dose 
change, drug-stop, or changes in clinical measurements cannot be defined using 
prescribing data collected from patients once and without a follow up, defining drug 
response or intolerance is not directly possible. However, it is possible to infer a 
tolerant/efficacy phenotype using the information about genotype distribution after 
applying assumptions underlining the HWE principle (review section 3.5). For 
instance, if the main interest was studying the association between a specific single 
nucleotide polymorphism (SNP) and statin-induced myopathy in the absence of 
longitudinal prescribing data, clinical measurements (e.g., creatine kinase), and GP 
reports about this side effect, the genotype distribution can be used to detect 
deviation away from HWE. According to the HWE principle, the random selection 
of any two groups within the same population will show no difference between 
them in the allele and genotype frequency. However, if the presence of a particular 
allele causes a person to stop the statin, then that allele will be underrepresented 
amongst statin users compared to the unselected population, i.e. there will be 
deviation away from HWE. Similarly, if that allele is associated with good response 
to statins, the allele will be over-represented in the statin-treated group. Therefore, 
HWE calculations should only performed on controls. In controls, there is no 
identifiable risk factor which could affect the distribution of the variant allele and, 
therefore, any deviation from HWE could be more likely explained by the presence 
of genotyping errors or different ethnicities. In contrast, deviations from HWE in 
cases, could be more likely explained by the presence of the risk factor rather than 






The drug response phenotypes recognized by this method would be classified into two 
categories, as follows: 
a) Increased therapeutic efficacy phenotype: this occurs when the variant 
allele found to be highly distributed within the drug users compared to non- 
users. 
 
b) Drug resistance/switch or increased toxicity phenotype: this occurs when 
the variant allele found to be significantly lower within the drug users 
compared to non-users. 
 
Figure 10 below displays different scenarios of drug response phenotypes based 




However, increased or decreased the distribution of the variant allele among drug 
users are not always a reflection of changes in drug response as these might also 
reflect an association with diseases for which the drug is prescribed for. For example, 
if a genetic variant was observed overrepresented among statin users, this wouldn't 
necessarily imply that this variant is associated with increased statin response; it may 
also imply that this variant could be associated with increased risk of hyperlipidemia. 
To deal with this issue, we investigate significant hits from the UKBB for their 
associations with diseases (this will be explained later in section 6.3 of this chapter) 
and also, we examine the same drugs using different and more accurate phenotypes 
identified from the longitudinal prescribing data from the combined cohort which is 
explained in the next section. 
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Figure 10: The differences in the genotype distributions between two 
random samples (8-a) (the normal situation) and two samples one of which 












Figure (8-a): When two samples (1 and 2) are selected randomly from the same population, 












Figure (8-b): Sample (2) is intentionally selected to include users of a specific drug. Aa and aa genotype carriers 
were highly tolerant of the drug, which results in an increased distribution of these genotypes in this sample 













Figure (8-c): Sample (2) is intentionally selected to include users of a specific drug. Aa and aa genotype carriers 
were intolerant to the drug, which results in a reduction in their distribution in this sample compared to the 







                        5.2 In longitudinal cohorts (GoDARTs, GS, and GoSHARE ). 
 
There are different methods to define drug response phenotypes given the availability 
of follow-up prescribing data. Depending on the nature of the research, phenotypes 
can be either general or specific to the drug of interest. 
We were interested in studying drug-gene and drug-drug-gene interactions of most 
commonly used drugs in the UK. As we aimed to investigate all common drugs but 
not only a specific drug class, we needed a method to define drug response which 
could be generalized to all different drugs. The most suitable phenotypes in this 
situation were a “drug-stop” or “dose-decrease” phenotype. If statistically significant 
findings emerge from this approach, then a more targeted drug-specific approach was 
used, for example, anti-hypertensive efficacy for blood pressure drugs. General 
(“drug-stop” and “dose-decrease”) and drug-specific response phenotypes for both 
drug-gene and drug-drug-gene interaction studies are illustrated below. 
          5.2.1 General drug response phenotypes: drug-gene interactions study. 
 
 
Stopping the drug would indicate experiencing intolerable side effects, lack of 
therapeutic efficacy, or both. Decreasing the dose may be a sign of toxicity 
(necessitating dose reduction) or marked efficacy (potentially causing symptoms or 
signs of overtreatment). 
For the ‘drug-stop’ phenotype, cases were those who only had one prescription of a 
drug that is usually prescribed chronically; controls were those who received two or 
more prescriptions of the same drug since prescribed (tolerability indicator). For all 
drugs examined, we observed that the majority of controls per drug receive 3 or more 
prescriptions of the same drug after the first prescription. 
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In general, side effects which could require dose reduction could occur any time after 
treatment initiation. They may occur directly, a couple of months after, or even one 
or more years after starting the treatment. Therefore, for "dose-decrease" phenotype 
any patient is considered a case when a reduction in his/her daily dose is observed at 
a certain point of time during the treatment period. Patients on the same treatment 




          5.2.2 General drug response phenotypes: drug-drug-gene interactions study. 
 
A similar approach to defining drug-stop and dose-decrease phenotypes was applied 
to drug-drug interaction studies. After identifying patients who have concurrently 
prescribed the drug combinations of interest, they are classified into cases and 
controls. Those who have been prescribed drug 1 or drug 2, which are both known to 
be used chronically, only once and this single prescription has been prescribed during 
the period of taking the other drug (the interaction time) are considered cases. The 
control group represents all other patients who are on the same drug combination but 
have never stopped any of the two drugs during the interaction time (as indicated by 
two or more prescriptions-for all combinations, the majority of controls we observed 
had 3 or more prescriptions of either of the two drugs during the interaction time). 
Similarly, for the dose-decrease phenotype, individuals who have reduced the daily 
dose of any of the two drugs during the interaction time are considered cases while 
those who do not reduce the daily dose of any of the two drugs during the period, they 
are co-prescribed are considered the control group. 
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In the clinical sitting, the undesirable drug-drug interaction outcomes can be dealt 
with by either stopping or reducing the dose of either the perpetrator or the victim 
drug. If the interaction is known, the decision regarding which drug to stop or to 
reduce its dose depends on the individual patient's needs. In some cases, the 
undesirable outcome might have happened due to unknown DDI, and in this 
situation, the prescriber is more likely to make modifications to the last added drug. 
For either of the above scenarios, modifications can occur for drug 1 or drug 2, and 
this is why we have considered our case groups to represent those who have 
experienced the phenotype of interest considering both drugs. 









Figure 11: Methods for defining drug-stop phenotype for drug-gene (a) and drug-drug-gene (b) interactions 
studies. Cases (who stop drugs) are those prescribed a chronic drug once while controls are those who have 
been prescribed the same drug multiple times. In the drug-drug-gene interaction study, stopping the drug 
occurs during the interaction time with the other drug. Cases include those who stop drug 1 during treatment 
with drug 2 and those who stop drug 2 during treatment with drug 1. 
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Figure 12: Methods for defining the dose-decrease phenotype for drug-gene (a) and drug-drug-gene (b) 
interaction studies. Cases are those who have decreased their daily dose at a certain point of time while 
controls are those who have never decreased the dose. In the drug-drug-gene interaction study, dose reduction 
should occur during the interaction time with the other drug. Cases include those who decrease drug 1 during 






Having identified cases and controls as per the above definitions, a case-control 
genetic association analysis can be then run to test the association between the SNPs 
of interest and the drug/drug combination of interest considering the two drug 




           5.2.3 Defining SBP response: drug-gene interactions study. 
 
Figure 13 below demonstrates the model fitting for studying SBP response in drug-
gene interaction studies. 
Having identified potential drug-gene interactions in the longitudinal combined 
Scottish cohort, the arrival of a larger longitudinal primary care data for UK Biobank 
late in my PhD studies, enable me to validate signals of interest. The phenotype of 
interest was systolic blood pressure reduction in response to antihypertensive agents. 
I included white-British individuals where systolic blood pressure measurements are 
available for them one year before and year after starting the treatment of interest. 
This one-year window specification reduces the effect of other potential anti-
hypertensive agents prescribed for the same patient. Then, mean systolic blood 
pressure is calculated for each patient for all measures in the pre-treatment, and again 
in the post-treatment year. A multiple regression model was then used to study the 
influence of the genetic variant of interest on the blood pressure response to the drug. 
The outcome (Y) continuous variable was the mean systolic blood pressure one-year 
post-treatment. The explanatory variables were the mean systolic blood pressure one- 
year pre-treatment (to adjust for the drug-only effect) and the SNP of interest 
(categorical genotypes) adjusted by age and sex. 
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Figure 13: Visual representation of outcome and explanatory 
variables included in the multiple regression model to study the 







          5.2.4 Defining SBP response: drug-drug-gene interactions study. 
 
Figure 14 below illustrates steps I followed to study blood pressure changes following 
a certain drug-drug-gene interaction. 
I employed two approaches to investigate drug-drug-gene interactions for systolic 
blood pressure (SBP) reduction. In the first approach, I was interested in what 
happened to the SBP in those treated with the antihypertensive of interest (victim 
drug) who started an interacting (perpetrator) drug. Initially, all patients on the drug 
combination of interest were identified. From these only those who started the anti-
hypertensive drug first who subsequently added the perpetrator drug were included. 
This ensured that a stable on-treatment SBP could be defined before initiation of the 
perpetrator drug. Even though this model resulted in a large reduction in sample size, 
the benefits are of a clean within-person response to the addition of the perpetrator 
drug. The mean SBP 1 year before starting the antihypertensive drug, the mean SBP 
in the first year after initiation of antihypertensive drug alone and before adding the 
perpetrator drug, and the mean SBP after adding the perpetrator drug to the 
antihypertensive drug were then calculated. As two SBP measurements are being 
compared from the same patient (i.e., before and after adding the perpetrator agent), 
these are considered dependent measurements which violate the assumption of 
independence in a regression model. Therefore, a linear mixed-effect model was used 
in this case. The outcome (Y) variable was mean SBP after the antihypertensive drug 
(taken as two measurements per patient within 1 year: the first one is while on the 
victim (antihypertensive) drug only and the second one is after adding the perpetrator 
agent to the victim drug). The explanatory (X) variables were mean SBP one year 
before the antihypertensive drug (to adjust for the effect of SBP levels before starting 
the antihypertensive), the treatment context (whether the mean SBP is during the 
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antihypertensive drug alone or after adding the perpetrator drug), age, and sex. The 
resulting significance of the "treatment context" variable will show if there is a 
significant difference in SBP levels before and after adding the perpetrator agent to 
the antihypertensive drug. 
Having examined the changes in SBP from measurements taken from the same 
patient, a second model was then developed for the purpose of increasing the sample 
size. In this model, two groups are defined – those treated with the antihypertensive 
alone, and those treated with the combination of antihypertensive and perpetrator 
drug. For the first group, all patients on the victim drug alone (i.e., have no preparator 
drug) are included and mean SBP 1 year after treatment is calculated. For the second 
group, all patients who started the perpetrator drug first and then added the victim 
(i.e., antihypertensive) drug are included. Mean SBP is calculated for these patients 
during the interaction time (i.e., after adding the antihypertensive drug to the 
perpetrator drug and within 1 year of interaction). Then I compare the SBP changes 
between these two groups. Although there is some inaccuracy of this phenotype as 
measurements are taken from different patients, we benefit from the advantage of 
greatly increasing our sample size as the first group includes all patients on the 
antihypertensive drug rather than only those who started the antihypertensive agent 
before adding the perpetrator agent as in our first model. We benefit from the large 
sample size in order to see if we can replicate the results from the first model and 
most importantly, to have enough sample for the drug-drug-gene interaction study. 
Our response and explanatory variables are the same as of the first model, but the 
difference is that in the first model, I compare SBP changes from the same subject 
while in the second model I compare SBP changes between two groups of patients.  
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As in the second model SBP measurements are taken from different subjects, these 
measurements are considered independent values. Therefore, a normal multiple 
regression model can be used here. The outcome (Y) continuous variable was mean 
systolic blood pressure after the victim drug (for two groups of patients, as explained 
above). The explanatory variables are mean systolic blood pressure 1 year before the 
antihypertensive drug (to adjust for both SBP levels before starting the 
antihypertensive drug for the first group and also to adjust for SBP levels just before 
the interaction time for the second group), a categorical variable answering the 
question whether the mean SBP belongs to group1(on the victim drug only) or group 
2 (on the combination) patients, the SNP of interest as a 3-level categorical variable, 
age and sex. The model is first run without the genotype data to identify the effect of 
the drug-drug interaction on SBP; then genotype is added in to study its effect on 
changing SBP levels between the two groups. 
Assessing compliance to the treatment in both cross-sectional and longitudinal 
prescribing data is quite challenging. In the cross-sectional data, there is no way to 
recognise this as no follow-up prescribing data are available. In the longitudinal 
prescribing data, compliance could be assessed via observing whether or not the drug 
is regularly prescribed for the same patient. However, this is a weak indicator for real 
compliance to the treatment as simply the drug can be dispensed but the patient is not 
actually taking his/her treatment regularly. In fact, non-compliance to long-term 
therapies is a very common issue in clinical practise. On the other hand, if the 
prescribing data shows irregular prescribing of a specific drug, this doesn't 
necessarily imply non-adherence as, for example, patients could move out of the area. 
Overall, we might be able to only define a measure of "coverage" but a real-world 
evaluation of compliance cannot be simply obtained from our data. 
…………………………………………………………            
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Step 3: Studying the 
influence of the 
genotype of interest on 
SBP changes between 
the two groups. 
Step 2: Further 
investigation for step 1 
results with a different 
model by comparing 
blood pressure changes 
between 2 groups: those 
on the victim drug alone 
and those on the 
perpetrator drug + the 
victim drug. 
Step 1: Examining 
whether there is a 
significant drug-drug 
interaction influencing 
blood pressure levels 
occurring after adding 
the perpetrator drug to 




                        5.3 Utilization of our drug response phenotypes in our project. 
 
In chapters III and IV, I have mainly used genotype distribution changes (UK 
Biobank cross-sectional data), and drug-stop and dose-decrease phenotypes (Scottish 
cohorts) and studied their associations with a selected group of genetic variants 
(focused on pharmacokinetic variants). In chapter V, beside drug-stop and dose- 
decrease phenotypes, I have used the change in Systolic Blood Pressure (SBP) 
phenotype (UK Biobank primary care data) for further investigation for some of our 
findings from chapters III and IV. 
 
 
 6. Auxiliary databases 
 
 
These are the databases which were used as helpful tools in this project. Although the 
main findings in this thesis are not directly dependent on these resources, they were 
used to identify variables to be incorporated into the models or used in validation. 
Here I describe three auxiliary databases utilized in our work with clarifying 
how/where they have been used. 
                       6.1 DrugBank database 
 
The database description below has been summarized from reference 124. 
 
 
DrugBank (https://www.drugbank.ca/) is a huge comprehensive database on drugs 
 
and is one of the most widely used worldwide. It started in 2006 by presenting 
chemical and physical properties of drugs approved by the FDA. The second 
release in 2008 included pharmacological and some pharmacogenomic data. In 
2010, pharmacokinetic data with drug classification into substrates, inhibitors, or 
inducers for metabolizing enzymes or transporters were added. The fourth release 
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in 2014 added a large amount of data on drug metabolism and structure-activity 
relationship. The final major update in 2018 added 522 newly FDA-approved drugs 
with dramatic improvements on the information available in all areas mentioned 
above with other new enhancements. The resource is well referenced with hundreds 
of published papers supporting the information available. 
The main purpose of utilizing DrugBank in this project was in chapter IV as it 
enabled us to identify potential routes of PK interaction for the common drug 
combinations in the UK. This can be achieved using the information on classifying 
drugs into substrates, inducers, or inhibitors. I used DrugBank at the beginning of this 
project in 2017 at the time when the last update about pharmacokinetic drug 
interactions information was released in 2014 (the 4th release) before the last update in 
2018. In 2014, the number of identified metabolizing enzymes and transporters was 
253 before it doubled in the last update into 497 reflecting that many novel drug- 
interactions were not recognized, and future research is likely to uncover even 
more. 
I have also used the database for another purpose in chapters III and IV. It helped to 
identify whether the gene, in which a genetic variant connected with the use of a 
certain drug was detected, belongs to a metabolizing enzyme or a transporter related 
to the drug of interest (i.e., the drug is a substrate for the gene product). 
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                      6.2 Pharmacogenomic knowledge database (PharmGKB) 
 
The database description below has been summarized from references 125 and 126. 
 
 
PharmGKB (https://www.pharmgkb.org/) is a large well-known dataset specializing 
 
in pharmacogenomic studies and their clinical impacts. It started in 2000 and is 
continuously updated as new research emerges. The dataset contains over more than 
600 drugs and describes more than 100 pharmacokinetic or pharmacodynamic 
pathways related to variability in drug response. 
The drug-gene associations are classified into 4 categories in PharmGKB as follows: 
 
Level 1A evidence: 
 
Represents associations which have been already translated into clinical practice or 
outlined by the Clinical Pharmacogenetics Implementation Consortium (CPIC). 
Level 1B evidence: 
 
Shows associations which have been replicated multiple times in different cohorts. 
 
Level 2A evidence: 
 
This category is related to associations found with very important genetic variants 
which are more likely to be functional variants. 
Level 2B evidence: 
 
Here are associations which have conflicting results or with small effect size. 
 
Level 3 evidence: 
 
Under this level are significant findings from a single paper which are not replicated. 
 
Level 4 evidence: 
 




The main purpose of PharmGKB in this project was in chapter III to select the 
candidate genetic variants. As shown above, the resource provides an informative 
collection of genetic variants which have been previously linked to at least a single 
drug response phenotype, or where there are no publications specifically related to 
drug response but the variant could be a potential variant affecting drug response 
based upon in-vitro or in-silico models. I extracted all of the potential variants related 
to PK pathways from this database. 
The other purpose of using PharmGKB was also in chapter III and IV when it helped 
us to identify whether any of our significant drug-gene associations had been 
identified previously, as recorded in the database. 
                          6.3 GeneATLAS database 
 
The database description below has been summarized from reference 127. 
 
 
The GeneATLAS dataset (http://geneatlas.roslin.ed.ac.uk/) is a rich resource of trait- 
 
variants associations. It is a result of a study conducted by Edinburgh University 
research team who used a cohort of 452,264 European participants from the UKBB 
study and performed genome-wide association study (GWAS) to test the association 
between 778 different traits and over more than 30 million variants (9,113,133 after 
quality control filtration). Each set of traits, non-binary (n= 118) and binary (n = 660) 
were tested against the 9,113,133 variants with a genome-wide significance level of  
< 1x10-8 for all traits. 
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In chapters III and IV, I used GeneATLAS as an investigational tool for our findings 
from the UKBB cross-sectional data. As discussed earlier, comparing those on the 
drug/drug combination (cases) with those who are not (controls) could yield 
significant results that reflect the indication for the drug (i.e., disease risk) rather than 
drug intolerance or efficacy. Therefore, I used GeneATLAS to investigate whether or 
not the significant SNP detected was linked with any of the disease phenotypes rather 




























Drug-Gene Interactions for the Most 
Commonly Used Chronic Drugs in the UK 
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     Abstract 
 
There has been increasing research in pharmacokinetic drug-gene interactions over 
the last few years. However, our knowledge in this area remains limited, given the 
large number of drugs entering the market annually and the multiplicity of elimination 
pathways for each drug. In the present study, we attempted to discover novel and 
clinically important drug-gene interactions among commonly used chronic drugs in 
the UK. We studied the associations between 50 common chronic drugs and 162 
selected genetic variants in important enzymes and transporters. We utilised two 
cohorts: a combined cohort of longitudinal prescribing data for three Scottish cohorts 
and the UK Biobank cross-sectional prescribing data. In the combined longitudinal 
cohorts, the drug-variant combinations were studied in relation to drug-stop or dose- 
decrease phenotypes while in the UK Biobank cross-sectional data, we compared the 
genotype distribution between drug users and non-users. 
8 novel drug-gene variants were identified in the combined longitudinal cohorts, and 
4 novel drug-gene variants were identified in UK Biobank. From the combined 
cohort, users of ramipril or metformin who carry the rs1135840 (G>C) CYP2D6 or 
rs1045642 (A>G) ABCB1 variants respectively were less likely to stop their treatment 
per allele: (OR (95%CI)) Ramipril/CYP2D6 0.7 (0.6-0.82), p=1.01 × 10-5; 
Metformin/ABCB1 0.75 (0.64-0.87), p=1.636 × 10-4 . On the other hand, those with 
the C allele at rs152023 variant in ABCC1 were more likely to stop nifedipine per 
allele OR 1.32 (1.15-1.53), p=1.168 × 10-4. Those with the A allele at rs5788 variant 
in PTGS1 were more likely to stop nicorandil treatment per allele OR 1.93 (1.39- 
2.69), p= 1.718 × 10-4. 
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Regarding the dose-decrease phenotype, carriage of the rs4918758 (T>C) CYP2C9 , 
rs9895420 (T>A) ABCC3, or rs868853 (C(minor allele)>T) ABCC4 minor alleles have 
been observed to be associated with decreased likelihood to reduce the dose of 
quinine OR 0.71 (0.6-0.85),p=8 × 10-5; doxazosin OR 0.54 (0.38-0.76), p= 1.2 × 10-4; 
amlodipine OR 0.55 (0.4-0.75), p= 2.8 × 10-4 respectively. The rs7916649 (T>A) 
CYP2C19 mutation was found connected with higher odds to decrease valproic acid 
dose (OR = 1.95 (1.37-2.76), p=1.475 × 10-4). 
The results from the UKBB cohort showed a decreased frequency of the minor 
alleles of rs555754 (G>A) SLC22A3, rs3743527 (C>T) ABCC1, or rs8187843 
(G>A) ABCC1 variants among users of lansoprazole OR 0.95 (0.93-0.97),p= 1.58 × 
10-5; bendroflumethiazide OR 0.95 (0.93-0.98),p= 4.87 × 10-5; or gabapentin OR 
0.78 (0.68-0.89),p= 2.12 × 10-4 respectively. Similarly, the minor allele frequency 
of rs2231135 (A>G) in ABCG2 was increased in rosuvastatin users (OR = 1.22 
(1.1- 1.35), p= 3.02 × 10-4). 
Finally, in an important validation of the method used, a number of previously 
reported drug-gene interactions were replicated. We also show other novel and 
potentially important associations. 
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   1. Introduction 
 
Adverse effects or loss of therapeutic efficacy are commonly seen after the initiation 
of new drug treatment. Many factors contribute to the risk of these adverse 
outcomes, including age, sex, weight, and drug-drug interactions (DDIs). 
DDIs can occur by two different processes: Pharmacodynamic (PD) or 
Pharmacokinetic (PK). PD interactions are mostly predictable, and therefore can be 
highly avoidable, as they include interactions between drugs with similar or opposing 
pharmacological effects resulting in increased toxicity or treatment failure, 
respectively. PK interactions, however, can occur between any combination of 
medications regardless of their pharmacological action, which make them more 
challenging to predict and avoid. These interactions occur when the precipitant drug 
influences the concentration of the object drug via affecting its absorption, 
distribution, metabolism, or excretion by inhibiting/inducing its metabolizing 
enzymes or transporters. In chapter I, I have shown the distribution of important 
transporters in different tissue types. PK interactions can also occur when patients, 
instead of being co-treated with the precipitant drug, carry reduced or increased 
activity genetic variants in these metabolizing enzymes or transporters. 
 
 
There has been an increasing number of drug-gene interaction studies in recent years. 
The recent update (2020) from Pharmacogenomic Knowledge Base (PharmGKB) 
(described in chapter II) shows ~ 23,000 published studies with 4,326 genotype-based 
clinical annotations presenting genotype-related differences in drug response (i.e. 
efficacy and toxicity). In addition,139 clinical guidelines for some drugs related to 
dosing recommendations are now available in the database. Of note, to date, there 
have been 321 drugs receiving pharmacogenomic labels from the Food and 
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Drug Administration (FDA) stating whether testing for a specific genetic variant is 
required, recommended, or not necessary before drug initiation. 
In spite of these recent advances, the knowledge on PK drug-gene interactions is still 
limited. Given the large number of drugs with new drugs available regularly and the 
presence of multiple elimination pathways for a single drug, it is nearly impossible for 
us to have DGIs studies performed on every single drug covering all of its different 
elimination pathways. Therefore, currently used drug-interaction tools mainly report 
"potential" rather than actual interactions based on clinical studies. In addition, some 
important interactions could be totally ignored in pharmacogenomic studies as the 
entire routes of drugs' absorption and elimination are not fully uncovered giving the 
fact that new drug targets are appearing from time to time. Thus, most of the current 
work on DGIs focus only on well-known drug absorption/elimination pathways and 
genetic variants. 
In this study, I aimed to uncover novel clinically important interactions between a 
large variety of commonly prescribed chronic medications and selected group of 
genetic variants in important metabolizing enzymes and transporters by utilizing four 
different UK cohorts. I begin by a brief description of the cohorts before discussing 
the methodology and results. 
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     2. Study populations 
 
Four cohorts have been utilized in this study which are: the UK Biobank (UKBB), 
Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTs), 
Generation Scotland: Scottish Family Health Study (GS:SFHS), and Genetics of the 
Scottish Health Research Register (GoSHARE). All of these cohorts have been 
prescribed in chapter II. In this chapter, the Scottish longitudinal cohorts (with ~ 27K 
participants) and the UKBB cross-sectional cohort (with ~ 500K participants) will be 
utilized to generate the discovery findings for our drug-gene interactions study. 
 
     3. Methodology 
 
The methods are summarized in the five steps below: 
 
                         3.1 Selection of commonly used drugs for inclusion 
 
The cross-sectional prescribing data from the UKBB study was utilized to identify the 
most frequently prescribed drugs for around 500,000 patients. More than 3100 drugs 
were observed as prescribed across the UK Biobank at least once. 48 drugs had 
duplicates, each of which has been recorded in different writing formats and were 
assigned different UKBB codes. A single format and UKBB code were selected, and 
the total drug frequency considering all of the different formats was calculated. 
Defining the common drugs as the drugs used by no less than a thousand participants, 
I have produced a list of the top 122 most frequently used drugs in the UK. From this 
list, we have selected the top common 50 drugs which are known to be used 
chronically (i.e., drugs which are commonly indicated for long-term use such as but 
not limited to antihypertensive, antilipidemic, and antidiabetic agents) rather than 




natural products and supplements, hormonal replacement treatments, eye drops, 
drugs in gel formulations, and inhalers. The list of the top 50 chronic drugs selected 
to be the target of our study are listed in Table 3 below. 
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Table 3: List of top 50 commonly 
used chronic drugs in the UK. 
 





















































Table 4: List of 36 important selected genes 
which could affect drug response. 
 
                      3.2 Selection of candidate genetic variants 
 
Figure 15 below clarifies the selection process of candidate genetic variants used in 
this chapter and subsequent chapters. 
 
          3.2.1 Identifying the initial list of candidate SNPs. 
 
In brief, we selected 34 genes from DrugBank that encoded all common drug-
metabolizing enzymes or drug transporters (see chapter I) or were not very common 
but affect at least one of the 50 selected drugs (i.e. the drug is a substrate for the gene) 
; 2 additional genes encoding relevant enzymes (PTGS1(COX-1) and CES1) were 
also included as they affect some important cardiovascular agents we selected in our 
study (see Table 4). 757 genetic variants in these 36 genes were extracted from 
PharmGKB (https://www.pharmgkb.org/downloads ). The genotype data for 156 SNPs were 
not available in any of the cohorts: GoDARTs, GS, GoSHARE, and the UKBB as 




    The selected genes     
ABCB1 ABCC1 ABCC2 ABCC3 ABCC4 ABCC5 ABCG2 CYP1A1 CYP1A2 CYP1B1 
CYP2A6 CYP2B6 CYP2C18 CYP2C19 CYP2C8 CYP2C9 CYP2D6 CYP2E1 CYP3A4 CYP3A5 
CYP3A7 SLC22A1 SLC22A11 SLC22A2 SLC22A3 SLC22A4 SLC22A5 SLC22A6 SLC22A8 SLCO1A2 




          3.2.2 SNPs selection based on MAF (>=0.05) and HWE (p >= 1*10-8) criteria. 
 
For the GoDARTs cohort, the genotype data were available for 509 out of 601 SNPs. 
The minor allele frequency (MAF) for each of these 509 SNPs was calculated with 
320 SNPs fulfilling the MAF condition of >= 0.05 (retaining two SNPs with MAF 
below than but very close to 0.05 as these passed MAF condition in the other two 
cohorts). Two of these SNPs were not in HWE (rs113667357 and rs59502379, p<= 
1*10-8) and were excluded. 
 
 
For the GS cohort, the genotype data were available for 455 SNPs. 322 SNPs had a 
MAF >= 0.05 (retaining one SNP with MAF below than but very close to 0.05 as it 




For the GoSHARE cohort, the genotype data were available for 509 SNPs. 312 SNPs 
had a MAF >= 0.05. All of the 312 SNPs passed HWE criteria. 
 
 
For the initial analyses, the three cohorts were combined together resulting in a 333 
SNPs, although 2 SNPs (rs2070676 and rs2515641) were now out of HWE and were 
excluded resulting in a total of 331 SNPs. 
 
 
           3.2.3 SNPs selection based on LD test results (r2 < 0.5). 
 
The SNPs were then pruned to retain independent SNPs, with r2<0.5. Initially, the 
pairwise correlation was assessed, with 53901 SNP pairs being considered 
independent, and 714 SNP pairs being correlated. To prune the 331 SNPs,  
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I first reviewed "Very Important Pharmacogenes (VIPs)" summaries from PharmGKP 
[128]. These summaries provide information on important variants which have been 
shown to affect drug response. PharmGKB included these variants based on many 
resources including the table of pharmacogenomic biomarkers issued by the Food and 
Drug Administration (FDA) (https://www.fda.gov/drugs/science-and-research-drugs/table-
pharmacogenomic-biomarkers-drug-labeling ), CPIC (https://cpicpgx.org/alleles/ ) , and the 
Pharmacogenomic Research Network (PGRN , https://www.pgrn.org/ ). After reviewing 
all VIPs summaries for all selected genes, I have identified 26 important genetic 
variants to be retained in my analysis (e.g., the known ‘classic’ variants such as 
CYP2C9*2 and *3). After comparing this list of 26 SNPs with the list of SNPs from 
the EU "Ubiquitous PGx (U-PGx)" (https://upgx.eu/wp-content/uploads/2018/08/Deliverable-
D2.1UPDATED_P6-KNMP.pdf ), I found that all of my selected SNPs are included in this 
list of SNPs (U-PGx) as long as they fulfil my selection criteria ( MAF >= 5% in the 
European ancestry). In my list of 331 SNPs, I have identified 82 variants to be 
correlated to at least one of these 26 SNPs and were not recognised as important 
variants by PharmGKB. These have been removed from my analysis. Table 5 below 
illustrates more details on the 26 important variants selected in our analysis. 


























No. Gene rsid * allele ChromosomeAmino acid [codon] change *
Codon number 
(nucleotide change)* Variant class *
Enzyme/transporter 
function *
1 ABCB1 rs1045642 *2/*13 7 I [ATT] > M [ATG] 3645(T>G) Missense Conflicting findings 
2 ABCB1 rs1128503 NA 7 G [GGT] > G [GGC] 1446(T>C) Synonymous Conflicting findings 
3 ABCB1 rs2032582 NA 7 S [TCT] > A [GCT] 2887(T>G) Missense Conflicting findings 
4 ABCG2 rs2231142 NA 4 Q [CAG] > E [GAG] 421(C>G) Missense Decreased 
5 CYP1A2 rs762551 *1F 15 NA NA Intron Increased 
6 CYP2A6 rs28399433 *9A/*9B/*13/*15 19 NA NA Upstream Decreased 
7 CYP2A6 rs8192726 *9b 19 NA NA  Intron Decreased 
8 CYP2B6 rs2279343 *4 19 K [AAG] > R [AGG] 785(A>G) Missense Increased 
9 CYP2C19 rs12248560 *17 10 NA NA Upstream Increased 
10 CYP2C19 rs4244285 *2 10 P [CCG] > P [CCA] 681(G>A) Synonymous No function
11 CYP2C8 rs10509681 *3 10 K [AAA] > R [AGA] 1196(A>G) Missense Increased 
12 CYP2C8 rs1058930 *4 10 I [ATC] > I [ATT] 792(C>T) Missense Decreased 
13 CYP2C8 rs11572080 *3 10 R [AGG] > M [ATG] 416(G>T) Missense Increased 
14 CYP2C8 rs17110453 *1C 10 NA NA Upstream Conflicting findings 
15 CYP2C8 rs7909236 *1B 10 NA NA Upstream Increased 
16 CYP2C9 rs1057910 *3 10 I [ATT] > L [CTT] 1075(A>C) Missense No function
17 CYP2C9 rs1799853 *2 10 R [CGT] > C [TGT] 430(C>T) Missense Decreased 
18 CYP2D6 rs1065852 *10 22 P [CCA] > S [TCA] 100(C>T) Missense Decreased 
19 CYP2D6 rs1135840 *2 22 S [AGC] > T [ACC] 1457(G>C) Missense Normal function
20 CYP2D6 rs16947 *2 22 R [CGC] > C [TGC] 886(C>T) Missense Normal function
21 CYP2D6 rs28371725 *41 22 NA NA  Intron Decreased 
22 CYP2D6 rs3892097 *4 22 NA NA Splice Acceptor No function
23 CYP3A4 rs2242480 *1G 7 NA NA  Intron Increased 
24 SLC22A1 rs12208357 NA 6 R [CGC] > C [TGC] 181(C>T) Missense Decreased 
25 SLCO1B1 rs2306283 *1B 12 N [AAT] > H [CAT] 388(A>C) Missense Increased 
26 SLCO1B1 rs4149056 *5 12 V [GTG] > A [GCG] 521(T>C) Missense Decreased 
Table 5: List of 26 important variants involved in drug response as defined by their 
molecular characteristics.   
 
* According to https://www.ncbi.nlm.nih.gov/snp/docs/refsnp_report/helpdoc/. 
  
* Amino acids: I = Isoleucine , M = Methionine , G = Glycine , S = Serine   ,  A = Alanine  ,   
Q = Glutamine , E = Glutamate , K =  Lysine  ,  R = Arginine   , P = Proline   ,  L = Leucine  ,   
C = Cysteine  , T = Threonine  , N = Asparagine  , H = Histidine  , V=  Valine . 
 
* Each codon consists of [3 nucleotides] encoding for a specific amino acid. There are 4 
nucleotides: A = Adenine , T = Thymine , G = Guanine , C = Cytosine.  
 




Secondly, I reviewed the remaining 223 SNPs for pairwise correlation and retained 76 
independent SNPs. Finally, for the correlated SNP pairs (where there was no reason to 
choose one over the other) one SNP was selected at random among any group of 
correlated SNPs (i.e. the SNP might be correlated with one or more SNPs) resulting in 
60 SNPs retained as proxies. Overall, this resulted in 162 independent SNPs (26 + 76 




Having identified our list of candidate variants for use in the combined cohort, I then 
extracted the genotype data for these 162 SNPs for only white British individuals in 
the UKBB cohort (n=408091). Of note, 9 SNPs were found to be of HWE including 
the important variants rs28399433 (CYP2A6*9A), rs16947(CYP2D6*2), rs3892097 
(CYP2D6*4), rs1065852 (CYP2D6*10), and rs1135840 (CYP2D6*2).  
 
However, these 9 SNPs were included in the UKBB analysis for the purpose of 
keeping the consistency, so we have the same list of SNPs across all cohorts. 
 
The final selected 162 SNPs with their MAF and HWE results from all cohorts, as 
classified into the 3 categories of SNPs presented in figure 15 below, are shown in 
supplementary material 2. 
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Figure 15: A summary workflow for the process of selection candidate 






                             3.3 Defining drug response phenotypes 
 
Drug response phenotypes were defined depending on the nature of the 
prescribing data available to us at the time of this study. The approach is outlined 
in detail in chapter II, and therefore only briefly reviewed here. 
In the cross-sectional UKBB data, we looked for a deviation of genotype 
frequencies in those prescribed a particular drug from the total UKBB population. 
In this way, two phenotypes were defined. 
• Increased drug tolerability phenotype: this occurs when the variant allele 
found to be highly distributed within the drug users compared to 
non-users. If those with a specific drug-variant pair are higher, this will 
reflect that this pair was advantageous for these patients in term of increased 
efficacy, low side effects, or both. 
• Decreased drug tolerability phenotype: this occurs when the variant allele 
found to be significantly lower within the drug users compared to non-users. If 
those with a specific drug-variant pair are lower; this would reflect that this 
pair was disadvantageous for these patients in term of decreased efficacy, 
increased side effects, or both. 
Importantly, deviation of genotype frequencies can occur due to the underlying 
disease for which a drug is prescribed and therefore not reflect drug tolerability. 
Therefore, for a variant to be considered potentially associated with drug 
tolerability, it had to not be associated with any known disease traits, which we 
assessed by undertaking a phenome-wide association study (PheWAS) in gene 




In the Scottish longitudinal data, we defined the generic "drug-stop" and "dose- 
decrease" phenotypes (as described in chapter II). Stopping the drug would indicate 
experiencing intolerable side effects, lack of therapeutic efficacy, or both. Decreasing 
the dose may be a sign of toxicity or extreme increase in the efficacy, which would be 
harmful such as sulphonylurea-induced hypoglycemia or warfarin-induced bleeding. 
These phenotypes are more likely to occur among poor CYP2C9 metabolizers. In 
chapter I, for example, I have highlighted that CYP2C9*2/*3 carriers required lower 
warfarin doses to overcome the bleeding risk of this anticoagulant treatment.   
                        3.4 Testing the association between the genetic variants and the phenotypes 
 
Users of each of the selected 50 chronic drugs from both the UKBB cross-sectional 
prescribing data and the combined cohort longitudinal prescribing data (including 
patients from all of the 3 cohorts (i.e. GoDARTs + GS + GoSHARE)) were extracted. 
The case groups from the UKBB were users of a certain drug while controls are those 
not on the drug under investigation. Regarding the combined cohort, for each of the 
50 drugs, users of the drug of interest are divided into case and control groups. The 
case groups are those who stop the drug or those who reduce their daily dose. The 
control groups are those who have never experienced any of these two phenotypes, 
respectively. 
A case-control genetic analysis using a log-additive genetic model was run to explore 
the associations between our 162 selected genetic variants and each phenotype under 
each cohort for all 50 drugs. Given that each drug phenotype was evaluated for 162 




                         3.5 Development of an online database to view the results 
 
Given the large number of results produced, a dynamic, user-friendly online database 
was developed to view all results visually (graphs) or as tables using Caspio software 
( https://www.caspio.com/ ). The user can view and download the results according to 




     4. Results 
 
 
In the combined Scottish data, examining the association between the drug-stop 
phenotype for 50 drugs and 162 genetic variants produced a total of 8,100 results; the 
same number of findings were also generated for the dose-decrease phenotype from 
the combined cohort taking the total findings into 16,200. For the UKBB cross-
sectional cohort, again, 162 variants were compared for 50 drugs producing a total of 
8,100 findings.  
In order to facilitate viewing the results, all results can be accessed via an online 
database under this link: 
https://c1abo933.caspio.com/dp/d81f7000c3c1854d29104a49b1d8 
This application enables the user to select the results of interest from a search form. 
The results can be selected by drug rank, drug name, cohort, phenotype, SNP rsid, 
gene, and/or the p-value threshold. The results are shown in two formats: a dynamic 
summary diagram showing the top hits (genetic variants) according to the p-values 
and a detailed report table for the full results. The user can also download the 
searched results. Figure 16 below shows some screenshots from the application. 
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(c) 
Figure 16: Screenshots from our online application showing 3 main parts for our drug-gene interactions results. For 
example, searching the results using specific criteria such as results significant after Bonferroni correction from the 
























































I have identified 815 drug-gene associations with a nominal significance level 
 
(p <= 0.05) from the combined cohort considering both drug-stop and dose-decrease 
phenotypes. In the UKBB cross-section cohort, 544 findings were identified at this 
nominal p-value. 
For a better representation of the results, we classified the results into 3 categories: 1) 
the associations which have passed Bonferroni significance level; 2) the known drug-
gene associations which have been previously reported; and 3) potentially important 
associations which didn't pass Bonferroni significance level. 




                      4.1 Significant associations after Bonferroni correction (p <=0.0003) 
 
Table 6, at the end of the results section, summarizes all associations under this category. 
 
 
            4.1.1 The combined cohort results (n= 8). 
 
8 novel drug-gene associations passed the Bonferroni significance level. Below I 
begin with a brief description of these findings before showing the replication 
results from the UKBB primary care data later in chapter V. 
 
 
           4.1.1.1 Ramipril-rs1135840 (CYP2D6) 
 
The rs1135840 (G >C, CYP2C6*2) variant at the CYP2D6 gene was associated with 
being less likely to stop ramipril treatment (p=1.01 × 10-5). The C allele is associated 
with 30% (95%CI 18-40%) reduced risk to stop the treatment. 
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           4.1.1.2 Quinine-rs4918758 (CYP2C9) 
 
Carriers of the C allele at rs4918758 (T>C) variant in CYP2C9 had a 29% (95% CI 
15-40%) lower tendency to reduce daily quinine dose per allele (p=8 × 10-5). 
          4.1.1.3 Nifedipine-rs152023 (ABCC1) 
 
Carriers of the minor allele (C) at rs152023 in ABCC1 were 1.32 (1.15 – 1.53) times 
more likely to stop nifedipine treatment per allele compared to TT individuals 
(p=1.168 × 10-4). 
          4.1.1.4 Doxazosin-rs9895420 (ABCC3) 
 
The odds of decreasing the daily dose of doxazosin in those carrying the minor (A) 
allele in rs9895420 ABCC3 SNP was reduced by 46% (95% CI 24-62%) per allele 
compared to non-carriers (TT individuals) (p=1.2 × 10-4). 
           4.1.1.5 Valproic acid- rs7916649 (CYP2C19) 
 
The A allele at rs7916649 (G>A) in CYPC19 was associated with 1.95 (1.37-2.76) 
times increased risk for daily dose reduction of valproic acid (p=1.475 × 10-4). 
           4.1.1.6 Metformin-rs1045642 (ABCB1) 
 
The rs1045642 (A>G) mutation in ABCB1 transporter was associated with a 25% 
(95% CI 13-36%) lower odds of stopping metformin treatment per allele compared to 




             4.1.1.7 Nicorandil-rs5788 (PTGS1) 
 
Those with an A-allele at rs5788 (C>A) variant in PTGS1 gene were 1.93 times 
(95% CI 1.39-2.69) more likely to stop nicorandil treatment per allele (p=1.718 × 
10-4). 
            4.1.1.8 Amlodipine-rs868853 (ABCC4) 
 
There was a large impact of the minor allele (C) at rs868853 variant on amlodipine 
daily dose. Individuals carrying the C allele were 45 % (95%CI 25-60%) less likely to 
decrease amlodipine daily dose per allele as compared to non-carriers (TT 
individuals) (p=2.8 × 10-4). 
 
 
        4.1.2 The UKBB (cross-sectional) cohort results (n=4) 
 
25 drug-gene pairs reached the Bonferroni significance threshold. However, as 
discussed, these may well represent disease associations rather than drug tolerance. 
Using GeneAtlas we identified 21 of these 25 variants were significantly associated 
with the disease for which the drug was indicated, and these are not discussed. 4 
drug-variant associations were not disease associations and may therefore represent 
drug tolerance phenotypes. I describe the results of these four findings below. 
           4.1.2.1 Lansoprazole-rs555754 (SLC22A3) 
 
The A allele at rs555754 (G>A) variant in SLC22A3 gene was significantly lower 
amongst lansoprazole users compared to non-users (p=1.58 × 10-5). It is 5% (3%-7%) 




              4.1.2.2 Bendroflumethiazide-rs3743527 (ABCC1) 
 
The T allele at rs3743527 (C>T) of ABCC1 was lower in those treated with 
bendroflumethiazide (p=4.87 × 10-5) with this allele being 5% (2%-7%) less likely to 
be detected in this group than the rest of UK Biobank. 
             4.1.2.3 Gabapentin-rs8187843 (ABCC1) 
 
The ABCC1 transporter also appeared to be associated with gabapentin use. The A 
allele at rs8187843 (G>A) was at a lower frequency in the gabapentin-treated group 
(p=2.12 × 10-4) compared to the rest of UK Biobank. There was a 22% (11%-32%) 
lower odds of observing this variant in this treatment group compared to the non-
treatment group. 
             4.1.2.4 Rosuvastatin-rs2231135 (ABCG2) 
 
The rs2231135 (A>G) variant in the ABCG2 gene was associated with 
rosuvastatin use (p=3.0 × 10-4). The G allele was more frequent amongst 
individuals on this drug, with a 22% (1%-35%) higher chance to see this variant 
within rosuvastatin users compared to non-users. 
 
 
                          4.2 The associations which have been previously reported 
 
The number of nominally significant results (p <= 0.05) totalled 815 from the 
combined cohort and 544 from the UKBB cohort. The PharmGKB database was 
reviewed for all of these findings to identify drug-variant pairs which have been 
previously reported. A literature search using PubMed was also undertaken to identify 
similar studies. I found that the majority of our associations have not been reported 
before (and are likely to be false-positive findings at this significance level). However, 
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there were 24 associations (15 from the combined cohort and 9 from the UKBB 
cohort) where at least one paper has been published previously studying the same 
drug-variant pair. 19 of our results (11 from the combined and 8 from the UKBB 
cohorts) appear to be consistent with the previous findings increasing their prior 
likelihood of a true association. 4 findings from the combined cohort and 1 other 
result from the UKBB cohort were not consistent with our results. Here I focus on the 
results that were consistent with prior literature. As we are looking for replicated but 
not novel associations, a p-value of <= 0.05 was considered sufficient; however, this 
can only be considered exploratory, and further replication would be required of 
these results. 
Table 6, at the end of the results section, summarizes all associations under this category. 
 
        4.2.1 The combined Scottish cohort results (n = 11). 
 
         4.2.1.1 Gliclazide-rs1057910 (CYP2C9) 
 
The rs1057910 (A>C, CYP2C9*3) polymorphism has been reported to be associated 
with increased risk of sulfonylurea-induced hypoglycemia (OR = 1.68, p=0.011) 
[129]. Consistent with this, the carriers of this variant were 26% (7%-48%) more 
likely to decrease their gliclazide daily dose per allele (p=0.00696). 
        4.2.1.2 Simvastatin-rs2231142 (ABCG2) 
 
The rs2231142 (G>T) variant in the ABCG2 gene has been associated with a 46% 
reduction in simvastatin clearance (p=0.017) [130]. Our results show that this variant 
is associated with 18% (p=0.0069) lower odds of stopping simvastatin treatment. 
126  
 
            4.2.1.3 Methotrexate-rs9895420 (ABCC3)/rs1128503 (ABCB1) 
 
The rs9895420 (T>A) ABCC3 SNP has been reported to be correlated with reduced 
methotrexate efficacy and side effects (p=0.01 and 0.06, respectively) [131]. Our 
findings show that this variant is correlated with being 90% (95%CI 25-99%) less 
likely to stop methotrexate treatment (p=0.0134). In addition, the minor allele (A) at 
the rs1128503 (A>G) SNP in the ABCB1 transporter was previously reported to be 
associated with increased methotrexate toxicity [132]. Consistent with this, our 
results show that carriers of the A allele were 1.68 (1.07-2.63) times more likely to 
stop their methotrexate treatment per allele compared to non-carriers (p=0.0227). 
 
 
      4.2.1.4 Carbamazepine-rs762551(CYP1A2)/ rs2242480(CYP3A4)/  
                     rs1128503(ABCB1) (3 associations) 
 
It has been previously reported that carriers of the C allele at rs762551 (C(minor 
allele)>A) variant in the CYP1A2 gene experienced lower carbamazepine clearance 
and increased concentrations (p =0.004) [133]. In the combined Scottish cohorts, I 
also show that this allele is associated with a 1.33 (1.05-1.67) times greater 
tendency to decrease carbamazepine daily dose (p=0.0168). 
It has also been reported that the T allele at rs2242480 (C>T) variant in the CYP3A4 
 
gene is associated with decreased carbamazepine concentrations (p =0.027) [134]. 
Our results show that this allele is also linked with a 37% lower odds to decrease the 
daily dose (p=0.0368). 
Finally, the A allele at rs1128503 (A(minor allele)>G) variant in ABCB1 gene was 
associated with increased carbamazepine clearance in African American but not 
Caucasian population (p= 0.036) [135]. However, I observed a weak association 
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between this variant and being 18% (1%-38%) more likely to stop the drug (p=0.047) 
in a British cohort. 
              4.2.1.5 Pioglitazone-rs10509681 (CYP2C8) 
 
The rs10509681 (T>C, CYP2C8*3) variant has been reported to be associated with a 
29.7% lower pioglitazone plasma levels (p=0.01) [136]. Consistently, our results 
show that this variant allele is correlated with 33% (3%-70%) increased risk of 
stopping the drug (p=0.026). 
               4.2.1.6 Warfarin-rs2242480 (CYP3A4) 
 
In a previous study [137], the rs2242480 (C>T) CYP3A4 SNP has been associated 
with increased warfarin clearance. In our study, I found that this SNP is also 
correlated with 58% (6%-134%) increased odds to stop warfarin therapy (p=0.032). 
             4.2.1.7 Atorvastatin-rs2032582 (ABCB1) 
 
The A allele at rs2032582 (A(minor allele)>T) ABCB1 variant has been shown to be 
connected with increased atorvastatin efficacy [138]. Consistently, our results reveal 
that there is 15% (1%-53%) lower likelihood for the A allele carriers to stop 
atorvastatin treatment per allele (p=0.035). 
             4.2.1.8 Clopidogrel-rs1057910 (CYP2C9) 
 
It has been reported that the CYP2C9 mutation, rs1057910 (A>C, CYP2C9*3), is 
linked with decreased clopidogrel efficacy (p=0.045) [139]. I have also noted that this 
variant allele (C allele) to be correlated with 86% (21%-98%) lower odds of 
decreasing daily clopidogrel dose (p=0.036). 
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      4.2.2 The UKBB (cross-sectional) cohort results (n=8). 
 
             4.2.2.1 Amitriptyline-rs1065852 (CYP2D6) 
 
The rs1065852 (G>A, CYP2D6*10) SNP has been consistently correlated with poor 
amitriptyline clearance and increased toxicity [140]. Our study shows that the 
distribution of the A allele is significantly lower in the amitriptyline treated group 
compared to non-treatment group (p=0.00075) with a 6% (3%-10%) lower chance to 
observe this allele among amitriptyline treated individuals. 
            4.2.2.2 Amlodipine-rs1045642 (ABCB1) 
 
There was a slight reduction in G allele frequency at rs1045642 (A>G) in ABCB1 has 
in amlodipine users (OR = 0.97(0.95-0.99), p=0.00452). This is supported by a 
previous study in which this variant was associated with decreased amlodipine 
clearance and increased concentrations [141]. 
            4.2.2.3 Simvastatin-rs4149056 (SLCO1B1) 
 
The rs4149056 (T>C, SLCO1B1*5) is a common SNP which has been frequently 
associated with simvastatin toxicity [142]. The C-allele was underrepresented in the 
simvastatin users with an OR of 0.98 (p=0.016) in the UKBB cohort treated with 
simvastatin. 
            4.2.2.4 Clopidogrel-rs12248560/rs4244285 (CYP2C19) (2 associations) 
 
Two common CYP2C19 SNPs, rs12248560 (C>T, CYP2C19*17) and rs4244285 
 
(G>A, CYP2C19*2), have been reported to be correlated with increased [143] and 
decreased [144] clopidogrel efficacy respectively. In the UKBB cohort, there was a 
significant increase (OR = 1.08(1.01-1.14), p=0.024) and reduction  
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(OR =0.92(0.86-1), p=0.039) in the distribution of the T and A alleles respectively 
among clopidogrel users. 
            4.2.2.5 Citalopram-rs28371725 (CYP2D6) 
 
The rs28371725 (C>T, CYP2D6*41) variant has been linked to higher citalopram 
efficacy [145]. There was a slight increase in T allele frequency amongst patients on 
citalopram when compared to non-users (OR = 1.06 (1.01-1.13), p=0.026). 
             4.2.2.6 Pioglitazone-rs10509681 (CYP2C8) 
 
As described above, there was an association between the rs10509681 (T>C, 
CYP2C8*3) variant and reduced pioglitazone plasma levels and increased the chance 
of stopping the drug in the combined Scottish cohorts. Interestingly, a consistent 
association was also seen in the UKBB cohort as the C-allele was underrepresented 
among pioglitazone users (OR = 0.9 (0.82-1), p=0.043). 
            4.2.2.7 Fluoxetine-rs1065852 (CYP2D6) 
 
The rs1065852 (G>A, CYP2D6*10) variant has been associated with increased 
fluoxetine AUC [146]. This SNP was also noted with lower distribution within 




                           4.3 Potential important associations which didn't pass Bonferroni significance level. 
 
Under this category of results, I include associations, which although not significant 
after Bonferroni correction, are still of interest as they fulfil 3 criteria together: 
Firstly, the p-value significance level is moderate (> 0.00030 and <= 0.009). 
Secondly, they occur in an enzyme/transporter known as a substrate for the drug 
(according to DrugBank database (described in chapter II) or external references). 
Thirdly, they also occur with a genetic variant has been previously associated with at 
least one drug response phenotype (according to PharmGKB). I have recognized 12 
findings belong to this category from the combined cohort and other 8 results from the 
UKBB cohort, which are summarized in Table 6 at the end of the results section. In 
the below sections, I describe these findings. 
 
 
       4.3.1 The combined cohort results (n = 12). 
 
        4.3.1.1 Clopidogrel-rs12353214 (PTGS1) 
 
In an interesting association with a large effect size, the T allele at rs12353214 (C>T) 
PTGS1 (COX-1) variant was associated with a 43% (95%CI 20%-59%) reduced risk 
to stop the treatment (p=5.3 × 10-4). 
         4.3.1.2 Valsartan-rs4918758 (CYP2C9) 
 
Carriage of the rs4918758 (T>C) CYP2C9 variant was associated with 33% (15%- 
47%) lower tendency to decrease daily valsartan dose (p=5.5 × 10-4). 
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          4.3.1.3 Ezetimibe-rs3842 (ABCB1) 
 
Patients harbouring the rs3842 (T>C) polymorphism in the ABCB1 gene were seen 
89% (34%-167%) more likely to stop ezetimibe treatment per allele (p=5.6 × 10-4). 
         4.3.1.4 Enalapril-rs2244614 (CES1) 
 
Carrying the G allele at rs2244614 (G(minor allele)>A) mutation in CES1 gene is 
associated with being 38% (17%-53%) at lower chance to decrease daily enalapril 
dose (p=8.73 × 10-4). 
         4.3.1.5 Lansoprazole- rs9282564 (ABCB1) 
 
Lansoprazole users carrying the C allele at rs9282564 (T>C) ABCB1 SNP had 18% 
(7%-30%) lower likelihood to reduce their daily dose per allele (p=0.0027). 
         4.3.1.6 Atenolol-rs628031 (SLC22A1) 
 
Harbouring the A allele at rs628031(A(minor allele)>G) SLC22A1 variant was 
associated with 21% (7%-38%) increased risk to stop atenolol treatment (p=0.0034). 
          4.3.1.7 Digoxin-rs4728709 (ABCB1) 
 
Our results also show that the rs4728709 (G>A) ABCB1 variant is correlated with 
46% (15%-66%) decreased chance to reduce daily digoxin dose (p=0.0045). 
           4.3.1.8 Nifedipine-rs4728709 (ABCB1) 
 
The same variant (rs4728709) was associated with a 40% (16%-57%) lower odds to 
stop nifedipine treatment (p=0.0063). 
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           4.3.1.9 Ranitidine-rs316019 (SLC22A2) 
 
Carriers of the A allele at rs316019 (A(minor allele)>C) SLC22A2 SNP were at 15% 
(4%- 25%) lower risk to reduce the daily dose of ranitidine per allele (p=0.0065). 
          4.3.1.10 Valproic acid-rs2279343 (CYP2B6) 
 
Individuals with rs2279343 (A>G) CYP2B6 polymorphism are at 69% (15%-148%) 
increased tendency to drop their valproic acid daily dose per allele (p=0.0082). 
          4.3.1.11 Clopidogrel-rs3815583 (CES1) 
 
A CES1 SNP, rs3815583 (A>C), was associated with 65% (13%-86%) lower chance 
to decrease the daily dose of clopidogrel (p=0.0083). 
          4.3.1.12 Simvastatin-rs1080985(CYP2D6) 
 
The CYP2D6 SNP, rs1080985 (G>C), has shown 16% (4%-27%) reduced odds of 
decreasing the daily simvastatin dose (p=0.0089). 
         4.3.2 The UKBB (cross-sectional) cohort results (n=8). 
 
             4.3.2.1 Atorvastatin-rs17287570 (ABCC1) 
 
The C allele at rs17287570 (A>C) variant in ABCC1 transporter has 5% (2%-8%) 
lower odds to be detected within the atorvastatin treated group compared to the non-
treatment group (p=0.000918). 
            4.3.2.2 Esomeprazole-rs12248560(CYP2C19)/rs1128503/rs1045642(ABCB1) 
                                                    (3 associations) 
 
While the minor alleles at rs12248560 (C>T) CYP2C19 and rs1128503 (A(minor 
allele)>G) ABCB1 SNPs had 12% (4%-21% , p=0.0023)) and 9% (2%-16% , 
p=0.0063) higher chance to be recognized among patients treated with esomeprazole 
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respectively, the G allele at rs1045642 ABCB1 (A>G) polymorphism has shown 8% 
(2%-14%) lower tendency to be identified in the esomeprazole-treated group 
(p=0.0086). 
                 4.3.2.3 Methotrexate-rs4793665 (ABCC3) 
 
In an association with very small effect size, the C allele at rs4793665 (C(minor 
allele)>G) ABCC3 variant has only 1% (3%-16%) less likelihood to be observed 
among patients on methotrexate therapy (p=0.0026). 
                 4.3.2.4 Allopurinol-rs2231135 (ABCG2) 
 
The distribution of the G allele at rs2231135 (A>G) variant in ABCG2 transporter 
was significantly lower among individuals on allopurinol (p=0.0035). We have 13% 
(4%-21%) lower odds to see this variant in this treatment group. 
                4.3.2.5 Enalapril-rs7317112 (ABCC4) 
 
The ABCC4 transporter SNP, rs7317112 (A>G), is significantly highly distributed 
within patients on enalapril (p=0.00455) with the odds being 8% (3%-14%) higher in 
the treatment group. 
                  4.3.2.6 Clopidogrel-rs9332197 (CYP2C9) 
 
Carriers of the rs9332197 (T>C) CYP2C9 variant were significantly lower in the 
clopidogrel-treatment group compared to the non-treatment group (p=0.0062). 
There is 15% (4%-25%) decreased likelihood for this SNP to be detected in the 
treatment group. 
Table 6 below summarizes our important drug-gene interaction findings as classified 
into the 3 categories I mentioned above. 
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Table 6: Summary of 51 most important drug-gene associations as classified into 3 categories. 
 
   1) Results significant after Bonferroni correction    
No. Drug Cohort Phenotype SNP_id Gene OR Lower Upper P.value 
1 Ramipril Combined Drug Stop rs1135840 (2D6*2) CYP2D6 0.7 0.6 0.82 1.01E-05 
2 Quinine Combined Dose Decrease rs4918758 CYP2C9 0.71 0.6 0.85 8.00E-05 
3 Nifedipine Combined Drug Stop rs152023 ABCC1 1.32 1.15 1.53 0.000117 
4 Doxazosin Combined Dose Decrease rs9895420 ABCC3 0.54 0.38 0.76 0.00012 
5 Valproic Acid Combined Dose Decrease rs7916649 CYP2C19 1.95 1.37 2.76 0.000148 
6 Metformin Combined Drug Stop rs1045642 ABCB1 0.75 0.64 0.87 0.000164 
7 Nicorandil Combined Drug Stop rs5788 PTGS1 1.93 1.39 2.69 0.000172 
8 Amlodipine Combined Dose Decrease rs868853 ABCC4 0.55 0.4 0.75 0.00028 
9 Lansoprazole UKBB NA rs555754 SLC22A3 0.95 0.93 0.97 1.58E-05 
10 Bendroflumethiazide UKBB NA rs3743527 ABCC1 0.95 0.93 0.98 4.87E-05 
11 Gabapentin UKBB NA rs8187843 ABCC1 0.78 0.68 0.89 0.000212 
12 Rosuvastatin UKBB NA rs2231135 ABCG2 1.22 1.1 1.35 0.000302 
   2) Results replicating previous studies' findings    
No. Drug Cohort Phenotype SNP_id Gene OR Lower Upper P.value 
1 Gliclazide Combined Dose Decrease rs1057910 (2C9*3) CYP2C9 1.26 1.07 1.48 0.00696 
2 Simvastatin Combined Drug Stop rs2231142 ABCG2 0.82 0.7 0.95 0.007 
3 Methotrexate Combined Drug Stop rs9895420 ABCC3 0.1 0.01 0.74 0.01347 
4 Methotrexate Combined Drug Stop rs1128503 ABCB1 1.68 1.07 2.63 0.0227 
5 Carbamazepine Combined Dose Decrease rs762551 (C(minor)>A) CYP1A2 1.33 1.05 1.67 0.01682 
6 Carbamazepine Combined Dose Decrease rs2242480 CYP3A4 0.63 0.39 1 0.03689 
7 Carbamazepine Combined Drug Stop rs1128503 ABCB1 1.18 1 1.38 0.04734 
8 Pioglitazone Combined Drug Stop rs10509681 (2C8*3) CYP2C8 1.33 1.03 1.7 0.02693 
9 Warfarin Combined Drug Stop rs2242480 CYP3A4 1.58 1.06 2.34 0.03297 
10 Atorvastatin Combined Drug Stop rs2032582 ABCB1 0.85 0.74 0.99 0.03545 
11 Clopidogrel Combined Dose Decrease rs1057910 (2C9*3) CYP2C9 0.14 0.02 0.97 0.03625 
12 Amitriptyline UKBB NA rs1065852 (2D6*10) CYP2D6 0.94 0.9 0.97 0.00075 
13 Amlodipine UKBB NA rs1045642 ABCB1 0.97 0.95 0.99 0.00452 
14 Simvastatin UKBB NA rs4149056 (1B1*5) SLCO1B1 0.98 0.96 1 0.01621 
15 Clopidogrel UKBB NA rs12248560 (2C19*17) CYP2C19 1.08 1.01 1.14 0.02417 
16 Clopidogrel UKBB NA rs4244285 (2C19*2) CYP2C19 0.92 0.86 1 0.039 
17 Citalopram UKBB NA rs28371725 (2D6*41) CYP2D6 1.06 1.01 1.13 0.02689 
18 Pioglitazone UKBB NA rs10509681 (2C8*3) CYP2C8 0.9 0.82 1 0.0436 
19 Fluoxetine UKBB NA rs1065852 (2D6*10) CYP2D6 0.96 0.91 1 0.04845 
   3) Potential important associations      
No. Drug Cohort Phenotype SNP_id Gene OR Lower Upper P.value 
1 Clopidogrel Combined Drug Stop rs12353214 PTGS1 0.57 0.41 0.8 0.00053 
2 Valsartan Combined Dose Decrease rs4918758 CYP2C9 0.67 0.53 0.85 0.00055 
3 Ezetimibe Combined Drug Stop rs3842 ABCB1 1.89 1.34 2.67 0.000569 
4 Enalapril Combined Dose Decrease rs2244614 CES1 0.62 0.47 0.83 0.000874 
5 Lansoprazole Combined Dose Decrease rs9282564 ABCB1 0.81 0.7 0.93 0.00275 
6 Atenolol Combined Drug Stop rs628031 SLC22A1 1.21 1.07 1.38 0.00345 
7 Digoxin Combined Dose Decrease rs4728709 ABCB1 0.54 0.34 0.85 0.00458 
8 Nifedipine Combined Drug Stop rs4728709 ABCB1 0.6 0.43 0.84 0.00633 
9 Ranitidine Combined Dose Decrease rs316019 SLC22A2 0.85 0.75 0.96 0.00654 
10 Valproic Acid Combined Dose Decrease rs2279343 (2B6*4) CYP2B6 1.69 1.15 2.48 0.00821 
11 Clopidogrel Combined Dose Decrease rs3815583 CES1 0.35 0.14 0.87 0.00833 
12 Simvastatin Combined Dose Decrease rs1080985 CYP2D6 0.84 0.73 0.96 0.00895 
13 Atorvastatin UKBB NA rs17287570 ABCC1 0.95 0.92 0.98 0.000919 
14 Esomeprazole UKBB NA rs12248560 CYP2C19 1.12 1.04 1.21 0.002366 
15 Esomeprazole UKBB NA rs1128503 ABCB1 1.09 1.02 1.16 0.006394 
16 Esomeprazole UKBB NA rs1045642 ABCB1 0.92 0.86 0.98 0.008608 
17 Methotrexate UKBB NA rs4793665 ABCC3 1.1 1.03 1.16 0.002604 
18 Allopurinol UKBB NA rs2231135 ABCG2 0.87 0.79 0.96 0.00357 
19 Enalapril UKBB NA rs7317112 ABCC4 1.08 1.03 1.14 0.004557 




       5. Discussion 
 
To the best of our knowledge, this is the first pharmacogenomic study covering a 
large variety of commonly used chronic drugs (n = 50) in the UK and study the 
influence of 162 different genetic variants in important enzymes and transporters on 3 
drug response phenotypes (drug-stop, dose-decrease, and genotype distribution 
changes) for each drug. A total of 16,200 (combined cohort) and 8,100 (UKBB 
cohort) results have been generated and are available to view from an online database. 
Below I discuss our associations as classified into three categories. 
 
 
                        5.1 Significant associations after Bonferroni correction. 
 
              5.1.1 The combined cohort results (n = 8) 
 
The 8 significant associations under this section will be investigated further in 
Chapter V. In Chapter V; I will use the UKBB primary care data, which became 
available towards the end of my PhD, to check for the replicability of these 8 
associations and provide a detailed discussion for each finding. 
 
 
               5.1.2 The UKBB (cross-sectional) cohort results (n = 4) 
 
                  5.1.2.1 Lansoprazole-rs555754 (SLC22A3) 
 
The rs555754 (G>A) variant in SLC22A3 (OCT3) transporter was modestly 
underrepresented among lansoprazole users with only 5% difference as compared to 
non-users. This transporter is expressed in the hepatic basolateral membrane 
facilitating the uptake of xenobiotics into the liver. The A allele was found associated 
with increased OCT3 expression [147] which indicates increased hepatic 
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uptake and decreased efficacy as a result of reduced plasma levels. Our finding 
could be linked with this proposed mechanism. The depletion of the variant 
allele seen among lansoprazole users could be explained by reduction of its 
therapeutic efficacy. However, it is unknown whether lansoprazole is an OCT3 
substrate. In addition, the small effect size seen with this association lessens its 
clinical importance.   
                    5.1.2.2 Bendroflumethiazide-rs3743527 (ABCC1) 
 
The T allele at rs3743527 (C>T) SNP in ABCC1 transporter was also seen 
underrepresented among bendroflumethiazide users. However, it is unknown if 
bendroflumethiazide is an ABCC1 substrate. It has been suggested that the majority 
of the drug is eliminated by a non-renal route as the drug seems to be extensively 
metabolized in the liver [148]. ABCC1 is expressed in the basolateral hepatic 
membrane facilitating the efflux of xenobiotics into the blood. SN-38, the active 
irinotecan metabolite, is transported by hepatic ABCC1 to increase circulating blood 
concentrations. The rs3743527 (C>T) polymorphism has been previously linked with 
decreased irinotecan-induced neutropenia [149] suggesting that this would be a loss-
of-function variant. Nevertheless, it is unclear how carrying this variant could be 
linked with decreased tolerability to bendroflumethiazide, as shown in our findings. 
However, if the drug was found to be a substrate for ABCC1, then decreased hepatic 
efflux into blood could result in reduced plasma levels and efficacy. On the other 
hand, decreased ABCC1 function in the kidney could result in increasing systemic 







               5.1.2.3 Gabapentin-rs8187843 (ABCC1) 
 
Another ABCC1 mutation, rs8187843 (G>A), was found to be associated with 
decreased frequency of the variant allele in the gabapentin treated group. It is 
unknown if gabapentin is a substrate for ABCC1 transporter. However, interestingly, 
this transporter is expressed in the basolateral membrane of the blood-brain barrier 
(BBB) protecting the brain from the entry of foreign substances; and therefore, 
genetic variability in this transporter could affect the pharmacokinetics of central 
nervous system (CNS) drugs which are substrates for the transporter. Reduced and 
increased the transporter function could increase and decrease the cerebral 
concentration of these agents, respectively.  
 
Our research team is collaborating with Professor Kathy Giacomini (world leader in 
drug transporters) to establish whether or not the above-mentioned drugs 
lansoprazole, bendroflumethiazide, and gabapentin are transported by OCT3, 
ABCC1, and ABCC1 transporters respectively. 
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                      5.1.2.4 Rosuvastatin-rs2231135 (ABCG2) 
 
The rs2231135 (A>G) ABCG2 transporter variant was overrepresented among 
rosuvastatin users suggesting increased tolerability to the drug. The majority of the 
drug, 72%-90%, is eliminated via the hepatic route [150] suggesting the importance of 
hepatic efflux transporters in its elimination. Rosuvastatin is a substrate for the 
ABCG2 efflux transporter [150]. The G allele at rs2231135 (A>G) ABCG2 gene was 
associated with increased methotrexate (an ABCG2 substrate) mucositis side effects 
[151] which could be attributable to increased methotrexate plasma levels as a result 
of reduced ABCG2 efflux activity. However, the decreased activity of this transporter 
could increase rosuvastatin therapeutic efficacy due to increased residence time in the 
liver, which is the primary site for rosuvastatin pharmacological action. Our finding is 
consistent with this mechanism. In fact, our finding is further supported by multiple 
previous pharmacogenomic studies in which another independent ABCG2 variant, 
rs2231142 (G>T), has been consistently linked with increased rosuvastatin efficacy as 
indicated by increased low-density lipoprotein (LDL) reduction [152]. 
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                       5.2 Associations replicating previous studies findings 
 
               5.2.1 The combined cohort results (n = 10). 
 
                   5.2.1.1 Gliclazide-rs1057910 (CYP2C9) 
 
The antidiabetic drug gliclazide is primarily metabolized by CYP2C9 and CYP2C19 
enzymes [153]. The reduced activity variant CYP2C9*3 (rs1057910 (A>C)) has been 
shown to be correlated with increased risk of gliclazide-induced hypoglycemia [129]. 
Consequently, prescribers could reduce the daily dose to overcome this side effect, an 
effect consistent with that seen in the CYP2C9*3 carriers in the Scottish combined 
data. 
                5.2.1.2 Simvastatin-rs2231142 (ABCG2) 
 
The T allele at rs2231142 variant in the ABCG2 gene is associated with a large 
decrease of simvastatin clearance [130]. The ABCG2 transporter is expressed in the 
apical membrane of the liver, facilitating drug efflux and excretion. The decreased 
clearance observed with carriers of this variant indicates reduced ABCG2 function. 
This could be associated with increased simvastatin hepatic concentration and, in 
turn, increased efficacy as the liver is where simvastatin works to exert its therapeutic 
efficacy. This is consistent with our observation that this variant allele was associated 
with being less likely to stop the treatment; probably due to increased efficacy. 
             5.2.1.3 Methotrexate-rs9895420 (ABCC3)/rs1128503 (ABCB1) 
 
Methotrexate is mainly eliminated via renal excretion, and it is an ABCC3 and 
ABCB1 substrate [154]. ABCC3 is expressed in the apical renal membrane 
transporting its substrates into the urine. The rs9895420 (T>A) mutation in this 
transporter has been shown to be associated with increased ABCC3 activity, lower 
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methotrexate efficacy, and lower risk of thrombocytopenia [131]. Consistent with 
this, I have also shown that carriers of this variant allele were less likely to stop their 
methotrexate treatment. Thrombocytopenia can be a life-threatening side effect, and 
therefore, the advantage of reduced toxicity with methotrexate can outweigh the 
disadvantage of reduced efficacy especially given the fact that methotrexate is usually 
combined with other disease-modifying antirheumatic drugs (DMARDs) to improve 
therapeutic efficacy. This would explain our findings that carriers of the rs9895420 
(T>A) had lower odds of stopping methotrexate treatment. In contrast, the reduced 
activity allele (A) at rs1128503 (A>G) SNP in ABCB1 were linked to increased 
methotrexate side effects [132]. This could explain our finding that this allele is 
associated with increased risk of stopping methotrexate treatment. It is expected that 
these observations are attributable to decreased renal ABCB1 efflux function resulting 
in increased methotrexate plasma concentration and toxicity. 
 
 
5.2.1.4 Carbamazepine-rs762551(CYP1A2)/ rs2242480(CYP3A4)/ rs1128503(ABCB1)               
(3 associations) 
 
The C allele at rs762551 (C(minor allele)>A) CYP1A2 and the T allele at rs2242480 
(C>T) CYP3A4 have been linked with increased and decreased carbamazepine plasma 
concentrations respectively [133,134]. In our data, the two variants were associated 
with being more or less likely to decrease carbamazepine dose, respectively. These 
two clinical behaviours are consistent with the changes in the plasma concentrations 
observed in the two studies outlined above. In addition, the A allele at rs1128503 
(A(minor allele)>G) ABCB1 SNP, has been connected with increased carbamazepine 
clearance in African Americans but not Caucasian population [135]. The authors of 
this study were not able to determine why there was a difference in the results 
between these two ethnic groups. However, increased carbamazepine clearance seen  
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with African Americans could result in decreased carbamazepine efficacy which is 
consistent with our finding in the British cohort that carriers of the minor allele (A) 
were more likely to stop the treatment 
 
                 5.2.1.5 Pioglitazone-rs10509681 (CYP2C8) 
 
It has been reported that Caucasian users of pioglitazone (a CYP2C8 substrate) 
harbouring the CYP2C8*3 (rs10509681 (T>C)) variant experience lower 
pioglitazone plasma levels as compared to non-carriers [136]. Consistently, and 
probably due to decreased efficacy, I have observed carriers of this variant allele 
were more likely to stop the treatment. 
                  5.2.1.6 Warfarin-rs2242480 (CYP3A4) 
 
I identified an association between stopping warfarin treatment (a CYP3A4 
substrate) and the rs2242480 (C>T) polymorphism in CYP3A4 enzyme. This is in 
consistent with a previous finding that the minor allele (T) was correlated with 
increased warfarin clearance [137], which could result in reduced efficacy and 
consequent treatment cessation. 
                  5.2.1.7 Atorvastatin-rs2032582 (ABCB1) 
 
The minor allele (A) at rs2032582 (A>T) SNP in ABCB1 is associated with enhanced 
atorvastatin efficacy as indicated by increased LDL reduction [138]. Our results are 
consistent with this, with the A allele being associated with a lower likelihood of 
treatment cessation. Of note, this is the third association I see confirming that reduced 
ABCB1/ABCG2 function is correlated with enhanced statin efficacy. 
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              5.2.1.8 Clopidogrel-rs1057910 (CYP2C9) 
 
Clopidogrel is a prodrug which requires metabolic activation to exert its therapeutic 
efficacy. This activation is catalyzed by CY3A4, CYP1A2, CYP2B6, CYP2C19, and 
CYP2C9 enzymes [155]. The loss-of-function variant CYP2C9*3 has been reported to 
decrease clopidogrel efficacy [139]. Decreased efficacy could be also associated with 
decreased side effects. Consistently, I have identified that carriers of this variant allele 
are less likely to decrease clopidogrel dose. This can be attributable to decreased 
activation and, consequently, decreased side effects which may manifest as dyspepsia 
or even haemorrhage. 
 
 
          5.2.2 The UKBB (cross-sectional) cohort results (n=8). 
 
                 5.2.2.1 Amitriptyline-rs1065852 (CYP2D6) 
 
Amitriptyline (a tricyclic antidepressant (TCA)) is mainly metabolized by CYP2C19 
into another active TCA nortriptyline. Nortriptyline is then metabolized primarily by 
CYP2D6 into less active metabolites (10-hydroxy metabolites) [156]. The reduced 
activity variant CYP2D6*10 (rs1065852 (G>A)) has been shown to be associated with 
increased nortriptyline plasma levels [140]. This might be correlated with increased 
side effects. Consistent with this, our results from the UKBB cohort show that this 
variant was underrepresented among amitriptyline users compared to non-users 
suggesting decreased tolerability to the treatment. 
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                 5.2.2.2 Amlodipine-rs1045642 (ABCB1) 
 
Our results also show a modest reduction in the distribution of the G allele at 
rs1045642 (A>G) in ABCB1 among amlodipine users suggesting reduced tolerability 
to the drug. In concordance with this result, this variant allele has been reported to be 
connected with increased amlodipine plasma levels [141] which could be associated 
with increased side effects. 
                 5.2.2.3 Simvastatin-rs4149056 (SLCO1B1) 
 
I have also identified that the well-known reduced function SNP SLCO1B1*5 
(rs4149056 (T>C)) is significantly lower within users of simvastatin (a SLCO1B1 
substrate). This is in alignment with the well-established fact that this variant has been 
frequently seen to be connected with increased simvastatin-induced myopathy [142]. 
SLCO1B1 facilitates simvastatin uptake into the liver, and as a result of its reduced 
activity, simvastatin plasma levels are increased, which increases the risk of 
myopathy. 
              5.2.2.4 Clopidogrel-rs12248560/rs4244285 (CYP2C19) (2 associations) 
 
As mentioned earlier, clopidogrel is activated by multiple CYP enzymes, including 
CYP2C19. The two well-known variants CYP2C19*17 (rs12248560 (C>T)) and 
CYP2C9*2 (rs4244285 (G>A)), defining the ultra-rapid and poor metabolizer 
phenotypes respectively, have a well-established correlation with increased and 
decreased clopidogrel efficacy as indicated by decreased and increased cardiovascular 
events respectively [143,144]. Consistent with these known associations, I have found 
that the distribution of the variant alleles of these two SNPs is higher and lower 
among clopidogrel users from the UKBB cohort compared to non-users, respectively. 
The higher distribution of the CYP2C19*17 variant indicates increased tolerability 
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which is most likely due to increased efficacy and vice versa with the CYP2C9*2 
variant. Clopidogrel efficacy could be evaluated by observing the frequency of 
cardiovascular (CV) events in a specific group of patients. For example, if carrying a 
certain variant results in increased clopidogrel efficacy as indicated by reduced CV 
events, then it is expected that carriers of this variant would be overrepresented 
among clopidogrel users. 
                5.2.2.5 Citalopram-rs28371725 (CYP2D6) 
 
The CYP2D6*41 (rs28371725 (C>T) variant, which is associated with decreased 
enzyme activity, has been reported to be linked with increased citalopram (a 
CYP2D6 substrate) efficacy [145]. Our findings also show a modest increase in the 
distribution of the minor allele (T) within citalopram users from the UKBB cohort, 
suggesting increased tolerability in term of efficacy. 
                 5.2.2.6 Pioglitazone-rs10509681 (CYP2C8) 
 
In the combined cohort results above, I have shown that the CYP2C8*3 variant was 
associated with higher odds to stop pioglitazone treatment; a result which was 
supported by a previous finding. Interestingly, I was also able to see a similar trend 
of association among pioglitazone users from the UKBB. This variant allele was 
less distributed within this treatment group suggesting decreased tolerability to the 
drug. 
                5.2.2.7 Fluoxetine-rs1065852 (CYP2D6) 
 
I have also shown that the CYP2D6*10 variant is underrepresented within fluoxetine 
(a CYP2D6 substrate) users from the UKBB cohort. This could be due to increased 
toxicity as the variant has shown a correlation with increased fluoxetine plasma 
concentrations from a previous study [146]. 
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                     5.3 Potential important associations which didn't pass Bonferroni significance level. 
 
                5.3.1 The combined cohort results (n = 12). 
 
                   5.3.1.1 Clopidogrel-rs12353214 (PTGS1(COX-1)) 
 
As this is the closest association to Bonferroni significance level occurring in an 
interesting gene, I decided to examine this association for replication from the UKBB 
primary care data. This association, along with its replication result, will be discussed 
in detail in chapter V. 
                    5.3.1.2 Valsartan-rs4918758 (CYP2C9) 
 
Among all of the other important CYP enzymes, CYP2C9 has been recognized as the 
only CYP enzyme responsible for metabolizing valsartan [157]. The liver has been 
identified as the main elimination route, but only 20% of the dose is subject to hepatic 
metabolism. Even though this is a minimal contribution of hepatic metabolism in the 
total elimination process, I have identified the rs4918758 (T>C) variant in CYP2C9 to 
be associated with a lower likelihood of a decrease in valsartan dose. Interestingly, 
here I see this variant showing a similar direction of effect with the same phenotype 
as has been identified with quinine treatment, which was one of top findings from the 
combined Scottish data that was replicated in UK Biobank primary care data 
(presented and discussed in chapter V). 
                5.3.1.3 Ezetimibe-rs3842 (ABCB1) 
 
In a previous study [158], induction of the intestinal ABCB1 expression by rifampicin 
resulted in a marked reduction in the ezetimibe plasma concentration and efficacy. 
Our study reveals that the variant allele (C) at rs3842(T>C) SNP in the ABCB1 
transporter is associated with 89% increased risk of stopping ezetimibe treatment. 
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This variant has been previously reported to be correlated with increased efavirenz 
systemic exposure [159] suggesting reduced ABCB1 transportation activity. 
Similarly, this variant could increase ezetimibe plasma concentration and side effects 
(e.g. fatigue, abdominal and muscle pain) resulting in stopping the drug, which is 
what we have found. 
               5.3.1.4 Enalapril-rs2244614 (CES1) 
 
The prodrug enalapril has been shown to be readily hydrolyzed by carboxylesterase1 
(CES1) into its active metabolite enalaprilat [160]. This enzyme also contributes to 
the first step in the activation of capecitabine into its active metabolite 5‐fluorouracil 
[161]. The minor allele (G) at rs2244614 (G>A) SNP in CES1 gene has been 
associated with increased CES1 overexpression and increased capecitabine-induced 
toxicity [161]. However, our results show that this variant allele is associated with 
decreased odds of dose reduction of enalapril suggesting reduced toxicity which is 
inconsistent with the direction of effect seen with capecitabine treatment. 
                       5.3.1.5 Lansoprazole- rs9282564 (ABCB1) 
 
Lansoprazole is a substrate for the ABCB1 transporter [162]. I have noted that the 
rs9282564 (T>C) in the ABCB1 gene is associated with a lower chance of decreased 
lansoprazole daily dose. This variant was previously linked with increasing plasma 
concentrations for multiple ABCB1 substrates [163]. However, it is unclear how this 
variant is associated with our observed phenotype. 
                     6.3.1.6 Atenolol-rs628031 (SLC22A1) 
 
It has been recently discovered that atenolol is transported by the OCT1 transporter 
expressed in the apical intestinal membrane [164] suggesting the potential role of this 
transporter in affecting atenolol absorption. Here, we report an association between 
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the minor allele (A) at rs628031(A>G) SNP in SLC22A1 and increased odds of 
stopping atenolol treatment. Of note, a similar trend of association was also detected 
from the UKBB cross-sectional data with carriers of this variant found to be depleted 
among atenolol group (OR = 0.97, p= 0.0245). This could be related to an increased 
intestinal accumulation of atenolol, causing abdominal side effects, as well as 
decreased bioavailability and efficacy. Interestingly, the same minor allele (A) was 
previously reported to be linked with increased metformin (a known OCT1 substrate) 
gastrointestinal tract toxicity [165] providing more support for our proposed 
mechanism of drug-gene interaction with atenolol. 
                   5.3.1.7 Digoxin/nifedipine-rs4728709 (ABCB1) (2 associations) 
 
Digoxin and nifedipine are both ABCB1 substrates [166,167]. I found that carriers of 
the A allele at rs4728709 (G>A) in ABCB1 transporter were less likely to decrease 
digoxin dose and less likely to stop nifedipine treatment. These phenotypes suggest 
increased tolerability and reduced side effects. Consistent with these findings, this 
variant was reported to be correlated with decreased vincristine-induced neurotoxicity 
[168]. All of these observations indicate that this variant could be linked with 
increased ABCB1 efflux activity. 
                 5.3.1.8 Ranitidine-rs316019 (SLC22A2) 
 
Ranitidine has been recently identified as an OCT2 substrate [169]. OCT2 is 
expressed in the basolateral renal membrane facilitating drug uptake into the kidney. I 
found that carriers of the minor allele (A) at rs316019 (A>C) variant in SLC22A2 
transporter were less likely to decrease their ranitidine dose, suggesting decreased 
side effects. This allele has been reported to affect multiple drugs but with conflicting 
directions of effects. For example, it has been correlated with lower 
cisplatin/anthracyclines toxicity (in concordance with our finding with ranitidine), but 
it has also been found linked with decreased metformin/l-tryptophan clearance [170]. 
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                   5.3.1.9 Valproic acid-rs2279343 (CYP2B6) 
 
Valproic acid is mainly metabolized by CYP2A6, CYP2B6, and CYP2C9 enzymes 
[171]. Our results show that the CYP2B6*4 (rs2279343 (A>G)) variant is correlated 
with an increased chance to decrease the valproic acid dose, suggesting increased side 
effects risk. However, the CYP2B6*4 variant is a gain-of-function variant [172] and 
therefore the mechanism by which our finding occurred is not clear. 
                    5.3.1.10 Clopidogrel-rs3815583 (CES1) 
 
Around 85% of clopidogrel is converted into inactive metabolites via 
carboxylestrase1 (CES1) [173]. I found that the variant allele (C) at rs3815583 (A>C) 
SNP in the CES1 gene is associated with a lower tendency to decrease clopidogrel 
dose which could indicate decreased risk for adverse events. In concordance with this 
result, the C-allele has been reported to be associated with decreased isoniazid (a 
suggested CES1 substrate)-induced hepatotoxicity [174]. 
                   5.3.1.11 Simvastatin-rs1080985 (CYP2D6) 
 
In previous studies [175], reduced function CYP2D6 variants were correlated with 
increased simvastatin (a CYP2D6 substrate) efficacy and side effects. On the other 
hand, I show that the C-allele at rs1080985 (G>C) CYP2D6 is associated with a lower 
tendency toward decreased simvastatin dose, suggesting reduced side effects. This 
would require rs1080985 to be a gain-of-function variant in CYP2D6. Interestingly, 
this is supported by a previous study in which the C-allele was found to be associated 
with increased debrisoquine (a CYP2D6 substrate) metabolism [176]. 
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          5.3.2 The UKBB (cross-sectional) cohort results (n=8). 
 
              5.3.2.1 Atorvastatin-rs17287570 (ABCC1) 
 
It has been shown that atorvastatin is an ABCC1 substrate [177]. The C-allele at 
rs17287570 (A>C) in the ABCC1 transporter has been previously associated with 
increased irinotecan-induced myelosuppression [178]. However, the authors 
mentioned that this association was significant in their first study but not in the second 
study and after combining both cohorts. SN-38 is the active metabolite of irinotecan, 
catalyzed by liver esterase, and is transported by the ABCC1 transporter. This 
transporter is expressed in the basolateral hepatic membrane pumping its substrates 
into the blood. Therefore, the increased activity of this transporter could be associated 
with irinotecan-induced side effects suggesting that the C-allele could be an increased 
activity variant. Our findings show that the C-allele at this ABCC1 SNP was 
underrepresented among atorvastatin users. Increased ABCC1 hepatic activity could 
decrease atorvastatin hepatic concentration (i.e., decreased efficacy) and increase its 
systemic exposure (i.e. increased side effects). 
            5.3.2.2 Esomeprazole-rs12248560(CYP2C19)/rs1128503/rs1045642(ABCB1) 
                                                  (3 associations) 
 
Esomeprazole is primarily metabolized by the CYP2C19 enzyme, and it is a substrate 
for the ABCB1 transporter [179]. Genetic variability in CYP2C19 was shown to 
affect esomeprazole efficacy. For instance, carriers of CYP2C19*2/*3 reduced 
activity variants have decreased esomeprazole metabolism and better response 
[180,181]. Here, I have also shown that patients carrying the CYP2C19*17 
(rs12248560) variant (ultra-rapid metabolizers [182]) are enriched within 
esomeprazole treatment group in UKBB. However, extensive metabolism will result 
in decreased efficacy and, therefore, one would predict an under-representation of  
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this SNP in esomeprazole users. I have also noted the same phenotype (i.e. 
overrepresentation of the allele) occurring with carriers of the A allele at rs1128503 
(A>G) ABCB1 SNP which could be attributable to better response due to reduced 
ABCB1 efflux activity as what has been observed with other multiple drugs [183]. 
The other ABCB1 SNP, rs1045642 (A>G), was extensively studied, but it shows 
different directions of effects with different drugs [184]. Our findings suggest that 
harbouring this variant could be associated with decreased tolerability for 
esomeprazole. Overall, these findings from the UKBB are not clear. 
               5.3.2.3 Methotrexate-rs4793665 (ABCC3) 
 
I have shown a correlation between methotrexate and the rs9895420 (T>A) ABCC3 
SNP from the combined Scottish cohort, as discussed above. Here, in UKBB I have 
also detected a very modest effect of the minor allele (C) at rs4793665 (C>G) SNP in 
the ABCC3 transporter on methotrexate use with this variant being underrepresented 
in this treatment group. This minor allele has been previously correlated with 
increased hepatic efflux of morphine metabolites into plasma [185]. 
                  5.3.2.4 Allopurinol-rs2231135 (ABCG2) 
 
In an association replicated multiple times from previous work, carriage of the 
reduced function T-allele at rs2231142 (G>T) in the ABCG2 transporter was 
associated with poor allopurinol response and increased likelihood for dose increase 
[186]. I couldn't find this SNP to be associated with any phenotype I have used in 
this study except for the strong association seen among allopurinol users from the 
UKBB cohort. However, this was clearly driven by disease (gout) rather than drug 
response. ABCG2 is involved in the transportation of uric acid and it has been shown 
that decreased intestinal ABCG2 function is associated with increased systemic 
exposure of uric acid [187]. Intestinal ABCG2 transporter returns substrates back    
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into the intestinal lumen and therefore, reducing this function could result in 
increasing serum uric acid levels and increased risk of gout. Nevertheless, I have 
identified another disease-independent SNP in the same gene (ABCG2), rs2231135 
(A>G) that is underrepresented among allopurinol users from the UKBB cohort. It is 
unclear why this SNP seemed to affect allopurinol response only while being gout 
disease independent, but genotype dosage differences between different variants 
could play a role. This SNP has been previously shown to be correlated with 
increased methotrexate (an ABCG2 substrate)-induced mucositis indicating reduced 
ABCG2 function [188]. Our findings regarding allopurinol support previous results 
that decreased ABCG2 activity could be linked with poor allopurinol response as 
indicated by the low distribution of the rs2231135 (A>G) SNP among allopurinol 
users but the exact mechanism of this DGI is unknown.  
                  5.3.2.5 Enalapril-rs7317112 (ABCC4) 
 
Enalapril is a prodrug which undergoes hepatic hydrolysis by esterases to produce its 
active metabolite enalaprilat. It has been recently reported that hepatic ABCC4 
transporters are responsible for the translocation of enalaprilat from hepatocytes into 
the systemic circulation for the drug to exert its blood pressure-lowering efficacy 
[189]. In the same context, our results reveal an ABCC4 polymorphism, rs7317112 
(A>G), to be overrepresented in the enalapril treatment group indicating increased 
tolerability to the drug. This can be explained by an increase in ABCC4 function, 
which could result in increased systemic enalaprilat exposure and efficacy. In fact, the 
increased activity could be predicted from a previous study in which the minor allele 
(G) has been correlated with decreased methotrexate-related mucositis [190]. 
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               5.3.2.6 Clopidogrel-rs9332197 (CYP2C9) 
 
As explained earlier, clopidogrel is activated by multiple CYP enzymes, including 
CYP2C9. I have also discussed the link between the CYP2C9*2 reduced function 
variant and loss of clopidogrel efficacy. In UKBB, I also detected another 
independent CYP2C9 SNP, rs9332197 (T>C), which has a similar effect as indicated 
by the reduced distribution of the variant allele (C) among clopidogrel users. This 
variant has also been reported to affect warfarin efficacy [191]. 
 
 
     6. Conclusion 
 
The present work has provided for the first time a large-scale coverage of clinical 
pharmacogenomic associations between 162 genetic variants in important enzymes 
and transporters and 50 commonly used chronic drugs using 3 different drug response 
phenotypes (drug-stop, dose-decrease, and changes in genotype distribution among 
drugs' users) in two cohorts (the Scottish cohort + the UKBB cohort). I have 
generated a total of 24,300 drug-genetic variants associations results which are 
accessible online via this link: 
https://c1abo933.caspio.com/dp/d81f7000c3c1854d29104a49b1d8. I have identified a 
total of 12 novel drug-genetic variant associations (passed Bonferroni significance 
level). I have also identified 19 results replicating previous study findings. Finally, I 
also show a total of 20 potentially important novel associations occurring in relevant 
genes. However, it is important to recognise that results that didn't pass Bonferroni 
significance should be interpreted with caution. We included these results in our 
discussion only to shed some light on candidate results which could merit further 





  We acknowledge that drug response phenotype defined from the UKBB cross-
sectional data approach can be easily influenced by disease associations, and 
generally difficult to interpret. In fact, we used this approach because the UKBB 
cross-sectional data was the only cohort available to us at the beginning of this PhD. 
The complete longitudinal Scottish cohort data didn't become available to us until 
after around two years from starting this PhD. Once these cohorts become available, 
we used them to define more accurate phenotypes (i.e. drug-stop and dose-decrease). 
In the next chapter (drug-drug-gene interactions), we used a similar methodology and 
























Drug-Drug-Gene Interactions for the Most 
Commonly Used Chronic Drug 
Combinations in the UK 
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     Abstract 
 
Most of the current work in relation to drug-interactions focuses on drug-drug 
interactions and, to a lesser extent, drug-gene interactions. In contrast, there is very 
limited research on drug-drug-gene interactions (DDGIs). In the present study, I 
attempted to uncover novel and clinically important drug-drug-gene interactions 
among commonly used chronic drug combinations in the UK. I studied the 
associations between 50 common chronic drug combinations and 162 selected genetic 
variants in important enzymes and transporters. These associations were studied in 
two cohorts: a combined cohort of longitudinal prescribing data for 3 Scottish cohorts 
and the UKBB cross-sectional prescribing data. In the combined cohort, these drug- 
drug-variant combinations have been studied with respect to a ‘drug-stop’ or ‘dose- 
decrease’ phenotype while in the UKBB cross-sectional data we studied differences in 
the genotype distribution between drug combinations of users compared to non-users. 
I have identified 3 and 7 novel drug-drug-gene associations which were significant 
after Bonferroni correction from the combined Scottish cohort and the UKBB cohorts 
respectively. 
From the combined cohort, users of the bisoprolol-atorvastatin combination who carry 
the rs9516519 (T>G) ABCC4 variant and users of the simvastatin-metformin 
combination who carry the rs622342 (C(minor allele)>A) SLC22A1 minor allele were 
more likely to stop one of the two drugs during their combined use per allele ( ORs = 
4.72 (2.44-9.13) and 3.1 (1.71-5.62), p-values = 1.48 × 10-5 and 9.3 × 10-5 
respectively). In addition, the G allele at rs1967120 (G(minor allele)>A) ABCC1 SNP 
has been observed to be correlated with increased risk of dose reduction of either 




The results from the UKBB cohort show depletion of the minor allele for the 
following four associations :1) bendroflumethiazide-metformin-rs2199939 (C>T) 
ABCG2 SNP (OR = 0.81 (0.73-0.9); p=5.29 × 10-5) 2) atorvastatin-metformin- 
rs2293001 (C>T) ABCC5 SNP (OR = 0.89 (0.83-0.94); p= 1.6 × 10-4) , 3) 
 
atorvastatin-metformin-rs17731538 (G>A) ABCG2 SNP (OR = 0.85 (0.78-0.93); 
p=1.6 × 10-4) , and 4) simvastatin-metformin-rs215095 (G(minor allele)>A) ABCC1 
SNP (OR = 0.9 (0.84-0.95); p=2.606 × 10-4) 
 
 
In contrast, the distributions of the minor allele was enriched in the following 3 
associations: 1) simvastatin-furosemide-rs4148739 (T>C) ABCB1 SNP (OR = 1.26 
(1.13-1.41); p=6.07 × 10-5), 2) atorvastatin-metformin-rs10937158 (T(minor allele)>C) 
ABCC5 SNP (OR = 1.13 (1.06-1.2); p=1.04 × 10-4) , and 3) amlodipine-atorvastatin- 
rs3735451 (T>C) CYP3A4 SNP (OR = 1.21 (1.1-1.34); p=1.3 × 10-4) . 
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     1. Introduction 
 
To date, the literature on drug-drug-gene interactions (DDGIs) is limited. In my 
review, which has been presented in chapter I, only 33 DDGI studies and case reports 
were identified (17 with metabolizing enzyme genes and 16 with transporter genes). 
The few papers on drug-drug-metabolizing enzyme genes focused only on CYP2C9, 
CYP2C19, and CYP2D6 genes and only for a few drugs. Genetic variants in other 
important genes such as CYP3A4, CYP2C8, CYP2E1, CYP1A2 and CYP2B6 were not 
detected in my search for DDGIs reports. The gap becomes even larger when we 
consider drug-drug-transporter gene interactions. Transporters are generally poorly 
studied compared to metabolizing enzymes, for drug interactions. This is probably 
due to the only recent evolution of transporter science after it was thought that 
metabolizing enzymes were the only major contributors to drug elimination. I have 
identified a limited number of DDGI papers which have studied limited drugs and 
limited variants in the ABCB1, SLCO1B1, and OCT1 transporters. In addition, there 
were no publications for DDGIs involving the ABCC1/2/3/4, SLCO2B1/1B3, 
OCT2/3, OAT1/2/3, and ABCG2 transporters. These kinds of interactions could 
intensify or ameliorate the predicted clinical outcomes seen with drug-drug only or 
drug-gene only interactions. 
Based on this literature, it is clear that there is currently a large information gap 
regarding DDGIs. Therefore, in this study, we attempt to broadly cover this topic by 
considering a large variety of common drug combinations and studying their 




     2. Study Populations 
 
 
Four UK cohorts have been the target of this study: 3 Scottish cohorts and one from 
across the UK. The Scottish data represents 3 cohorts: GoDARTs, Generation 
Scotland (GS), and GoSHARE longitudinal prescribing data which are combined 
together. The combined cohort, along with the UKBB cross-sectional data, are used 




      3. Methodology 
 
The methods we have applied can be summarized in the below five steps: 
 
3.1 Selection of candidate common chronic drug combinations 
 
                3.1.1 Identifying a list of common drug combinations in the UK. 
 
In chapter III, I utilized the UKBB cross-sectional prescribing data to produce a list of 
the top 122 most frequently used drugs in the UK. This list was used to generate a 
second list of the most frequently prescribed drug combinations. A drug combination 
is considered common when both drugs are within our list of the 122 top drugs. 
Therefore, a matrix of size 122*122 was produced, and the frequency of each 
possible unique combination (n=7333) was calculated. 
Table 7 below clarifies the structure of the matrix produced. 
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Table 7: Part of the matrix which consists of a head row of our top 122 common drugs and a first 
column of the same list of drugs. This enabled us to identify and calculate the frequency of each 
possible unique combination between the drugs in the list. The frequencies are recorded in the cells 
for each combination. For example, the frequency of using paracetamol-aspirin combination is 14231 
times. Combinations where both drugs are the same take the frequency of "0" and duplicated 
combinations where the frequency has already been calculated before take the frequency of "NA". 








This matrix was then converted into a table showing the frequency of unique drug 
combinations starting from the highest usage frequency. 
            3.1.2 Development of a customized DDIs database for the 7333 combinations 
 
Table 8 below summarizes the steps for producing the drug-drug interactions database 
showing 3 different scenarios for interactions. 
Pharmacokinetic drug interactions can be inhibitory or induction interactions 
depending on whether the metabolizing enzymes (MEs) and/or transporters (Trs) of 
the victim drug are inhibited or induced by the perpetrator drug. The majority of DDIs 
are expected to be inhibitory rather than induction interactions as the majority of 
perpetrator drugs are inhibitors rather than inducers. Therefore, we will focus on 
identifying inhibitory drug interactions occurring in the 7333 drug combinations. To 
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do so; first, we extracted information about the MEs/Trs involved in PK of the 122 
commonly used drugs in UK Biobank from the DrugBank database (described in 
chapter II). MEs/Trs inhibited by each drug were also extracted, resulting in each 
drug having two columns of information: "substrate of" and "inhibitor of". I then 
extracted information from this table into the table of 7333 combinations, so each 
drug in each combination has the two columns of information. This table was then 
utilized to identify possible routes of interaction between drugs in each combination. 
There are two possible mechanisms for interaction within each drug combination: 
drug1 as the substrate drug and drug 2 as an inhibitor drug or vice versa. Considering 
both sides of the interaction, I produced results showing the interacting genes for 
each combination. 
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Table 8: The steps of producing our drug-drug interactions database for common drug combinations 
in the UK showing 3 different scenarios of interactions. We first produced a list of 7333 different 
drug combinations used in the UK from the UKBB cohort (1). Then, information about metabolizing 
enzymes or transporters and enzymes or transporters inhibited by each drug were extracted from 
DrugBank for each drug in each combination (2/2). Finally, the interacting gene was recognized for 
each combination considering both modes of interaction (3/3). 
The table shows 3 possible scenarios of interaction. The first row shows an interaction occurring 
where both drug 1 and drug 2 are the victim drug (e.g. ibuprofen is an inhibitor for CYP2C9 which is 
one of the metabolizing enzymes for paracetamol. On the other hand, paracetamol is an inhibitor for 
ABCB1 which is a transporter for ibuprofen). The second row shows an interaction where only one 







                3.1.3 Selecting common drug combinations of interest 
 
Our results show that the 7333 combinations can be classified into two categories: 
interacting combinations (n = 1,503) and combinations with unknow routes of 
interactions (n = 5,830). The first category represents any combination where there is 
at least one route of interaction between the two drugs, while the second category 
shows combinations with no identifiable interaction between the two drugs. From 
each category, I selected the top 25 commonly used chronic combinations. Our final 
list of top 50 commonly used combinations (25 interacting combinations and 25 
combinations with unknown routes of interactions) is shown in Table 9 below. As the 
knowledge regarding drug-metabolizing enzymes and transporters, and the ability of 
drugs to inhibit these enzymes or transporters, is limited we chose to include 25 
combinations where there is as yet no known route of interaction between the drugs 
used in combination, in addition to the 25 where routes of interaction were better 
recognized. 
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Table 9: List of top 50 commonly used drug combinations in the UK as classified into interacting 
combinations (n =25) and combinations with unknown interaction routes (n=25).  












Interacting gene (Drug 1 as a 
substrate/ drug 2 as an inhibitor) 
Interacting gene (Drug 2 as a 
substrate/ drug 1 as an inhibitor) 









CYP2C8, CYP3A4, CYP2C9, 
CYP2C19 
3 10 Simvastatin-Lansoprazole CYP3A4, CYP2C8 CYP2C8, CYP3A4, CYP2C19 
4 16 Simvastatin-Bisoprolol NA CYP3A4 











7 26 Simvastatin-Gliclazide NA CYP2C9, CYP2C19 
8 28 Amlodipine-Atorvastatin NA CYP3A4 
9 32 Omeprazole-Amlodipine CYP3A4 , CYP1A1 NA 





























CYP3A4, CYP2C8, CYP2C19, 
ABCB1 
14 39 Simvastatin-Losartan CYP3A4, CYP2C8 CYP2C8, CYP3A4, CYP2C9 
15 40 Atorvastatin-Bisoprolol NA CYP3A4 
16 41 Simvastatin-Clopidogrel CYP3A4, CYP2C8 CYP3A4, CYP2C9, CYP2C19 
17 42 Amlodipine-Lansoprazole NA CYP3A4 
18 43 Atenolol-Lansoprazole ABCB1 ABCB1 









CYP2C8, CYP3A4, CYP2C9, 
CYP2C19 
21 46 Simvastatin-Ranitidine CYP3A5, CYP3A4 CYP2D6, CYP2C19 
22 47 Simvastatin-Furosemide ABCC2 NA 
23 48 Simvastatin-Citalopram NA CYP2D6, CYP3A4, CYP2C19 









CYP3A4, CYP2C9, CYP2C19, 
ABCB1 







Interacting gene (Drug 1 as a 
substrate/ drug 2 as an inhibitor) 
Interacting gene (Drug 2 as a 
substrate/ drug 1 as an inhibitor) 
1 1 Simvastatin-Ramipril NA NA 
2 2 Simvastatin-Bendroflumethiazide NA NA 
3 3 Simvastatin-Metformin NA NA 
4 5 Simvastatin-Atenolol NA NA 
5 7 Simvastatin-Lisinopril NA NA 
6 8 Bendroflumethiazide-Amlodipine NA NA 
7 9 Bendroflumethiazide-Ramipril NA NA 
8 11 Bendroflumethiazide-Atenolol NA NA 
9 12 Ramipril-Amlodipine NA NA 
10 13 Metformin-Gliclazide NA NA 
11 14 Ramipril-Atorvastatin NA NA 
12 15 Ramipril-Atenolol NA NA 
13 17 Ramipril-Metformin NA NA 
14 18 Bendroflumethiazide-Lisinopril NA NA 
15 20 Amlodipine-Atenolol NA NA 
16 21 Atorvastatin-Metformin NA NA 
17 22 Simvastatin-Perindopril NA NA 
18 23 Omeprazole-Bendroflumethiazide NA NA 
19 25 Bendroflumethiazide-Atorvastatin NA NA 
20 27 Omeprazole-Ramipril NA NA 
21 29 Amlodipine-Metformin NA NA 
22 30 Ramipril-Bisoprolol NA NA 
23 31 Omeprazole-Atenolol NA NA 
24 34 Amlodipine-Lisinopril NA NA 




                             3.2 Selection of candidate genetic variants 
 
In chapter III, I have shown the detailed process of selecting the genetic variants of 
interest in genes encoding drug-metabolizing enzymes and transporters. The same list 
of 162 SNPs in important enzymes and transporters selected previously will be 
considered here in this DDGI study. 
 
 
                            3.3 Defining drug response phenotypes 
 
I have also presented the detailed methods in defining drug response phenotypes in 
chapter III, considering both cross-sectional and longitudinal prescribing data. I 
briefly describe these in terms of DDGIs below. 
                  3.3.1 In cross-sectional prescribing data (UK Biobank) 
 
Here we again use deviation from HWE as an indication of selection seen where an 
allele is enriched or depleted in patients exposed to a particular drug combination. 
This enrichment or depletion may reflect one of two ‘drug response’ phenotypes: 
• Increased efficacy and/or decreased side effects: 
 
this occurs when the variant allele is found to be enriched within the drug 
 
combination users compared to non-users. If those with a specific drug-drug- 
variant combination have a higher allele frequency, this would suggest that the 
enriched allele is beneficial for these patients in term of increased efficacy, 
low side effects, or both. 
• Decreased efficacy and/or increased side effects: 
 
this occurs when the variant allele is found to be significantly depleted within 
 
the drug combination users compared to non-users. If those with a specific 
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drug-drug-variant combination have lower allele frequency; this would reflect 
that the depleted allele was disadvantageous for these patients in term of 
decreased efficacy, increased side effects, or both. 
 
 
Of note, deviation from HWE can be caused by other reasons rather than using 
the drug combination such as a deviation occurring due to diseases for which 
the drug combination is used. We have dealt with this issue by using 
GeneAtlas database to identify whether the significant SNP we have 
discovered is correlated with diseases for which any of the two drugs are 
usually prescribed for. If a clear disease association was found, I exclude the 
result from our list of UKBB results. The second issue is that the discovered 
SNP might be correlated with using only one of the two drugs but not 
necessarily because of using the drug combination. To deal with this issue, I 
discuss our results in the light of our findings from our DGIs study from 
chapter III and explain whether the discovered SNP is exclusively correlated 
with using the drug combination only or it is also correlated with using one of 
the two drugs. 
 
 
          3.3.2 In longitudinal prescribing data (the combined cohort) 
 
Two drug response phenotypes were studied: drug-stop and dose-decrease. After 
identifying patients who were prescribed the drug combination of interest, they were 
classified into cases and controls. Cases were those who stopped (i.e. had only one 
prescription) any of the two chronic drugs during their interaction. The control group 
represented patients who were on the same drug combination but had two or more 
prescriptions from both drugs during the interaction time. 
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Similarly, for the dose-decrease phenotype, individuals who reduced the daily dose of 
any of the two drugs during the interaction time were considered cases while those 
who never reduced their daily dose of any of the two drugs since being co-prescribed 
were considered controls. 
                        3.4 Testing the association between the genetic variants and the phenotypes 
 
Using "SNPassoc" R package, I ran a case-control genetic analysis under the log- 
additive model to explore the associations between the 162 selected genetic variants 
and each drug response phenotype for each cohort, for all 50 drug combinations. The 
Bonferroni adjusted p-value for significance was p < = 0.00030 (0.05/162). 
                          3.5 Development of an online database to view the results 
 
Given the large number of results produced, in parallel to work presented on DGIs 
in chapter III, I developed a dynamic, user-friendly online database to view all 
results visually (graphs) or as tables using Caspio software. 
 
 
      4. Results 
 
For the combined Scottish data, examining the association between the drug-stop 
phenotype for 50 drug combinations and 162 genetic variants produced a total of 
8,100 results; the same number of findings were also produced for the dose-decrease 
phenotype from the combined cohort taking the total findings into 16,200. 
Considering the UKBB cross-sectional cohort, I tested changes in the genotype 
distribution of the 162 variants between users of each of the 50 drug combinations 
versus non-users which produced a total of 8,100 findings. 
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In order to facilitate viewing of the results, all results can be accessed via an online 
database under this link: 
https://c1abo933.caspio.com/dp/d81f7000033513b3ab1c4431b5a2 
There were 769 findings with a nominal significance level (p <= 0.05) from the 
combined cohort when considering both the drug-stop and dose-decrease phenotypes. 
381 of these results belong to the ‘interacting combinations’ while the other 388 
findings are from the ‘combinations with unknown interaction routes’ category. 
The results from the UKBB cross-section cohort show a total of 489 findings with p- 
values <= 0.05. Of which, 239 results are from the ‘interacting combinations’, and 
the other 250 findings are from the ‘combinations with unknown interaction routes’ 
category. 
The classification for the significant DDGI results differs from the DGI results 
classification presented in chapter III. The number of published DGIs papers (n ~ 
23,000, according to PharmGKB) is much higher than the ones published on DDGIs 
(n = 33, according to our review in chapter I). This means it will not be possible to 
show prior published results that we replicate in our analysis, meaning the majority, if 
not all, of our DDGIs findings, should be considered novel but in need of replication. 
The results for our DDGI study are structured as follows: 1) the associations which 
have passed Bonferroni significance level; 2) potentially important associations from 
the ‘interacting combination’ category which didn't pass Bonferroni significance 
level; 3) potentially important associations which didn't pass Bonferroni significance 
level from the ‘combinations with unknown interaction routes’ category. In the below 
sections, I present results belonging to these 3 categories. 
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                           4.1 Significant associations after Bonferroni correction (p <=0.0003) 
 
Table 10, at the end of the results section, summarizes all findings under this category. 
 
 
                 4.1.1 The combined Scottish cohorts (n = 3). 
 
There were 3 associations significant after Bonferroni correction in the combined 
Scottish cohorts; these are outlined below. 
 
 
                       4.1.1.1 Atorvastatin-Bisoprolol-rs9516519 (ABCC4) 
 
The ABCC4 variant, rs9516519 (T>G) was strongly associated with atorvastatin- 
bisoprolol use (p=1.48 × 10-5). The G- allele was associated with a 4.72 (2.44-9.13) 
times increased risk of stopping any of the two drugs when administered together. 
                        4.1.1.2 Simvastatin-Metformin-rs622342 (SLC22A1) 
 
There was an interaction between simvastatin and metformin use in combination with 
 
rs622342 (C(minor allele)>A) in SLC22A1 (p=9.3 × 10-5). The C-allele was associated 
with a 3.1 (1.71-5.65) times greater odds of stopping any of the two drugs during their 
combined use. 
                      4.1.1.3 Metformin-Gliclazide-rs1967120 (ABCC1) 
 
We also found that the rs1967120 (G(minor allele)>A) variant in ABCC1 gene is 
associated with increased odds of decrease in daily dose of either metformin or 
gliclazide when used in combination (OR 1.21 (1.01-1.33); p= 9.3 × 10-5). 
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                4.1.2 The UKBB (cross-sectional) cohort results (n = 7) 
 
There were 15 results significant after Bonferroni correction. However, using 
GeneAtlas it was apparent that 8 of these were associated with the underlying disease, 
with 7 appearing disease independent. These 7 results are outlined below: 
                   4.1.2.1 Bendroflumethiazide-Metformin-rs2199939 (ABCG2) 
 
Our results show a significant depletion of the T-allele at rs2199939 (C>T) in ABCG2 
gene within patients on this drug combination (p=5.29 × 10-5). Detection of the T-
allele in this group is 19% (10%-27%) less likely compared to individuals not on this 
drug combination. 
                    4.1.2.2 Simvastatin-Furosemide-rs4148739 (ABCB1) 
 
There was a 26% (13%-41%) higher chance for the C-allele at rs4148739 (T>C) in 
ABCB1 gene to occur among users of the simvastatin-furosemide combination 
compared to non-users (p=6.07 × 10-5). 
          4.1.2.3 Atorvastatin-Metformin-rs10937158/rs2293001 (ABCC5) / 
rs17731538(ABCG2) ( 3 associations) 
 
Two ABCC5 variants, rs10937158 (T(minor allele)>C) and rs2293001 (C>T) , were 
associated with atorvastatin-metformin use (p-values = 1.04 × 10-4 and 1.6 ×10-4 
respectively). The odds carrying the T-allele was 13% (6%-20%) higher and 11% (6%- 
17%) lower among users of this drug combination for both variants respectively. 
Another ABCG2 variant, rs17731538 (G>A), was also associated with this drug pair as 
there was a 15% (7%-22%) lower odds for carriage of the A-allele among users of this 
drug combination (p=1.9 × 10-4). 
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                       4.1.2.4 Amlodipine-Atorvastatin-rs3735451 (CYP3A4) 
 
There was an interesting association between the rs3735451 (T>C) polymorphism in 
CYP3A4 gene and the concomitant use of amlodipine and atorvastatin (p=1.3 × 10-4). 
There was a 21% (1%-34%) higher chance of being a C-allele carrier among the 
combination users compared to non-users. 
                      4.1.2.5 Simvastatin-Metformin- rs215095 (ABCC1) 
 
The frequency of the G-allele at rs215095 (G(minor allele)>A) ABCC1 variant was 10% 
(5%-16%) lower within those on the simvastatin-metformin combination (p=2.606 × 
10-4) compared to non-users of these drugs. 
 
 
                4.2 Potential important associations which didn't pass Bonferroni significant level from the                
interacting combinations. 
 
Under this category of results, I include associations, which although not significant 
after Bonferroni correction, are still of interest as they fulfil 5 criteria: Firstly, the p-
value significance level was modest (p > 0.00030 and <= 0.009). Secondly, there is a 
predicted interaction between the two drugs (from our list of top 25 interacting 
combinations). Thirdly, at least one of the two drugs is a substrate for the gene 
relevant to the detected variant (according to DrugBank or external references). 
Fourthly, they occur with a genetic variant that has been previously associated with at 
least one drug response phenotype (according to PharmGKB). Finally, there was also 
a clear route of interaction consistent with the observed direction of effect. 
There were 8 drug-drug-variant associations in this category from the combined 
Scottish cohort and other 10 results from the UKBB cohort. 
Table 10, at the end of the results section, summarizes all findings under this category. 
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                       4 .3 Potential important associations which didn't pass Bonferroni significance level from the 
combinations with unknown routes of interactions 
 
Under this category, I include results fulfilling the same criteria as in before, but it 
differs in that the drug combinations selected here belong to the top 25 combinations 
with no prior known mechanism to support an interaction. As explained earlier, a 
‘combination with unknown interaction routes’ doesn’t necessarily imply a 
completely safe combination as there might be some undiscovered routes of 
interactions between the two drugs. In this category, we focus on results with a 
moderate p-value significance level, one of the two drugs is a known substrate for the 
associated gene, and existence of at least one study linking the variant with any drug 
response phenotype. A total of 11 findings from the combined cohort and other 10 
findings from the UKBB cohort have been identified under this category. 
Table 10 below, summarizes all findings under this category and all other 
categories. 
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Table 10: Summary of 49 most important drug-drug-gene associations as classified into 3 categories. 
 
  1) Results significant after Bonferroni correction     
No. Drug_Combination Cohort Phenotype SNP_id Gene OR Lower Upper P.value 
1 Atorvastatin-Bisoprolol Combined Drug Stop rs9516519 ABCC4 4.72 2.44 9.13 1.48E-05 
2 Simvastatin-Metformin Combined Drug Stop rs622342 SLC22A1 3.1 1.71 5.62 9.30E-05 
3 Metformin-Gliclazide Combined Dose Decrease rs1967120 ABCC1 1.21 1.1 1.33 9.30E-05 
4 Bendroflumethiazide-Metformin UKBB NA rs2199939 ABCG2 0.81 0.73 0.9 5.29E-05 
5 Simvastatin-Furosemide UKBB NA rs4148739 ABCB1 1.26 1.13 1.41 0.0000607 
6 Atorvastatin-Metformin UKBB NA rs10937158 ABCC5 1.13 1.06 1.2 0.000104 
7 Amlodipine-Atorvastatin UKBB NA rs3735451 CYP3A4 1.21 1.1 1.34 0.00013 
8 Atorvastatin-Metformin UKBB NA rs2293001 ABCC5 0.89 0.83 0.94 0.00016 
9 Atorvastatin-Metformin UKBB NA rs17731538 ABCG2 0.85 0.78 0.93 0.00019 
10 Simvastatin-Metformin UKBB NA rs215095 ABCC1 0.9 0.84 0.95 0.0002606 
  2) Potential important associations form the interacting drug combinations  
No. Drug_Combination Cohort Phenotype SNP_id Gene OR Lower Upper P.value 
1 Simvastatin-Warfarin Combined Drug Stop rs4148386 ABCC2 16.07 2.08 124.4 0.0005896 
2 Simvastatin-Warfarin Combined Drug Stop rs3814637 CYP2C19 9.04 2.66 30.67 0.002732 
3 Atorvastatin-Bisoprolol Combined Drug Stop rs4149032 SLCO1B1 2.95 1.51 5.75 0.001353 
4 Atorvastatin-Bisoprolol Combined Dose Decrease rs9561778 ABCC4 1.28 1.09 1.52 0.003919 
5 Omeprazole-Atorvastatin Combined Dose Decrease rs3814637 CYP2C19 1.5 1.14 1.97 0.005291 
6 Amlodipine-Lansoprazole Combined Drug Stop rs3814637 CYP2C19 2.61 1.37 4.97 0.005736 
7 Atorvastatin-Lansoprazole Combined Dose Decrease rs4148739 ABCB1 1.34 1.08 1.67 0.00851 
8 Atorvastatin-Clopidogrel Combined Dose Decrease rs4149118 SLCO1B3 1.38 1.09 1.76 0.00905 
9 Simvastatin-Lansoprazole UKBB NA rs4148739 ABCB1 1.11 1.04 1.18 0.00327 
10 Simvastatin-Omeprazole UKBB NA rs1128503 ABCB1 1.05 1.01 1.1 0.00822 
11 Simvastatin-Furosemide UKBB NA rs8187707 ABCC2 1.28 1.09 1.5 0.00398 
12 Simvastatin-Furosemide UKBB NA rs1045642 ABCB1 1.13 1.04 1.22 0.00415 
13 Simvastatin-Bisoprolol UKBB NA rs4149057 SLCO1B1 0.92 0.87 0.98 0.004773 
14 Simvastatin-Amlodipine UKBB NA rs3842 ABCB1 0.93 0.88 0.98 0.0067 
15 Simvastatin-Amlodipine UKBB NA rs1045642 ABCB1 0.95 0.92 0.99 0.00935 
16 Atorvastatin-Bisoprolol UKBB NA rs2306283 SLCO1B1 1.11 1.03 1.2 0.00853 
17 Atorvastatin-Bisoprolol UKBB NA rs899494 ABCC4 0.83 0.74 0.94 0.00238 
18 Atorvastatin-Bisoprolol UKBB NA rs2712807 SLCO2B1 0.88 0.79 0.97 0.00966 
  3) Potential important associations form combinations with unknown routes of interactions 
No. Drug_Combination Cohort Phenotype SNP_id Gene OR Lower Upper P.value 
1 Ramipril-Metformin Combined Drug Stop rs12208357 SLC22A1 3.13 1.5 9.32 0.0007356 
2 Ramipril-Amlodipine Combined Dose Decrease rs2054675 CYP2B6 0.61 0.44 0.84 0.0017 
3 Simvastatin-Ramipril Combined Dose Decrease rs34671512 SLCO1B1 1.82 1.3 2.55 0.00102 
4 Ramipril-Bisoprolol Combined Drug Stop rs3735451 CYP3A4 0.67 0.24 1.86 0.00127 
5 Omeprazole-Atenolol Combined Dose Decrease rs12248560 CYP2C19 1.3 1.1 1.54 0.00269 
6 Ramipril-Atorvastatin Combined Drug Stop rs4149032 SLCO1B1 2.33 1.34 4.05 0.00292 
7 Atorvastatin-Metformin Combined Drug Stop rs10937158 ABCC5 2.53 1.29 4.97 0.00462 
8 Simvastatin-Perindopril Combined Dose Decrease rs3814637 CYP2C19 1.9 1.24 2.93 0.006436 
9 Ramipril-Bisoprolol Combined Drug Stop rs10306135 PTGS1 3.25 1.47 7.2 0.0076 
10 Simvastatin-Perindopril Combined Drug Stop rs4148386 ABCC2 2.32 1.22 4.44 0.00814 
11 Simvastatin-Atenolol Combined Drug Stop rs622342 SLC22A1 0.51 0.3 0.87 0.009777 
12 Simvastatin-Ramipril UKBB NA rs4149118 SLCO1B3 1.06 1.03 1.1 0.0004548 
13 Simvastatin-Metformin UKBB NA rs11045879 SLCO1B1 0.93 0.89 0.98 0.00657 
14 Simvastatin-Atenolol UKBB NA rs1080985 CYP2D6 1.06 1.02 1.1 0.00367 
15 Omeprazole-Bendroflumethiazide UKBB NA rs4728709 ABCB1 1.17 1.04 1.31 0.00879 
16 Omeprazole-Atenolol UKBB NA rs2472297 CYP1A1 1.11 1.03 1.19 0.00669 
17 Ramipril-Atorvastatin UKBB NA rs4148386 ABCC2 1.08 1.03 1.14 0.00325 
18 Bendroflumethiazide-Atorvastatin UKBB NA rs3743527 ABCC1 0.88 0.82 0.96 0.00152 
19 Omeprazole-Atenolol UKBB NA rs628031 SLC22A1 0.91 0.85 0.98 0.00839 
20 Amlodipine-Lisinopril UKBB NA rs1045642 ABCB1 0.89 0.83 0.95 0.001134 




     5. Discussion 
 
To the best of our knowledge, this is the first pharmacogenomic study covering the 
drug-drug-gene interaction topic for a large variety of commonly used drug 
combinations in the UK. A total of 16,200 (combined cohort) and 8,100 (UKBB cohort) 
results have been generated and are available to view from an online database. In the 
sections below, I will only focus on discussing the first two categories of associations I 
have presented in the results section. 
                       5.1 Significant associations after Bonferroni correction 
 
              5.1.1 The combined cohort results (n = 3). 
 
The 3 significant associations under this section are investigated further in chapter V, 
where the UK Biobank primary care data is used for replication; a more detailed 
discussion will also follow in chapter V for these findings. 
5.1.2 The UKBB (cross-sectional) cohort results (n = 7) 
 
                   5.1.2.1 Bendroflumethiazide-Metformin-rs2199939 (ABCG2) 
 
Due to the lack of pharmacokinetic information for bendroflumethiazide, it is 
challenging to predict any potential pharmacokinetic route of interaction for 
bendroflumethiazide-containing combinations. However, it has been reported that 
high dose bendroflumethiazide significantly increases endogenous glucose production 
[192] suggesting increased potential for reducing metformin glucose-lowering effect. 
 
The minor allele (T) at rs2199939 (C>T) variant in the ABCG2 transporter is 
significantly depleted in patients treated with bendroflumethiazide and metformin, 
suggesting decreased tolerability or reduced efficacy with this drug combination. We 
also saw the same variant had a similar, but weaker, association for metformin-only 
174  
 
users from the UKBB cohort (OR = 0.97, p=0.098) in DGI study. This SNP was 
previously linked with increased rosuvastatin efficacy [193], suggesting reduced 
ABCG2 function resulted in increased rosuvastatin hepatic concertation and efficacy. 
However, it is unclear how ABCG2 transporter could influence bendroflumethaizde- 
metformin interaction. 
                   5.1.2.2 Simvastatin-Furosemide-rs4148739 (ABCB1) 
 
Simvastatin is a substrate for both ABCB1 and ABCC2 transporters [194,195] while 
furosemide is an ABCC2 inhibitor [196]. Inhibiting hepatic efflux transporters of 
simvastatin could results in increased efficacy, due to increased hepatic simvastatin 
accumulation, and increased toxicity as a result of increased plasma concentration. 
Both of these two phenotypes have been observed. For example, the rs717620 (C>T) 
SNP in the ABCC2 transporter has been reported to be associated with switching of 
and decreasing the dose of simvastatin therapy [197]. However, the minor reduced 
activity allele (A) at rs2032582 (A>C) ABCB1 SNP has been repeatedly seen to be 
correlated with improved efficacy of simvastatin [198]. In the same context, another 
reduced function variant in ABCB1 gene, rs4148739 (T>C), has been associated with 
increased antidepressant efficacy (due to decreased efflux of these drugs from the 
brain where these agents produce their efficacy) [199]. Consistent with this prior 
literature, our finding shows that simvastatin users carrying this variant allele in the 
ABCB1 transporter and co-treated with the ABCC2 inhibitor furosemide were more 
likely to be on this drug combination than people with the wild-type allele; probably 
due to increased simvastatin efficacy. This variant allele was only significant with 
users of simvastatin-furosemide combination but not with any of the two drugs 
individually according to our DGI study. 
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             5.1.2.3 Atorvastatin-Metformin-rs10937158/rs2293001 (ABCC5) / rs17731538 
(ABCG2) and Simvastatin-Metformin-rs215095 (ABCC1) 
 
To date, no route of pharmacokinetic interaction has been reported between 
atorvastatin and metformin. However, our results suggest that such a novel interaction 
could exist between the two drugs. I have shown that two independent variants in the 
ABCC5 transporter, rs10937158 (T(minor allele)>C) and rs2293001(C>T) seem to be 
associated with the usage of this drug combination. We show that harbouring the 
minor allele (T) is associated with increased (rs10937158) and decreased (rs2293001) 
tolerability for this drug combination. A previous study has demonstrated that 
atorvastatin is transported by ABCC5 and that this transporter is expressed on the 
skeletal muscles protecting the muscles from the intracellular accumulation of statins 
[200]. Interestingly, in our study the rs2293001(C>T) ABCC5 variant was associated 
with decreased tolerability to each drug individually (atorvastatin: OR = 0.98, 
p =0.03, metformin: OR = 0.96, p=0.0031), as well as in combination (atorvastatin- 
metformin: OR = 0.89, p=0.00016). Regarding the rs10937158 (T(minor allele)>C) 
ABCC5 variant, this variant is also present at slightly higher frequency among 
metformin-only users (OR = 1.05 , p =1.9 × 10-4), and further enriched with when 
combined with atorvastatin (OR = 1.13 , p=1.0 × 10-4). In keeping with the direction 
of effect we observed (increased tolerability), the T allele at this variant has also been 
reported to be linked to decreased irinotecan-induced severe diarrhoea [201]. 
 
 
Furthermore, genetic variants in ABCG2 transporter markedly alter atorvastatin 
plasma concentration [202]. In this DDGI study, the A-allele at rs17731538 (G>A) in 
ABCG2 gene is at a lower frequency in atorvastatin-metformin users than non-users 
suggesting decreased tolerability or efficacy. Consistent with this, the A-allele at this 
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variant has also been linked with decreased methotrexate therapeutic efficacy [203]. 
Although we are not aware of any pharmacokinetic route of interaction between the 
two drugs, our results outlined here merit further investigation in in-vitro systems. 
 
 
In addition, as mentioned earlier, there is no known route of interaction between 
simvastatin and metformin. However, our DGI study reveals that the minor allele (G) 
at rs215095 (G(minor allele)>A) variant in the ABCC1 transporter was associated with 
reduced tolerability to each drug individually (simvastatin : OR = 0.98 , p=0.071 , 
metformin : OR = 0.94 , p=0.0034) before observing a larger effect when both drugs 
are combined together (simvastatin-metformin : OR = 0.90 , p=2 × 10-4). 
Interestingly, this is the second metformin-containing combination showing a 
correlation with the ABCC1 transporter in an independent variant and toward the 
same direction of effect (increased likelihood to decrease the dose). 
                        5.1.2.4 Amlodipine-Atorvastatin-rs3735451 (CYP3A4) 
 
Both atorvastatin and amlodipine are extensively metabolized in the liver with the 
CYP3A4 being the major metabolic pathway of both agents [204,205]. This 
suggests the potential for a competitive inhibition of the victim drug (atorvastatin) 
by the perpetrator drug (amlodipine) due to a shared route of elimination. In a 
drug-drug interaction study presented by Food and Drug Administration (FDA), 
atorvastatin did not change the pharmacokinetics of amlodipine while the latter 
resulted in an 18% increased atorvastatin plasma drug concentration which was 
deemed not to be clinically significant [206]. However, the finding from our study 
suggests that genetic variation in CYP3A4 could affect the therapeutic efficacy of 
atorvastatin when combined with amlodipine. The C-allele frequency of the 
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rs3735451 (T>C) CYP3A4 variant in patients on this drug combination were 
higher compared to those not on the combination suggesting a beneficial drug- 
drug-gene interaction. A couple of pharmacogenomic studies have linked CYP3A4 
polymorphisms with atorvastatin efficacy and pharmacokinetics. Carriers of the 
reduced activity allele T of rs35599367 (C>T) in CYP3A4 required lower 
atorvastatin dose compared to non-carriers [207]. In contrast, the CYP3A4 gain-of-
function variant rs2740574 (C>T) was associated with a low risk to reduce 
atorvastatin dose, low risk to switch it to an alternative drug, or increased 
atorvastatin plasma concentration [208]. Here, we also report another CYP3A4 
variant (rs3735451 (T>C)) which was significant with the use of both drugs 
together but not atorvastatin alone. This is predicted to be a reduced activity 
variant as a previous report shows it is correlated with increased methadone (a 
CYP3A4 substrate)-related side effects [209].The exact mechanism of the 
atorvastatin-amlodipine-rs3735451 (T>C) interaction remains uncertain, but it 
seems likely that the combined competitive inhibitory effect of amlodipine on 
CYP3A4 and the reduced CYP3A4 activity (by rs3735451 (T>C) variant) would 
result in elevated hepatic atorvastatin concentration leading to the increased 
therapeutic efficacy of atorvastatin since the liver is its site of action. 
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                      5.2 Potential important associations which didn't pass Bonferroni significance level from the 
interacting combinations 
 
                   5.2.1 The combined cohort results (n = 8). 
 
                      5.2.1.1 Simvastatin-Warfarin-rs4148386 (ABCC2) /rs3814637(CYP2C19) 
 
The interaction route between simvastatin and warfarin is complex as both drugs 
share multiple elimination pathways and can inhibit each other in multiple pathways. 
Both drugs are substrates for CYP3A4, CYP2C8, and CYP2C19 with warfarin being 
an inhibitor for CYP2C8 and simvastatin being a substrate for ABCB1 and ABCC2 
transporters and an inhibitor for CYP2C8 and CYP2C9 enzymes [210-212]. These 
complex interaction routes suggest that toxicity could be seen from either of the two 
drugs. For example, a previous report has shown that warfarin was one of the 
common interacting drugs among patients who developed statin-induced 
rhabdomyolysis and that simvastatin was the most frequently reported statin among 
the affected individuals [213]. Genetic variability could influence this risk. I have 
shown that minor allele (G) at rs4148386 (G (minor allele)>A) in ABCC2 was 
associated with increased risk for stopping either of the two drugs combined use. This 
could result from the double inhibitory effects on two simvastatin elimination 
pathways: ABCC2 (by the G allele which was reported previously to be linked with 
decreased carbamazepine clearance [214] suggesting reduced ABCC2 function) and 
CYP2C8 (by warfarin treatment) resulting in increased simvastatin toxicity. 
On the other hand, it has been illustrated that warfarin users co-treated with 
simvastatin have a moderate increase in warfarin-induced bleeding [215]. It has been 
reported that carriers of the CYP2C9*3 reduced function variant required lower 
warfarin doses compared to non-carriers when co-treated with simvastatin [216]. 
Similarly, our results identified that a variant, rs3814637 (C>T), in another warfarin 
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elimination pathway (CYP2C19) is linked with stopping any of the two drugs during 
their combined use. It is worth noting that this variant was previously linked with the 
need for lower warfarin doses [217] which is consistent with our finding. The 
difference, however, is that in the DDGI study this variant is linked with the drug-stop 
phenotype only where there is concomitant use of the two drugs but not with 
warfarin-only users (see DGI study results). 
 
                 5.2.1.2 Atorvastatin-Bisoprolol-rs4149032 (SLCO1B1) / rs9561778 (ABCC4) 
 
Atorvastatin and bisoprolol could interact through the CYP3A4 enzyme pathway. 
Bisoprolol is metabolized by the CYP3A4 enzyme [218] while atorvastatin is an 
inhibitor for CYP3A4 [219] suggesting potential changes in the pharmacokinetics of 
bisoprolol due to both atorvastatin use and the CYP3A4 genotype. We identified two 
genetic variants, rs4149032 (C>T) and rs9561778 (G>T), in SLCO1B1 and ABCC4, 
respectively that seemed to influence this interaction. The former SNP has been 
previously reported to decrease letermovir and rifampicin (SLCO1B1 substrates) 
systemic exposure [220,221]; two findings suggesting the variant is gain-of-function 
for SLCO1B1 hepatic uptake activity. I found that this SNP is linked with increased 
odds of stopping one of the two drugs, bisoprolol or atorvastatin, during their 
combined use. I propose that increased atorvastatin hepatic uptake by SLCO1B1 will 
result in increased atorvastatin hepatic accumulation, which in turn, could result in an 
increased CYP3A4 inhibitory effect and therefore, increased bisoprolol toxicity even 
though this could be also associated with increased efficacy. The other ABCC4 variant 
(rs9561778) has been reported to increase cyclophosphamide side effects [222]. 
Cyclophosphamide is a prodrug which is heavily activated and metabolized in the 
liver [222]. This drug and its active metabolites are transported by ABCC4 [222]. 
ABCC4 is expressed in the basolateral hepatic membrane facilitating the efflux of 
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xenobiotics into the systemic circulation. One proposed mechanism for the increased 
cyclophosphamide toxicity is that the rs9561778 (G>T) variant might be associated 
with increased ABCC4 function and increased systemic cyclophosphamide exposure 
accordingly. We show that carriers of this variant who were on the atorvastatin- 
bisoprolol combination were at increased risk of a decrease in the daily dose of either 
of the two drugs when taken concomitantly. One possible mechanism is that the 
combined effect between CYP3A4 inhibition by atorvastatin and the SNP associated 
increased efflux by ABCC4 could result in increased bisoprolol plasma concentration 
and toxicity. None of the two variants significantly altered drug response phenotype 
with each of the drugs individually, only when combined. 
                 5.2.1.3 Omeprazole-Atorvastatin-rs3814637 (CYP2C19) , Lansoprazole-
Amlodipine-rs3814637 (CYP2C19), and Lansoprazole-Atorvastatin-rs4148739 (ABCB1) 
 
Omeprazole and lansoprazole are primarily metabolized by CYP3A4 and CYP2C19 
enzymes with some contribution of CYP2C9 and CYP2C8 [223,224]. The two drugs 
are also substrates and inhibitors for ABCB1 transporter [223,224]. Atorvastatin is a 
substrate and inhibitor for CYP3A4 and ABCB1; it is also an inhibitor for CYP2C8, 
CYP2C9 and CYP2C19 [219,225] while amlodipine is a substrate and weak inhibitor 
for CYP3A4 enzyme [205,226]. The reduced activity variants CYP2C19*2/*3 have 
been repeatedly correlated with increased omeprazole/lansoprazole therapeutic 
efficacy [227,228]. CYP2C19*3 is extremely rare in the European ancestry, but even 
for the common CYP2C19*2 variant, we couldn't see this SNP to be significantly 
correlated with drug-stop or dose-decrease phenotype for any of the two drugs. 
Nevertheless, our findings show another independent low activity CYP2C19 SNP 
(rs3814637 (C>T)) seemed to be associated with increased toxicity from these two 
proton pump inhibitors (PPIs) when they are co-administered with other interacting 
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drugs. Carriers of this variant who were either treated with omeprazole-atorvastatin or 
lansoprazole-amlodipine combinations were more likely to decrease the dose of or 
stop any of the two drugs during their combined use respectively. The existence of 
other risk factors such as atorvastatin (a CYP3A4/CYP2C19 inhibitor) or amlodipine               
(a CYP3A4 inhibitor/competitive inhibitor) could have resulted in increased PPIs-
related side effects. 
As outlined above, lansoprazole and atorvastatin are both substrates and inhibitors for 
ABCB1 transporters suggesting that the victim drug could be either of the two drugs. 
As with the other two PPI-containing combinations above, no pharmacokinetic drug- 
drug interaction studies have been reported for lansoprazole and atorvastatin. 
However, our results demonstrate that those with the low activity ABCB1 variant 
rs4148739 (T>C) had higher odds to reduce the dose of either lansoprazole or 
atorvastatin when the two drugs are used concomitantly. 
                    5.2.1.4 Atorvastatin-Clopidogrel-rs4149118 (SLCO1B3) 
 
The interaction between atorvastatin and clopidogrel could be primarily mediated via 
CYP3A4 competitive inhibition pathway as both drugs are substrates for CYP3A4 
[204,155]. One previous study reported that the percentage of cardiovascular events 
was higher among users of both atorvastatin and clopidogrel compared to users of 
clopidogrel alone [229]. This clinical outcome could occur as a result of reduced 
efficacy of either of the two drugs. The authors have suggested that the mechanism 
could be as a result of the competitive inhibition of CYP3A4 by atorvastatin resulting 
in decreased activation of clopidogrel into its active metabolites. However, an 
alternative explanation could be mediated via SLCO1B3. I have shown that carriers of 
the minor allele (G) at rs4149118 (G>A) in SLCO1B3 were more likely to decrease 
the dose of atorvastatin or clopidogrel during their combined use. In a previous study, 
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the G-allele has been reported to be associated with decreased clearance and increased 
plasma concentration of docetaxel (a SLCO1B3 substrate) indicating reduced hepatic 
uptake of the drug [230]. It could be the case that decreased atorvastatin uptake into 
the liver in addition to the competitive CYP3A4 inhibition by clopidogrel have 
resulted in increased atorvastatin plasma concentration and reduced efficacy. 
Increased toxicity could lead to dose reduction (according to our finding), and 
reduced efficacy could lead to increased cardiovascular events as has been shown in 




                  5.2.2 The UKBB (cross-sectional) cohort results (n=10). 
 
All results under this category represent statin-containing combinations. There are 7 
simvastatin- and 3 atorvastatin-containing associations which are discussed below. 
5.2.2.1 Simvastatin-Lansoprazole-rs4148739 (ABCB1) and Simvastatin-Omeprazole-
rs1128503 (ABCB1) 
 
As mentioned previously, simvastatin is a substrate for CYP3A4, CYP2C8, and 
CYP2C19 enzymes and is transported by ABCB1 and ABCC2 transporters. The drug 
is an inhibitor for CYP2C8, CYP2C9, and ABCB1. As also previously mentioned, 
lansoprazole and omeprazole are metabolized by CYP3A4 and CYP2C19 enzymes 
and are substrates for ABCB1 transporter. The two drugs are also inhibitors for 
CYP3A4 and ABCB1 genes. The elimination pathways presented here for simvastatin 
and these two PPIs suggest that they can interact with each other via multiple routes 
either by direct or competitive inhibition, mainly mediated by CYP3A4, CYP2C19, 
and ABCB1 pathways. In one previous study [231], PPIs use was shown to have a 
modest increase of statin lipid-lowering efficacy. In keeping with this, the results from 
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our DDGI study shows that carriers of the ABCB1 variants: rs4148739 (T>C) or 
rs1128503 (A(minor allele)>G) are more likely overrepresented in the simvastatin- 
lansoprazole or simvastatin-omeprazole combinations respectively. In fact, in two 
previous studies [232,233], the latter variant allele (A allele at rs1128503 SNP), has 
been associated with increased low-density lipoprotein (LDL) reduction among 
simvastatin users. However, the results from our DGI study from the UKBB found no 
association between this variant and efficacy/tolerability of simvastatin (OR = 1.01, 
p=0.41). The association was only significant among simvastatin users who are co-
treated with omeprazole. Thus, the evidence indicates the existence of a favourable 
interaction between simvastatin and PPIs which may be consequent to reduced 
ABCB1 function by PPIs and/or carriage reduced activity variants in ABCB1 
transporter, in addition to the known CYP3A4/CYP2C19 competitive inhibition by 
PPIs on simvastatin elimination pathway. Statin-PPI interactions need to be further 
investigated considering different clinical outcomes such as the effect of statins on 
PPIs safety and efficacy. 
               5.2.2.2 Simvastatin-Furosemide-rs8187707 (ABCC2)/ rs1045642 (ABCB1) 
 
As outlined previously, furosemide could interact with simvastatin by inhibiting the 
hepatic efflux transporter ABCC2 which contributes to simvastatin biliary excretion. I 
have also reported a DGI study linking the rs717620 (T>C) ABCC2 SNP with 
increased odds of simvastatin dose reduction, although in UK Biobank we did not see 
such an association. However, in the DDGI study, I have identified another 
independent ABCC2 variant which is associated with the opposite direction of effect 
when simvastatin is co-administered with furosemide. Carriers of the rs8187707 
(C>T) variant in ABCC2 transporter seemed more tolerant to this drug combination 
as indicated by enrichment of this variant in this treatment group. This SNP has been 
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previously been reported to be associated with increased tenofovir renal-related 
adverse reactions [234]. It has also been reported that tenofovir is a substrate for the 
ABCC2 transporter and that inhibition of this transporter by ritonavir increased 
tenofovir-related toxicity [235]. These observations could indicate that the rs8187707 
(C>T) is a reduced activity variant. As a result of this, this reduced function variant 
could combine with furosemide to inhibit ABCC2, resulting in reduced simvastatin 
hepatic efflux and, in turn, increased efficacy which could explain our observation. 
There could be a similar explanation for those carrying the rs1045642 (A>G) ABCB1 
 
variant and co-treated with the ABCC2 inhibitor furosemide. 
 
                  5.2.2.3 Simvastatin-Bisoprolol-rs4149057 (SLCO1B1) 
 
As discussed previously, bisoprolol is mainly metabolized by CYP3A4; which 
implies that simvastatin and bisoprolol could interact with each other via competitive 
inhibition on CYP3A4 enzyme. The SLCO1B1 variant, rs4149057 (T(minor allele)>C, 
SLCO1B1*18), has been reported to be associated with decreased rosuvastatin          
(a SLCO1B1 substrate) hepatic uptake [236]. Our results show that this variant was 
found in a lower frequency within individuals treated with simvastatin and bisoprolol. 
Both reduced simvastatin hepatic uptake and the competitive inhibitory effect of 
bisoprolol on CYP3A4 could result in increased simvastatin plasma levels and 
toxicity as well as a loss of its efficacy. These phenotypes could explain our finding 
that the SLCO1B1*18 variant is linked to decreased tolerability to this drug 
combination. 
                      5.2.2.4 Simvastatin-Amlodipine-rs3842/rs1045642 (ABCB1) 
 
Both simvastatin and amlodipine are metabolized by CYP3A4, suggesting a 
competitive inhibition could result between the two drugs. Results from drug-drug 
interaction studies demonstrate that amlodipine has significantly increased the plasma 
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concentrations of simvastatin [237]. Therefore, the Medicines and Healthcare 
Products Regulatory Agency (MHRA) has recommended reducing simvastatin dose 
from 40 mg to 20 mg for patients who are co-treated with amlodipine [238] to avoid 
simvastatin-induced myopathies. Amlodipine can also interact with simvastatin via 
the ABCB1 transporter as it is a substrate and inhibitor for this transporter [239,240]. 
In the UK Biobank DDGI study, the minor alleles of the ABCB1 variants rs3842 
(T>C) and rs1045642 (A>G) were depleted among users of this drug combination 
suggesting decreased tolerance and/or efficacy. rs3842 has been reported to be 
associated with increased systemic exposure to efavirenz, suggesting decreased 
ABCB1 activity [241] while rs1045642 has shown conflicting results regarding its 
functional impact on simvastatin pharmacokinetics [242]. It might be the case that 
the existence of two risk factors (CYP3A4 inhibition by amlodipine + ABCB1 
reduced activity) have resulted in increased simvastatin toxicity leading to the 
decreased tolerability we have observed. It is worth noting that none of these two 
variants was significant with simvastatin-only users from the UKBB (OR = 0.98, p= 
0.1096, and OR = 0.99, p=0.1408 respectively) and were only significant with those 
on simvastatin and amlodipine combination. 
 
 
5.2.2.5 Atorvastatin-Bisoprolol-2306283 (SLCO1B1)/ rs2712807 (SLCO2B1)/                    
rs899494 (ABCC4) 
 
As outlined previously, the two drugs could interact via CYP3A4 route. Interestingly, 
our results from both the combined and the UKBB cohorts show multiple lines of 
evidence that the use of atorvastatin-bisoprolol combination could be influenced by 
genetic variability in the ABCC4 transporter and SLCO family of transporters. Firstly, 
for the ABCC4 transporter from the combined cohort, I have shown a significant 
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association after Bonferroni correction between the rs9516519 variant in ABCC4 
transporter and stopping any of the two drugs when used concomitantly. Secondly, 
another independent ABCC4 variant (rs9561778) from the same cohort was also 
observed to be associated with increased risk of reducing the dose of any of the two 
drugs during their interaction. Thirdly, I have identified another independent ABCC4 
SNP (rs899494 (A(minor allele)>G)) from an independent cohort (UKBB) to be linked 
with decreased tolerability to this combination. 
For the SLCO family, I have shown, firstly, an association of rs4149032 SLCO1B1 
SNP and stopping any of the two drugs when used together from the combined 
cohort. Secondly, from the UK Biobank, I showed that the minor allele (G) at 
rs2712807 (G(minor allele)>A) of SLCO2B1 was underrepresented in this treatment 
group suggesting increased side effects or reduced efficacy. Thirdly, I have also 
shown in the UK Biobank that carriers of the rs2306283 (A>G) SLCO1B1 variant 
seemed more tolerant to this combination. This variant has been previously reported 
to be associated with increased atorvastatin lipid-lowering efficacy [243]. However, 
another study found no association with atorvastatin response [244]. Our DGI study 
also shows no association between this variant and tolerability to atorvastatin. 
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      6. Conclusion 
 
In the light of the very limited knowledge we have to date on drug-drug-gene 
interactions (only 33 publications in the field according to our review in chapter I), 
the present work has provided for the first time a large-scale coverage of clinical 
pharmacogenomic associations between 162 genetic variants in important enzymes 
and transporters and 50 commonly used chronic drug combinations using 3 different 
drug response phenotypes (drug stop, dose decrease, and changes in genotype 
distribution among drugs' users) in two cohorts (the Scottish cohort + the UKBB 
cohort). I have generated a total of 24,300 drug-drug-genetic variants associations 
results which are accessible online via 
https://c1abo933.caspio.com/dp/d81f7000033513b3ab1c4431b5a2 . 
I have discovered a total of 10 novel drug-drug-genetic variant associations. I have 
also identified 18 potentially important novel associations within the list of interacting 
drug combinations. Finally, I also show other 21 potentially interesting associations 
between drugs not known to interact according to current knowledge. These might 
suggest novel routes of interactions which will require further investigation in the 
future. 
However, replication of DDGI results will be more challenging than that of DGI 
findings due to the small sample sizes in general requiring very large cohorts and 
the complexity of the phenotypes themselves. Instead of replication, validation of 
the findings by in-vitro studies would provide supportive evidence that our 





















Replication Results from the UKBB Primary Care 




     Abstract 
 
In this chapter, I undertake replication of the top 9 DGI results (8 passed Bonferroni 
significance level and 1 being the closest association to the Bonferroni significance 
level occurring in an interesting gene) and 3 DDG interactions findings from the 
combined cohort using the UKBB primary care data. 
Out of 9 novel DGIs associations; 3 associations have been replicated, validated, or 
have supporting evidence. 1)The C allele at rs4918758 (T>C) CYP2C9 SNP was 
associated with 30% (15%-40%; p= 8 × 10-5) and 19% (1%-33%; p=0.037) lower 
odds of quinine daily dose reduction for the discovery and the replication cohorts 
respectively (replicated). 2) Carriage of the A allele at rs9895420 (T>A) ABCC3 
variant was associated with a 46% (24%-62%) reduced odds for doxazosin dose 
reduction (p= 1.2 × 10-4, discovery) and 1.0mmHg greater reduction in systolic blood 
pressure (p =0.0089, validation). 3) In addition, the CYP2D6*2 variant representing 
an extensive metabolizer phenotype was observed to be linked with a 30% (18 %- 
40%) reduction in odds of stopping ramipril treatment (p = 1.01 × 10-5, discovery) 
while the CYP2D6*4 variant representing a poor metabolizer phenotype was 
associated with a 29% (8%-54%) increased odds of stopping the drug (p= 0.00654, 
supporting evidence). 
 
We have also detected one finding to be directionally consistent with a p-value close 
to the significance level in the replication cohort. The C allele at rs868853 ABCC4 
variant was correlated with reduced odds for decreasing amlodipine daily dose in the 
discovery (OR = 0.55, p = 2.8 × 10-4) and the replication cohort (OR = 0.86, p = 
0.092). We have also noted one other finding (Clopidogrel-rs12353214 (C>T, 
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PTGS1(COX-1))-drug-stop) to be close to the Bonferroni significance level in the 
discovery cohort (OR = 0.57; p= 5.3 × 10-4); this was also close to significance level 




In addition, 3 novel DDGIs were identified in the discovery analysis with one 
association supported (validated) using an alternative phenotype in UK Biobank but 
not replicated with the same phenotype. In the discovery cohort, the G allele at 
rs9516519 (T>G) variant in the ABCC4 transporter was associated with 4.72 (2.44-
9.13) times increased risk to stop bisoprolol or atorvastatin treatments when they are 
used concomitantly (p=1.48 × 10-5). Although this finding did not replicate directly, 
in the replication cohort, the drug combination alone was associated with great SBP 
reduction (~ 8 mmHg drop in mean SBP (p < 2 × 10-16)). When the genotype data for 
rs9516519 (T>G) SNP was included, it seems that it has an added effect on SBP 
reduction. Compared to the normal genotype (TT), the heterozygous (TG) and 
recessive (GG) genotypes have shown a clear trend toward increased SBP drop 
among the combination users with the difference being - 2.46 and - 4.54 mmHg for 
both genotypes respectively (p (trend) = 0.02242). 
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     1. Introduction 
 
 
There have been numerous pharmacogenomic associations which are published 
without replication. It should also be noted that even for the studies where there have 
been attempts to replicate findings, only few associations have been successfully 
replicated. In fact, in one large study assessing the replication rate in genetic disease 
studies for publications from 2007 until 2010, authors have found that only 13 out of 
the 1151 (~ 1%) genotype-phenotype associations were successfully replicated [245]. 
This led to a clear move in disease genetics for a requirement for robust replication 
for all published studies. This has yet to fully translate into pharmacogenetics, 
however, as the findings outlined in chapters III and IV use a generic response 
phenotype across many drugs, there is clearly a need to establish which of the results 
replicates in an independent cohort. This was not possible for us until the release of 
the UK Biobank primary care data late in 2019. Therefore, in this chapter, we will 
attempt to replicate the top 9 drug-gene and 3 drug-drug-gene associations which 
were initially discovered in the combined Scottish cohort by utilizing an independent 
larger cohort, the UKBB primary care data. 
 
     2. Methodology 
 
 
I used the UKBB primary care data in order to investigate the replicability of our top 
DG and DDG interactions findings from the combined Scottish cohort. Primarily, the 
same phenotype was used (i.e. drug-stop or dose-decrease, see chapters III and IV for 
the definition of these phenotypes) to check for replication. However, for some 
findings, I undertook a further investigation to examine a specific hypothesis related 
to the particular drug in question. A number of the drugs implicated were 
antihypertensives, so I used the reduction in mean systolic blood pressure due to the 
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DGI or DDGI. Drug response phenotype definitions for these two scenarios 
were explained in detail in chapter II. Here, I briefly re-describe them. 
                          2.1 Drug-gene interaction-related systolic blood pressure changes. 
 
After calculating the mean of the SBP measures 1-year before and 1-year after the 
antihypertensive agent, a multiple regression model, is then used to study the 
influence of the genetic variant of interest on the blood pressure. The outcome (Y) 
continuous variable was the mean of the SBP measures 1-year after treatment. The 
explanatory variables were mean SBP one-year pre-treatment (to adjust for the drug-
only effect), the SNP of interest as a 3-level categorical variable, age and sex. 
                          2.2 Drug-drug-gene interaction-related systolic blood pressure changes. 
 
Two approaches were used to investigate drug-drug-gene interactions for systolic 
blood pressure (SBP) reduction. In the first approach, only those who started the 
antihypertensive drug first then added the perpetrator drug are included. For these 
patients, a mixed effect model was utilized to identify whether there was a significant 
difference in SBP during treatment with the antihypertensive drug alone and during 
treatment with the combination (antihypertensive drug + perpetrator drug) for the 
same patient. 
In the second approach, in order to increase the sample size, two groups of patients 
were compared: 1) all patients starting the antihypertensive drug alone and 2) those 
who started the perpetrator drug first before adding the antihypertensive drug. In this 
approach, a multiple regression model adjusted by SBP before starting the 
antihypertensive agent, age, and sex is run to identify whether there was a significant 
difference in mean SBP levels between the two groups (i.e. during bisoprolol-only 
SBP vs during interaction SBP). The analysis is run first without the genotype data to 
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investigate whether there is a significant drug-drug interaction. Then, the genotype 




    3. Results 
 
                        3.1 The replication results for the top 9 drug-gene interactions findings 
 
Table 11 at the end of DGI results section summarizes all results under this category.  
We present these results in order starting from the ones with the best evidence. 
             3.1.1 Replicated findings (n = 1). 
 
Quinine-rs4918758 (T>C, CYP2C9): low likelihood to decrease the dose. 
This association was observed in GoDARTs and GoSHARE cohorts with a consistent 
direction of effect, with the Generation Scotland results being non-significant 
(p=0.835). GoDARTs subjects with this rs4918758 CYP2C9 variant experienced a 
28% (11%- 41%) lower odds of quinine dose decrease (p=0.00160). A similar 
scenario was also seen with GoSHARE participants carrying this variant who 
experienced a 50% (23%-67%) per-allele lower odds of quinine dose decrease          
(p = 8.14 × 10-4). 
I then investigated the replicability of this finding in the UKBB primary care data, 
where a similar picture was seen. The quinine group carrying the C allele had a 19% 
(1%- 33%) lower odds of a decrease in quinine dose per allele (p= 0.0374, log- 
additive model). Compared to TT homozygotes, the heterozygous genotype (TC) was 
associated with a 10% lower odds of quinine dose reduction, and those CC at this 




After meta-analyzing both the discovery and the replication findings, carriers of the 
variant allele were 25% (15%-44%) less likely to reduce quinine daily dose (p=1.64 
× 10-5). Interestingly, consistent with this finding, our data also show that the other 
two known loss-of-function variants rs1799853 (C>T, CYP2C9*2) and rs1057910 
(A>C, CYP2C9*3) are associated with a 25% (4%-42%, p= 0.017) and 31% (1%-
51%, p=0.0325) lower tendency to reduce the daily dose of quinine respectively.    
 
            3.1.2 Validated findings (n = 1).  
                           
Doxazosin-rs9895420 (T>A, ABCC3): low likelihood to decrease the dose. 
The rs9895420 A-allele was associated with lower odds of doxazosin dose-decrease 
in GoDARTs (OR = 0.51 (0.33-0.77); p = 0.00477). A similar direction of effects is 
seen among GS and GoSHARE participants (29% and 43% lower odds for dose 
reduction) even individually, the associations in these cohorts were not significant. 
In the UKBB primary care data, there was a similar trend of association as this variant 
showed a 10% less chance for dose reduction, but this result was not statistically 
significant (p=0.33857). 
The above observations suggest increased tolerability in term of side effects. I then 
examined the effect of this variant on SBP reduction. Interestingly, there was an 
association between the A-allele at rs9895420 and increased doxazosin efficacy 
(p=0.008946). The A allele was associated with a 1.037 mmHg increase in mean SBP 
reduction 1 year after doxazosin. Compared to TT homozygotes, the SBP reduction 
was 1.03 mmHg greater in TA heterozygotes and 2.13 mmHg greater in AA 
homozygotes. (see Table 12 below). 
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Table 12: rs9895420 (T>A, ABCC3)-genotype-based changes in mean 
SBP 1 year after doxazosin adjusted by mean SBP 1 year before 
doxazosin, age, and sex. 
 
 
  Influence of rs9895420 (T>A) variant on doxazosin SBP lowering efficacy 
 n mean St. error difference lower upper p-value 
Codominant  
A/A 4326 147 0.2193 0   0.032808 
A/a 1023 146.1 0.4394 -1.031 -1.873 -0.1896  
a/a 44 145 1.7791 -2.132 -5.8 1.5356  
  






          3.1.3 Findings with supporting evidence (n =1). 
 
Ramipril-rs1135840 (G>C, CYP2D6): low likelihood to stop treatment. 
 
This association was significant in all of the 3 cohorts individually with a consistent 
direction of effect. Per C-allele at rs1135840, ramipril users carrying this variant from 
GoDARTs , GS and GoSHARE cohorts were 25% (8%-39% , p = 0.005417) , 38% 
(9%-58%, p = 0.01287) , and 34% (9%-40%, p = 0.008746) less likely to stop 
ramipril treatment. 
Unfortunately, the rs1135840 (CYP2D6*2) SNP, representing the extensive 
metabolizer phenotype, deviated markedly from HWE in the UKBB cohort and 
therefore cannot be used. However, in the combined cohort another SNP rs3892097 
(CYP2D6*4), representing a poor metabolizer phenotype, was associated with 
stopping ramipril therapy (OR = 1.29 (1.08-1.54)), p=0.00654) providing more 
evidence on a potential ramipril-CYP2D6 correlation. Further support for this 
finding can be seen with other angiotensin converting enzyme (ACE) inhibitors in 
our data. The CYP2D6*4 variant was also associated with a 31% (1%-72%) 
increased odds of decreasing enalapril daily dose (p=0.053) while the CYP2D6*2 











3.1.4 Findings where their replications were not significant but directionally consistent 
with a p-value close to the significance level (n =2). 
 
1) Amlodipine-rs868853(C(minor allele)>T, ABCC4): decreased likelihood to 
decrease the dose. 
There was a large and consistent effect of rs868853 on amlodipine response in all of 
the 3 Scottish cohorts. Amlodipine users from GoDARTs, GS, and GoSHARE 
carrying the C-allele were 44%, 52%, and 45% less likely to decrease amlodipine 
daily dose per allele. This finding was significant for GoDARTs cohort (p=0.0060) 
and after combining all cohorts together (p=2.8 × 10-4). This drug-gene correlation 
has then been examined using the UKBB primary care data. There was a similar 
association of rs868853 and likelihood to lower amlodipine dose with C-allele 
carriers having a 14% lower odds to reduce amlodipine daily dose, although the 
result was not significant in the UKBB cohort (p=0.092, log-additive; p=0.069 
dominant). 
2) Clopidogrel-rs12353214 (C>T, PTGS1): decreased likelihood to stop the drug. 
In GoDARTs, GS, and GoSHARE, the T-allele was associated with being 24% 
(p=0.044), 58% (p=0.34), and 54% (p=0.12) less likely to stop clopidogrel treatment. 
This finding was found close to the Bonferroni significance level after combing all 
cohorts together (p=5.3 × 10-4) as outlined earlier. 
Examining this association in a larger UKBB cohort showed a similar, although not-
statistically significant effect: carrying the T-allele was associated with a 14% lower 






              3.1.5 Other non-replicated/non-validated associations (n = 4). 
 
1) Nifedipine-rs152023 (C(minor allele)>T, ABCC1): increased 
likelihood to stop the drug. 
 
This finding was significant in the GoDARTs cohort (OR 1.37 (1.15-1.64), p = 5.184 
× 10-4). The results from GS and GoSHARE cohorts showed consistent directions of 
effects even though they were not significant (OR 1.07 (0.77-1.47), p=0.6961, and  
OR 1.43 (0.97-2.1), p=0.06848 respectively). However, a further investigation from 
the UKBB primary care data for this association showed no significant association 
between rs152023 and stopping nifedipine treatment (p=0.9825).  
                                            2) Valproic acid-rs7916649 (T>A, CYP2C19): 
                                                   increased likelihood to decrease the dose. 
The results from GoDARTs and GS cohorts show a significant association between 
the rs7916649 A-allele and being 2.03 (1.23-3.35) and 2.01 (1.07-3.78) times more 
likely to decrease valproic acid daily dose (p-values = 0.0044 and 0.027 
respectively). The GoSHARE result was directionally consistent (OR=1.62 (0.74-
3.54), p = 0.22). However, there was no replication of these results in the UKBB 
primary care data (OR = 0.95, p = 0.732). 
                                    3) Metformin-rs1045642 (A>G, ABCB1): low likelihood to stop the drug. 
GoDARTs , GS, and GoSHARE individuals on metformin and carrying the G-allele 
at rs1045642 were 29% , 28%, and 17% less likely to stop metformin treatment. The 
only cohort individually significant was GoDARTs (p=0.000717). This result did not 








                                4) Nicorandil-rs5788 (C>A, PTGS1): increased likelihood to stop the drug. 
 
 
In the three Scottish cohorts, there was an increased odd of stopping nicorandil in 
A-allele carriers at rs5788 for the GoDARTs and GoSHARE cohorts (ORs = 2.57 
and 1.37 respectively); the GS result was not directionally consistent and was non-
significant (OR = 0.55, p=0.35). This result did not replicate in UK Biobank. 
 
Table 10 below summarizes the results of our top 9 associations from the combined 
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Table 11: The top 9 drug-gene interaction findings and their replication 
results from the UKBB primary care data. 
 
* The results from the UKBB cohort is adjusted by age and sex. 
** (2) is replicated, (4) is validated, and (8) and (9) being directionally 
consistent with borderline significance and (1) has a supporting evidence 
with another SNP (CYP2D6*4: poor metabolism) known to has an opposing 
effect to the one initially discovered (CYP2D6*2: normal metabolism). 
 
      
GoDARTs 
   
GS 
   
GoSHARE 


































































                  
2 Quinine CYP2C9 rs4918758 (T>C) Dose decrease 0.72 (0.59-0.89) 0.001602  1.05 (0.65-1.7) 0.8385  0.5 (0.33-0.77) 0.000814  0.7 (0.6-0.85) 8.00E-05 0.81 (0.67-0.99) 0.0374 
                  
3 Nifedipine ABCC1 rs152023 (C(minor)> Drug stop 1.37 (1.15-1.64) 0.000518  1.07 (0.77-1.47) 0.6961  1.43 (0.97-2.1) 0.06848  1.32 (1.15-1.53) 1.17E-04 1 (0.91-1.1) 0.9825 
                  
4 Doxazosin ABCC3 rs9895420 (T>A) Dose decrease 0.51 (0.33-0.77) 0.00477  0.71 (0.28-1.78) 0.4418  0.57 (0.26-0.24) 0.1264  0.54 (0.38-0.76) 1.20E-04 0.9 (0.73-1.12) 0.33857 
4 Doxazosin ABCC3 rs9895420 (T>A) SBP changes NA NA  NA NA  NA NA  NA NA -1.037 (-1.814 , -0.25) 0.008946 






























































                  
7 Nicorandil PTGS1 rs5788 (C>A) Drug stop 2.57 (1.72-3.84) 1.01E-05  0.55 (0.14-2.09) 0.3579  1.37 (0.69-2.72) 0.1729  1.93 (1.39-2.69) 1.72E-04 1.09 (0.86-1.37) 0.4779 
                  
8 Amlodipine ABCC4 rs868853 (C(minor)> Dose decrease 0.56 (0.39-0.81) 0.006059  0.48 (0.15-1.53) 0.5257  0.55 (0.28-1.08) 0.2551  0.55 (0.4-0.75) 2.80E-04 0.86 (0.71-1.03) 0.09279 
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   3.2 The replication results for the top 3 drug-drug-gene findings from the UKBB 
primary care data. 
 




In this section, none of the 3 associations has been replicated. However, I was able to 
validate our first association. Here, I present the results for all associations starting 
from the validated finding. 
1) Atorvastatin-Bisoprolol-rs9516519 (T>G, ABCC4): 
increased risk of drugs' stopping. 
 
The significance of this association was mainly driven by findings from GS and 
GoSHARE cohorts. GS participants on atorvastatin-bisoprolol combination who were 
G-allele carriers at rs9516519 were 15.84 (4.5-55.7) times more likely stop any of the 
two drugs during their combined used per allele (p=1 × 10-6). Similarly, the 
concomitant use of this combination among GoSHARE patients carrying this allele 
was associated with a 3.26 (1.12-9.51) times higher likelihood to stop either of the 
two drugs per allele (p=0.045). However, in UK Biobank, there was no association 
between the use of this drug combination and rs9516519 ABCC4 variant (p=0.56). 
As mentioned in the previous chapter, bisoprolol is primarily metabolized by 
CYP3A4, and atorvastatin is a CYP3A4 inhibitor. Accordingly, we examined the 
hypothesis that bisoprolol users co-treated with atorvastatin had a larger SBP drop 
than when bisoprolol was used alone (studying it as a drug-drug interaction (DDI)), 
and whether this response could increase with the presence rs9516519 ABCC4 
variant (studying it as a drug-drug-gene interaction (DDGI). 
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Two approaches were used: 1) comparing SBP levels before and after adding 
atorvastatin for bisoprolol users and 2) comparing SBP changes between two groups 
of patients (i.e. those on bisoprolol only vs those on atorvastatin + bisoprolol). For the 
first approach, 734 users of bisoprolol-atorvastatin combination from the UKBB 
cohort were identified. However, from these patients, we have only identified 69 
patients who started bisoprolol first and then added atorvastatin; the rest (the majority, 
n= 665) of users started atorvastatin first and then added bisoprolol. The first group 
(n= 69) represents patients who are eligible for the first model as they have had a 
period while they were on bisoprolol alone before starting atorvastatin. Interestingly, 
examining the difference in SBP level for these 69 patients before and after adding 
atorvastatin using a linear mixed effect model provided some evidence supporting our 
proposed hypothesis: the mean SBP for bisoprolol users is reduced by ~ 3 mmHg 
after adding atorvastatin, p=0.062. 
In the second method, a multiple regression model was utilized to study the difference 
in mean SBP levels between two groups of patients :1) all patients on bisoprolol alone 
(i.e. have no atorvastatin, n = 17,333) and 2) all patients who started atorvastatin first 
before adding bisoprolol (n= 665). Very interestingly, there was strong evidence 
supporting our hypothesis and confirming our first observation. I have observed a 
large difference in SBP levels between users of atorvastatin-bisoprolol combination 
and bisoprolol-only users. Atorvastatin users co-treated with bisoprolol experienced 
~ 8 mmHg increased reduction in SBP as compared to the bisoprolol-only group 
(p < 2 × 10-16). 
205  
When the genotype variable for the rs9516519 (T>G) ABCC4 SNP is added to the 
treatment group variable (i.e. on bisoprolol vs on the combination), a statically 
significant interaction has been observed between the two variables (p (interaction) = 
0.02242). 
When patients are stratified by their rs9516519 (T>G) ABCC4 genotype, this variant 
was found to be linked with increasing the risk of SBP drop (p (trend) = 0.0059446). 
Carriers of the wild-type genotype (TT) and on this drug combination have shown ~ 
7.4 mmHg lower mean SBP as compared to carriers of the same genotype but are on 
bisoprolol only. Those carrying the heterozygous genotype (TG), who are on the 
atorvastatin-bisoprolol combination, have experienced a mean SBP reduction by ~ 10 
mmHg as compared to carriers of the same genotype from the bisoprolol-only group. 
This risk has increased even more with carriers of the recessive genotype (GG) as the 
mean SBP drop has reached to ~ 12 mmHg among the combination users compared to 
the bisoprolol-only group. 
When results are stratified by treatment group, compared to the normal genotype 
(TT), the heterozygous (TG) and recessive (GG) genotypes have shown a clear trend 
toward increased SBP drop among the combination users (p (trend) = 0.02242) with 
the difference being - 2.46 and - 4.54 mmHg for both genotypes respectively. 
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2) Simvastatin-Metformin-rs622342 (A>C, SLC22A1): 
increased risk of drug stopping. 
 
I have observed a consistent direction of effects across all cohorts with the results 
being significant for the GoDARTs cohort. Carrying the minor allele (C) at this 
variant in SLC22A1 gene was associated with a 3.07 (1.31-7.2) , 3.66 (1.05-12.81) , 
and 2.4 (0.81-7.08) times increased chance of stopping simvastatin or metformin used 
in combination for GoDARTs (p=0.0074) , GS (p=0.057) , and GoSHARE (p=0.12) 
respectively . Nevertheless, I was not able to see a similar association within users of 
this combination from the UKBB primary care data (OR = 0.94, p=0.51). 
 
 
3) Metformin-Gliclazide-rs1967120 (G>A, ABCC1): increased risk of dose decrease. 
 
 
The minor allele (G) at this ABCC1 variant was associated with a 19 % (p=0.0018), 
19 % (p=0.54), and 26% (p=0.017) higher odds of decreasing the daily dose any of 
the two drugs when used in combination among GoDARTs , GS, and GoSHARE 




Figure 17 below summarizes the results of the top 3 DDGI associations from the 
combined Scottish cohort and their replication results from the UKBB primary care 
data, showing the steps used for the validation of the atorvastatin-bisoprolol- 
rs9516519 (ABCC4) association. 
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(b) (c) 
Figure 17: The top 3 drug-drug-gene interaction findings and their replication results 
from the UKBB primary care data as adjusted by age and sex. 
* The last 3 genetic models show the significance of interaction between genotype and 
treatment group (a), the results as stratified by genotype (b), and the results as 











































































































































                    4.1 The top 9 drug-gene interactions findings 
 
Here, I discuss our findings, starting from the best evidence as ordered in the results section. 
 
 
          4.1.1 Replicated findings (n = 1). 
 
Quinine-rs4918758 (CYP2C9) 
Users of quinine from the combined cohort who carry the C allele at rs4918758 (T>C) 
SNP in the CYP2C9 gene were found less likely to decrease their dose. Interestingly, 
this novel observation has been replicated among quinine users from the UKBB 
cohort as the same allele was found significantly linked with the same phenotype in a 
similar direction of effect. Quinine is extensively metabolized in the liver primarily 
by CYP3A4, but other enzymes including CYP2D6, CYP2E1, CYP2C8, CYP2C19, 
and CYP2C9 have been reported to be involved in quinine metabolism [246]. The C 
allele at rs4918758 CYP2C9 SNP has been previously associated with decreased 
warfarin dosage requirements in Korean populations [247] suggesting that the variant 
might be associated with decreased enzyme activity. In addition, the CYP2C9 
reduced activity variants CYP2C9*2/*3*/11 were previously associated with 
decreased therapeutic efficacy of quinine derivatives chloroquine and primaquine in 
treating malaria [248]. Consistent with this, our results also show that both 
CYP2C9*2 and CYP2C9*3 variants are associated with decreased odds of reducing 
quinine dose. Taken together these results suggest that the observed quinine/CYP2C9 
interaction with reduced efficacy or increased tolerability is associated with reduced 
function of CYP2C9. This seems unlikely to be an effect in quinine metabolism per 





As discussed above, the interaction observed may not be mediated via a PK 
interaction. A recent study [249] reported that rs4918758 was associated with 
decreased coronary heart disease risk. Given that a main side effect of quinine is 
cardiac toxicity (i.e. prolongation of QT and arrhythmias), the drug-gene interaction 
could be explained by a reduction in cardiac toxicity with quinine in carriers of this 
cardioprotective variant. The importance of this novel finding lies in the fact this 
variant allele is very common among the British population with a minor allele 
frequency of ~37% as shown from the UKBB cohort. In addition, quinine is known 
by its undesirable and life-threatening side effects profile; and therefore, identifying 
patients' subgroups who might be well- tolerated to the drug could be a crucial clinical 
addition to prescribers.  
         4.1.2 Validated findings (n = 1). 
  Doxazosin-rs9895420 (ABCC3) 
The combined cohort findings show that carriers of rs9895420 (T>A) mutation in 
ABCC3 transporter were at decreased risk to reduce their daily doxazosin treatment. 
Although I couldn’t find this correlation to be significant from the UKBB primary 
care data, the best OR estimate was found consistent with the same direction of effect. 
Doxazosin is mainly metabolized in the liver, and 63% of the dose is excreted in the 
feces [250] suggesting a potential role of hepatic transporters in its elimination. It is 
unknown whether ABCC3 transporter contributes to the elimination process of 
doxazosin, but our findings show that the A allele at rs9895420 ABCC3 variant could 
be associated with increased tolerability of the drug in term of side effects. 
Interestingly, I was also able to uncover an association between this variant and 
increased doxazosin SBP lowering capacity. The mechanism by which this 
observation occurs is uncertain, but this variant has been previously linked with 
increased ABCC3 activity [251] suggestion its potential role to increase doxazosin  
efflux from the liver into systemic circulation leading to increased anti-hypertensive 
efficacy. 
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     4.1.3 Findings with supporting evidence (n =1). 
 
Ramipril-rs1135840 (CYP2D) 
I have observed a strong correlation between rs1135840 (G>C) variant 
 
in CYP2D6 gene and low likelihood of stopping ramipril treatment; an association 
which passed the nominal significance level (p <=0.05) and shows consistent 
directions of effects across all of the 3 cohorts formulating the combined cohort in 
which I find the association significant after the Bonferroni correction. However, and 
potentially due to genotyping issues related to this variant in the UKBB as it deviates 
from HWE, I couldn't find this association significant or with a similar direction of 
effect among the UKBB participants. Ramipril is a prodrug which undergoes renal 
and hepatic metabolism to be converted into its active metabolite ramiprilat [252]. 
75% of the total ramipril metabolism occurs in the liver, with 25% catalyzed by 
esterases [252]. However, it is unknown whether CYP2D6 enzyme could contribute 
to the total ramipril metabolism. The minor allele (C) at the well-known rs1135840 
(G>C) (CYP2D6*2) variant represents the extensive (normal) metabolizer phenotype 
[253]. Assuming ramipril as a CYP2D6 substrate, the C allele could increase ramipril 
metabolism and increases its therapeutic efficacy consequently. This is consistent 
with our observation that this variant is linked with decreased chance to stop the 
treatment. Interestingly, our results also show that the other well-known loss-of-
function variant, rs3892097 (C>T) (CYP2D6*4) [253], is correlated with a 29% 
increased risk to stop ramipril treatment. Loss of the enzyme activity could inhibit 
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production of the active metabolites causing loss of efficacy which could lead to 
stopping of the drug. This other observation provides more evidence on a potential 
ramipril-CYP2D6 correlation. In fact, rs1135840 and rs3892097 are in LD to each 
other (D’ = 1) with the C allele at rs1135840 correlated with the C allele at 
rs3892097. Further support of these findings can be also observed from our data 
as we find similar signals in the Scottish discovery cohort for both enalapril and 
lisinopril suggesting that our findings are consistent and applies to all ACE 
inhibitors. Interestingly, we also note a case report for a patient homozygous for 
the CYP2D6*4 variant and discontinued ramipril therapy shortly after starting it 
due to ramipril-induced dry cough which is consistent with our finding that this 
variant is linked with increased likelihood of stopping ramipril [254].   
 
 
4.1.4 Findings where their replications were not significant but directionally consistent 
with a p-value close to the significance level (n =2). 
 
1) Amlodipine-rs868853(ABCC4) 
The minor allele (C) at rs868853(C>T) ABCC4 SNP was observed to be correlated 
with a large reduced chance to decrease the daily amlodipine dose within the 
combined cohort participants. The result from the UKBB cohort shows that the same 
SNP is linked with the same phenotype in a similar direction of effect, but this wasn't 
statistically significant. 90% of the drug is metabolized in the liver, with 10% of the 
parent compound and 60% of the metabolites to be renally excreted [255]. It is 
unknown whether amlodipine is an ABCC4 substrate, but a previous study has shown 
that the C allele is linked with reduced methotrexate plasma levels and increased 
ABCC4 activity [256]. Similarly, our findings show that this variant is associated with 
lower odds to decrease the dose suggesting decreased likelihood for side effects which  
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could be attributable to decreased amlodipine plasma levels. This suggested 
mechanism of interaction could occur if the site of interaction is in the kidney 
assuming amlodipine being an ABCC4 substrate. 
2) Clopidogrel-rs12353214 (PTGS1) 
I have also noted carriers of the rs12353214 (C>T) mutation in PTGS1 gene to be less 
likely to stop clopidogrel therapy; an association which was directionally consistent 
although not significant in UKBB. PTGS1 (COX-1) is a known contributor in the 
regulation of the coagulation process by the production of prostaglandins which 
facilitate clotting formation [257]. Aspirin exerts its anticoagulant effect by inhibiting 
PTGS1 activity and is often co-prescribed with clopidogrel for enhanced 
anticoagulation efficacy. Similarly, genetic variants in PTGS1 gene could influence 
the therapeutic efficacy of clopidogrel. Among clopidogrel users, the rs10306114 
(A>G) and rs1330344 (T>C) variants in PTGS1 gene have been previously reported 
to be linked with increased and decreased cardiovascular events (reduced and 
increased clopidogrel efficacy) for both SNPs respectively [258, 259]. In the same 
context, I have uncovered another novel and independent PTGS1 variant, rs12353214 
(C>T), as linked with lower odds to stop the treatment suggesting enhanced 
clopidogrel therapeutic efficacy. 
 
 
4.1.5 Other non-replicated/non-validated associations (n = 4). 
 
 
1) Nifedipine-rs152023 (ABCC1) 
Although the minor allele (C) at rs152023 ABCC1 variant was detected to be 
associated with increased likelihood to stop nifedipine treatment in the combined 
cohort, I couldn’t see any evidence supporting this observation from the UKBB 
primary care data. Nifedipine undergoes hepatic metabolism by CYP3A4 enzyme and 
60-80% of the drug is excreted in urine as inactive metabolites with the reminder 
eliminated via biliary excretion [260]. The ABCC1 transporter is expressed in the  
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basolateral and apical membrane of the liver and kidney, respectively. However, 
currently, there is no evidence that nifedipine is an ABCC1 substrate. In addition, the 




2) Valproic acid-rs7916649 (CYP2C19) 
Valproic acid users from the combined cohort who carry the A allele at rs7916649 
(T>A) SNP in CYP2C19 enzyme have shown an increased tendency to reduce their 
daily dose. Nevertheless, this association was neither significant nor in the same 
direction of effect among the UKBB participants. The majority of the drug is 
eliminated via the liver where it is metabolized by multiple CYP enzymes, including 
CYP2C19 [262]. While there have been no previous studies linking the rs7916649 
(T>A) variant with any drug response phenotypes, there is some evidence supporting 
the contribution of CYP2C19 genotype in affecting valproic acid pharmacokinetics. 
The two well-known loss-of-function variants, CYP2C19*2 and CYP2C19*3, have 
been associated with increased valproic acid-induced weight gain in Japanese females 
and increased steady-state serum concentrations in Chinese patients [263,264]. 
 
 
3) Metformin-rs1045642 (ABCB1) 
Carriers of the G allele at rs1045642 (A>G) ABCB1 SNP from the combined cohort 
were less likely to stop metformin treatment which was also seen among the UKBB 
participants but wasn't statistically significant. 
Metformin is mainly eliminated via renal excretion [265], and it has been suggested 
that metformin-induced gastrointestinal side effects could be linked to its intestinal 
accumulation due to the lack of its transportation, due to OCT1 reduced activity 
variants for example, from the intestine into systemic circulation [266]. Metformin 
has been shown to be transported by ABCB1 transporter [267]. The rs1045642 (A>G)  
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variant has been extensity studied and was correlated with multiple drug response  
phenotypes with mixed evidence regarding its linkage with decreased/increased 
ABCB1 expression [268]. The decreased ABCB1 intestinal expression could 
reduce intestinal metformin accumulation leading to reduced side effects and 
increased tolerability to the drug in term of side effects. On the other hand, reduced 
renal and intestinal ABCB1 activity could also result in increased metformin 
bioavailability leading to increased tolerability of the drug in term of its efficacy. 
These proposed mechanisms are consistent with our findings that carriers of this 
variant were less likely to stop the drug. 
 
4) Nicorandil-rs5788 (PTGS1) 
I have also detected a PTGS1 variant, rs5788 (C>A), to be associated with an 
increased risk to stop nicorandil treatment among the combined cohort users. The best 
OR estimate from the UKBB results shows a similar trend of association with a 
modest effect size which wasn't statistically significant. Due to its vasodilatory effect, 
the angina treatment nicorandil is associated with hypotension-related side effects 
[269]. Prostaglandin synthas1 (PTGS1/COX1) has an important role in the conversion 
of arachidonic acid into prostaglandins which work as blood pressure regulators 
[270]. Therefore, genetic variants in this gene could influence nicorandil-induced 
hypotension. Our findings suggest that the A allele at rs5788 PTGS variant could 
augment nicorandil-induced hypotension as indicated by an increased tendency to 





                      4.2 The top 3 drug-drug-gene interactions findings 
 
Here we discuss our 3 findings starting from the one which has been validated before 
discussing the other two associations which have not been replicated/validated. 
 
 
1) Atorvastatin-Bisoprolol-rs9516519 (ABCC4) 
 
To date, there is no pharmacokinetic interaction study on this combination. However, 
as clarified in the results section, atorvastatin is predicted to interact with bisoprolol 
via inhibiting its metabolizing enzyme: CYP3A4. This could result in increased 
bisoprolol efficacy/toxicity. Our finding from the combined cohort shows a large 
chance to stop any of the two drugs during their interaction for carriers of the G allele 
at rs9516519 (T>G) variant in ABCC4 transporter. Nevertheless, I couldn't replicate 
this result in the UKBB cohort using the same phenotype. 
 
 
Attractively, I was able to uncover a novel drug-drug interaction between bisoprolol 
and atorvastatin. In a small sample of 69 patients, I found that there was a reduction in 
SBP when atorvastatin was prescribed to patients already on bisoprolol. Then, using a 
large sample of patients (~ 18K individuals), I was able to confirm this initial finding 
as the mean SBP was greatly lower among atorvastatin-bisoprolol users compared to 
bisoprolol-only users. Furthermore, I have then shown that carrying the rs9516519 
(T>G) ABCC4 variant is associated with increasing the likelihood of SBP drop among 
the users of this drug combination. The greater SBP drop in this treatment group was 
seen among carriers of the recessive genotype (GG) followed by the heterozygous 
genotype (TG) and then the wild-type genotype (TT). This variant has been 
previously correlated with decreased toxicity and plasma levels of methotrexate [271]. 
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The authors suggested that this could have resulted from increased renal ABCC4 
efflux activity since the kidney is the primary route for methotrexate elimination 
[272]. On the other hand, bisoprolol is eliminated equally via both the kidney and the 
liver [273]. The drug is also mainly metabolized in the liver by CYP3A4 suggesting 
the importance of hepatic transporters in bisoprolol pharmacokinetic. ABCC4 
transporter is expressed in the hepatic basolateral membrane facilitating the efflux of 
xenobiotics into the systemic circulation. Our results from the combined cohort show 
that carriers of the rs9516519 (T>G) ABCC4 variant are more likely to stop 
atorvastatin or bisoprolol when used concomitantly. This could result from increased 
bisoprolol toxicity which is what I was able to confirm in my DDGI analysis. The 
proposed mechanism for this drug-drug-gene interaction is that inhibiting CYP3A4 
activity by atorvastatin in addition to increasing hepatic ABCC4 function by carrying 
the rs9516519 (T>G) variant could both result in a large bisoprolol systemic exposure 
and toxicity due to both decreased metabolism and increased efflux into the blood. 
This SNP is only significant with the use of both bisoprolol and atorvastatin but not 
with bisoprolol only according to our results from the DGIs study. 
2) Simvastatin-Metformin-rs622342 (OCT1) 
Our results from the combined cohort indicate that patients on this drug combination 
and carry rs622342 (A>C) variant in OCT1 transporter were more likely to stop any 
of the two drugs during their interaction. However, I couldn't replicate this association 
from the UKBB primary care data. Although OCT1 is a known transporter for 
metformin [274], currently, there is no known route of interaction between 
simvastatin and metformin. Nonetheless, in a previous study [275], the variant allele 
(C) has been observed to be associated with poor response to metformin which was  
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proposed to be resulting from reduced metformin uptake into the liver. On the other 
hand, our results from our drug-gene interactions study presented in chapter III show 
no significant correlation between this variant allele and stopping metformin 
treatment (p=0.39). Having said that, the association was only significant among 
metformin users co-treated with simvastatin but not metformin-only users. According 
to GeneATLAS, this variant was found to be highly correlated with hyperlipidaemia 
as well. Thus, it may be that this variant is interacting with statins and metformin via 
its effect on lipids rather than as a drug transporter.  
3) Metformin-Gliclazide-rs1967120 (ABCC1) 
I have found that carriage of the minor allele (G) at rs1967120 (G>A) SNP in ABCC1 
transporter is correlated with higher chances to decrease the dose of any of the two 
drugs when used concomitantly. However, I was not able to see this association 
significant within users of this combination from the UKBB cohort. There is no 
known route of interaction between the two drugs, and this is a common safe 
combination usually prescribed for patients not well controlled with metformin alone. 
One recent report shows that metformin contributes to the reduction of ABCC1 
transporter expression [276]. However, it is unclear why patients carrying the G allele 
at rs1967120 (G>A) SNP needed lower doses from either of the two agents. In fact, 
my results from the DGI study show a strong correlation between carriers of this 
variant allele and increased risk to decrease the daily dose of metformin (OR = 1.12, 
p=0.00075). The same trend but with a weaker correlation has also been observed 
among gliclazide users (OR = 1.09, p=0.06). These findings suggest that there might 
be a potential novel DG and/or DDGI within carriers of this variant allele occurring in 
an unknown mechanism of interaction which requires further investigation. 
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   5. Conclusion 
 
 
Out of 9 DGIs, 1 association was replicated (quinine-rs9418758 (CYP2C9)), one 
finding was validated (doxazosin-rs9895420 (ABCC3)), one finding has supporting 
evidence (Ramipril-CYP2D6*2), and two signals were directionally consistent with p- 
values close to the significance level (amlodipine-rs868853 (ABCC4) and 
clopidogrel-rs12353214 (PTGS1)). In addition, out of 3 DDGIs, one association was 
validated using an alternative phenotype but not replicated with the same phenotype 
(atorvastatin-bisoprolol-rs9516519 (ABCC4)). It is important to highlight that all 
results that didn't replicate or validate in this chapter should be interpreted with 
caution. I have classified all findings in this chapter into categories starting from 
higher to lower level of evidence depending on whether or not these have been 
replicated, validated, or have supporting evidence. This should provide some 
guidance on which results are more likely to be genuine. Regarding non-
replicated/validated findings, these were included in the category of "lower level of 
evidence". We discussed these results only to highlight any potential clinical 
relevance to them which could worth further investigation but not to claim any 
definitive conclusions from them. One lesson I have learnt from our DDGI study is 
that it is really worth considering an alternative phenotype for replication if the 
same ‘generic’ phenotype did not replicate. In general, examining alternative 
phenotypes should always be encouraged even for the replicated findings as this 
will allow us to understand the novel discovered finding more deeply. For example, 
stopping the drug as a result of a certain DG/DDGI is a crucial clinical association 
since it could be linked with a change in the clinical practice. However, the exact 

































Final General Discussion 
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   1. Introduction 
 
The field of pharmacogenomics has been growing rapidly in the last few years. This is 
reflected by the increasing number of publications each year. However, most of the 
work usually focuses on studying specific genotype-phenotype associations based on 
previous knowledge on the functional characteristics of the studied variant and the 
common elimination pathways of the studied drug. Nevertheless, our work has 
attempted not only to uncover novel pharmacogenomic associations but also 
potentially new and clinically significant genetic variants and/or novel drug targets. 
To do so, I have studied the associations between genetic variants in all important 
enzymes and transporters and their influence on commonly used drugs in the UK. I 
have covered the topic by considering both drug-gene and drug-drug-gene 
interactions. The latter is relatively a new topic in the field of pharmacogenomics with 
very limited publications to date. Therefore, in the first chapter, I established a 
detailed classification framework for these kinds of interactions by covering different 
mechanisms by which these interactions can occur based on observations from 
previous studies. 
This thesis provides, for the first time, extensive coverage of clinical 
pharmacogenomic associations for 50 common chronic drugs and 50 commonly used 
chronic drug combinations in the UK. Studying the association of 162 genetic 
variants with 3 drug response phenotypes (drug-stop, dose-decrease, and genotype 
distribution changes among drug users) for each drug and each drug combination has 
generated a total of 48,600 results divided equally between the two studies (DG and 
DDGI) and are accessible via 2 online databases. I have utilized two cohorts with 
different nature: the UKBB cross-sectional prescribing data and the combined cohort 
longitudinal prescribing data for our discovery findings (i.e., the 48,600 findings).  
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Then, I have made further investigations for our top findings from the combined 
cohort by utilizing another larger and independent longitudinal cohort based upon the 
UKBB primary care data. 
The main findings from this PhD project can be classified into three categories: novel 
associations from the combined cohort which have been replicated, validated, or were 
directionally consistent with p-values close to but not reaching significance level in 
the UKBB primary care data (n=5); associations consistent with previously reported 
findings ( n = 19); and associations which are significant after Bonferroni correction 
from the UKBB cross-sectional cohort but require further investigation when larger 
cohorts become available (n = 11). In the sections that follow, I discuss the first 
category in more details with a brief review of the other two categories, highlighting 
points of strength and weakness of the research, and finally, I discuss my future 
directions. 
 
2. The main PhD project findings 
 
                        2.1 Novel associations which have been replicated, validated, or were directionally consistent 
with  p-values close to significance (n=5). 
 
                 2.1.1 Quinine-rs4918758 (T>C) CYP2C9 variant [replicated] 
 
Quinine is an FDA-approved drug for the treatment of uncomplicated Plasmodium 
falciparum malaria [277]. However, its use is challenged by concerns about its safety 
profile and the presence of safer and more efficacious agents. The recent evidence 
 
suggests that intravenous artesunate is the drug of choice in the treatment of severe 
 
malaria with quinine being an alternative agent [278]. In addition, artemisinin-based 
 
combination therapy (ACT), which consists of artemisinin derivatives combined with 
 
another anti-malaria agent from a different class such as lumefantrine, mefloquine or 
223  
 
amodiaquine, now represents the first-line option for the treatment of uncomplicated 
 
malaria [278]. However, quinine is still widely used for the management of 
 
uncomplicated malaria due to the limited availability of ACT. 
 
In malaria-free countries, quinine is commonly used for the treatment of nocturnal leg 
 
cramps (NLC) which are painful chronic muscle strains usually occur at bedtime 
 
causing severe disruption of sleep. As the exact cause of these cramps is unknown, to 
 
date, there is no proven treatment for this condition [279]. In fact, quinine is used as 
 
off-label treatment for this condition and it is not approved by the FDA as risks of 
 
taking the treatment outweigh its modest therapeutic efficacy against nocturnal leg 
 
cramps [280]. The FDA's Adverse Event Reporting System (AERS) (2005-2008), 
 
shows 38 cases of serious adverse events from quinine such as hearing loss, rash, 
electrolyte disturbances, thrombocytopenia (the most common side effect), mucosal 
bleeding, and even two cases of death [280]. Despite this FDA warning, quinine is 
still commonly prescribed in the UK for nocturnal leg cramps as indicated by our 
findings from the UKBB prescribing data that shows that quinine is ranked 30th within 
the list of most commonly used chronic drugs in the UK. However, its usage in the 
UK is not recommended as a routine treatment for NLC but is only allowed if the 
cramps are very painful and continuous, other causes of cramps which can be treated 
have been excluded, and other non-pharmacological options are not working [281]. 
These adverse events restricting the use of the drug could be influenced by the 
individual variability in genes controlling the pharmacokinetics of quinine. In two 
case reports [282,283], individual differences can affect quinine plasma levels and 
therapeutic efficacy. In spite of the adequate dosing in the two cases, quinine plasma 
levels were abnormally low, leading to the death of the first case as a result of malaria 
exacerbation. As outlined earlier in chapter III, quinine is mainly metabolized by 
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CYP3A4 but other enzymes, including CYP2C9, are also involved in quinine 
metabolism. In one clinical trial, ciprofloxacin (a CYP3A4 inhibitor) has been shown 
to significantly increase quinine plasma levels suggesting increased quinine side 
effects, and therefore dose reduction could be recommended [284]. Regarding 
CYP2C9, no previous studies were found connecting CYP2C9 and quinine 
safety/efficacy. Nevertheless, in chapter V, I have presented a study showing that 
reduced CYP2C9 activity variants were linked with decreased 
chloroquine/primaquine treatments efficacy against malaria. Here, I have discovered 
for the first time a novel and replicated association between the rs4918758 (T>C) 
genetic variant in the CYP2C9 gene and quinine daily dose. Individuals carrying this 
variant allele had a lower tendency to decrease their quinine dose. This could reflect 
that this subgroup of patients may have lower side effects and/or reduced efficacy. 
The latter phenotype could provide some potential explanation for the treatment 
failure seen in the two case reports mentioned above. Interestingly, the variant allele 
(C) at this SNP is very common in the UK with a frequency of ~ 37% in the UKBB 
cohort. This variant is also generally very common across all ethnicities with 
distribution frequencies of ~ 30%, 25.5%, ~39.4%, 36.4%, and 49.8% among 
Africans, Americans, East Asians, Europeans, and South Asians respectively [285]. 
Therefore, if future clinical or in-vitro studies confirm our finding, there may be a 
large clinical impact on quinine prescribing. Based on the rs4918758 (T>C) CYP2C9 
variant, patients might be stratified into two groups: those at a decreased risk for 
quinine toxicity but also could have a higher chance for low efficacy and those who 
are with expected increased toxicity and efficacy. This stratification would be helpful 
to guide the prescriber which groups of patients are at higher risk for toxicity, and 




prescribing the drug for leg cramps since toxicity was the main concern raised by the 
FDA. Regarding prescribing the drug for malaria, identifying patients who might 
experience lower efficacy is very helpful to protect patients from death caused by 
malaria exacerbation due to poor quinine response. 
 
 
             2.1.2 Doxazosin-rs9895420 (T>A) ABCC3 variant [validated] 
 
Doxazosin is an alpha-1 receptor antagonist indicated for the treatment of benign 
prostatic hyperplasia, but it is more commonly used for the treatment of 
hypertension. Inhibiting alpha-1 receptor results in vasodilation of arteries and veins, 
which in turn, results in decreasing peripheral resistance and blood pressure [286]. 
The current treatment guidelines for hypertension recommend using alpha-blockers 
as an add-on treatment for patients with resistant hypertension who are not well 
controlled, even with three different classes of antihypertensive agents [287]. 
The findings from the combined Scottish cohorts indicate that carriage of the A allele 
at rs9895420 (T>A) SNP in the ABCC3 transporter is associated with decreased odds 
of dose reduction of doxazosin which was directionally supported by the UKBB 
primary care analysis. This evidence of a potential rs9895420 (ABCC3)-doxazosin 
correlation has led us to study the effect of this SNP on the SBP reduction achieved 
by doxazosin. Excitingly we were showed that this SNP was significantly linked with 
increased antihypertensive efficacy of doxazosin. The exact mechanism by which this 
drug-gene interaction has occurred needs further investigation, but as outlined in 
chapter III, this could be resulting from increased doxazosin efflux into systemic 
circulation as this variant was reported to be associated with increased hepatic 
ABCC3 transporter activity if doxazosin was uncovered to be an ABCC3 substrate. 
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As doxazosin is mainly prescribed for difficult to manage patients, data on which 
patient subgroups could achieve better hypertension management could be of great 
clinical importance. The frequency of the variant allele (A) is 10% among the UKBB 
cohort participants (according to our findings) and ~ 12 % in Europeans [288]. It 
represents 6.20 %,11.25 %, and 8.43% of the American, South Asians, and East 
Asians populations respectively with its highest distribution being in Africans (~21%) 
[288] suggesting that our finding could be most relevant for patients from this 
ethnicity. 
    2.1.3 Amlodipine-rs868853 (C(minor allele)>T) ABCC4 variant [directionally 
consistent with a p-value close to the significance level] 
 
Hypertension management includes the use of four common drug classes: thiazides 
diuretics, angiotensin-converting enzymes inhibitors (ACEIs), angiotensin receptor 
blockers (ARBs), and calcium channel blockers (CCBs). The latter class is classified 
into two categories: non-dihydropyridines (non-DHPs) CCBs, such as verapamil and 
diltiazem, and dihydropyridines (DHPs) CCBs such as nifedipine, felodipine and, 
amlodipine. In addition to its usage in the management of chronic stable angina, 
amlodipine has been recently (2016) suggested to be considered the first-line agent in 
the management of hypertension compared to antihypertensive agents of other classes 
[289,290]. This drug is very commonly used in the UK as it was the 5th commonly 
prescribed chronic medication among the UKBB cohort participants. In addition to its 
once-daily tablet direction which increases adherence to the drug, amlodipine is also 
highly effective in the management of angina and hypertension with compelling 




However, the use of CCBs could be hindered by their common and troubling side 
effect, which is peripheral oedema (PO). The incidence of peripheral oedema has 
been observed to be significantly higher among CCB users compared to the placebo 
group (10.7% vs 3.2%) with the discontinuation percentage being also significantly 
higher among CCBs users (2.1% vs 0.5%) [291]. The incidence of peripheral oedema 
was also seen significantly higher among DHPs CCBs (including amlodipine) users 
compared to non-DHPs CCBs users (12.3% vs 3.1%) [291]. Amlodipine side effects 
and efficacy could be influenced by genetic variability in metabolizing enzymes or 
transporters. As clarified previously, amlodipine is mainly metabolized by CYP3A4. 
Genetic variants in this gene have been shown to affect amlodipine blood-pressure-
lowering efficacy in African-American population [292]. It has also been recently 
(2018) reported that carriers of the minor allele (C) at rs1045642 (C>T) SNP in the 
ABCB1 transporter experienced low amlodipine efficacy and increased side effects 
risk [293]. Our study has also uncovered another novel drug transporter may affect 
amlodipine tolerability. I have found that carriage of the minor allele (C) at rs868853 
(C >T) mutation in the ABCC4 transporter is associated with being less likely to 
decrease amlodipine daily dose; an association which was nearly replicated in a larger 
independent cohort. The C allele frequency is ~ 7% of the UK population (according 
to our results from the UKBB cohort) with a similar percentage in Europeans [294]. 
Of note, the highest frequency of this minor allele is seen among Africans where it 
represents ~ 37% of the population with the frequencies being 6.7 %, 16.2%, and 




The lower tendency to reduce amlodipine dose among carriers of this variant allele 
could indicate reduced side effects. If these findings are confirmed in future studies, 
use of this genotype in prescribing decisions could reduce the incidence of 
amlodipine-induced side effects especially peripheral oedema; the most annoying 
adverse event of this very common drug in the treatment of hypertension. Patients can 
be stratified by their rs868853 (C >T) ABCC4 genotype into increased or decreased 
risk groups to develop side effects so amlodipine dose could be decreased, or the drug 
can be switched into an alternative anti-hypertensive agent for the first group while 
the drug can be safely prescribed for the second group. Of note, the minor allele (C) is 
highly distributed in Africans, and therefore they may be the most affected ethnic 
group by our finding. Currently, there are no clinical trials comparing safety/efficacy 
profiles of amlodipine in different ethnic groups. Trials of this kind could help in 
understanding our results. Our findings suggest that the variant allele (C) could be 
linked with reduced side effects or efficacy of amlodipine. Therefore, if Africans 
(who have a greater frequency of the C-allele) were found to be more likely to 
develop any of these two phenotypes compared to other ethnic groups, this will 
provide more support to our finding. In addition, our result could also raise the 
attention into a potential novel amlodipine transporter (ABCC4) or could lead to the 




        2.1.4 Clopidogrel-rs12353214 (C>T) PTGS1 variant [directionally consistent with 
a p-value close to the significance level] 
 
According to the World Health Organization (WHO), cardiovascular diseases 
(CVDs) represent the top leading cause of death globally, with ~ 18 million lives lost 
annually [295]. Decreased blood supply is mainly caused by the development of 




the most common therapeutic options to prevent thrombus formation by inhibiting 
platelet aggregation. Clopidogrel and aspirin are the most frequently prescribed 
antiplatelet drugs; each of which works on a different pathway to inhibit clot 
formation. Clopidogrel active metabolites inhibit P2RY12 receptor on the platelet 
and prevents binding of adenosine diphosphate (ADP) with the receptor. This leads 
to a series of inhibitions of other molecules ending by inhibiting fibrinogen 
formation which, in turn, results in inhibiting platelet activation. On the other hand, 
aspirin works by inhibiting the PTGS1 (COX-1) enzyme which initiates a series of 
inhibitions of other molecules that differ from those seen with clopidogrel inhibition 
but end by inhibiting the same molecules as with clopidogrel leading to a similar 
outcome. Figure 18 below (extracted from reference 296) summarizes mechanisms 
of actions of both drugs. 
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Figure 18: The different inhibitory pathways for both clopidogrel and aspirin which 
lead to the same pharmacological action (inhibiting platelet aggregation). 










In one study [297], clopidogrel was shown to be as effective as aspirin in the 
prevention of stroke and myocardial infarction. However, a previous clinical trial 
found that clopidogrel was superior to aspirin in reducing stroke and myocardial 
infarction [298]. Nevertheless, clopidogrel resistance is not an uncommon issue in 
clinical practice. The data from 10 previous studies show that the percentage of 
clopidogrel resistance among users of the drug is generally more than 20% with a 
minimum percentage being 5% and a maximum percentage reaching up to 44% [299]. 
Antiplatelet drug resistance could be defined by either development of 
atherothrombotic episodes during the treatment period or lack of antiplatelet-induced 
inhibitory effect on platelet aggregation as tested in the laboratory [300]. Resistance to 
antiplatelets could occur as a result of many factors such as lack of compliance, 
underdosing, and drug interactions. Antiplatelet resistance could also be related to 
platelet function as it could occur as a result of increased rate of platelet production or 
increased sensitivity of platelets to ADP. In fact, it has been previously reported that 
clopidogrel resistance is associated with the variability in platelet response to ADP 
between different individuals and that administration of clopidogrel did not increase 
this variability [301]. This suggests that clopidogrel resistance might not be only 
linked to the drug itself but with the presence of pre-existing factors. Aspirin could be 
also affected by these factors in addition to the variability in PTGS1 activities 
between individuals.    
 As aspirin and clopidogrel work in a complementary way on different pathways to 
inhibit platelet aggregation, the combination therapy of both agents has been 
considered the gold standard treatment option for ACS in the recent years [302,303]. 
Interestingly, I have found a novel genetic variant (rs12353214 (C>T)) in the PTGS1 




allele (T) on this SNP were less likely to stop clopidogrel treatment. There was a 
similar association in UK Biobank which was close to, but not reaching, the 
significance level. Attractively, the recessive genotype (TT) at this variant has been 
previously reported to be associated with increased risk of myocardial infarction (MI) 
and unstable angina among non-steroidal anti-inflammatory drugs (NSAIDs) users 
[304]. As clopidogrel is indicated for the management of these two conditions, which 
seemed to be triggered furthermore by carrying this variant allele, it is more likely 
that carriers of this variant to show more adherence to this treatment due to a potential 
increased risk of CHD events. This is consistent with our finding that carrying of this 
variant was associated with decreased likelihood to stop clopidogrel treatment. 
However, currently, there are no studies to show whether or not this variant alone is 
directly linked with increased MI risk; the current available evidence only shows an 
association among NSAIDs users. More research is required to validate our finding.   
The frequency of the variant allele (T) is 10% among the UKBB cohort participants 
and ~ 11% in Europeans [305]. It is very rare among Africans (0.91%), represents 
9.22% and 15.8% of the American and South Asians populations respectively, and is 
highly distributed among East Asians (~ 41%) [305]. The fact that a considerable 
percentage of patients could fail to achieve therapeutic targets with clopidogrel makes 
it crucial to identify those at increased or decreased risk in order to prevent further 
deaths caused by ACSs. There are many factors affecting clopidogrel efficacy 
including genetic variants in the ABCB1 transporter and CYP2C19 and CES1 
enzymes [306]. In addition, in chapter V, I presented two studies linking genetic 
variability in PTGS1 gene to clopidogrel efficacy. Our findings show another novel 
genetic variant (rs12353214 (C>T)) in PTGS1 gene associated with decreased risk of 
stopping clopidogrel therapy; an association which could mostly affect East Asians 




Confirming this in future clinical studies will provide another piece of information to 
prescribers to enable more precise management of ACS or stroke with clopidogrel. 
Patients could be divided according to their CYP2C19, CES1, and/or PTGS1 genetic 
profiles into responders or non-responders and/or those at increased/decreased risk for 
clopidogrel-induced bleeding enabling targeted, genotype determined dosing or use of 




               2.1.5 Bisoprolol-Atorvastatin-rs9516519 (T>G) ABCC4 variant [validated]. 
 
Bisoprolol belongs to the family of selective beta-1-blockers, which also include 
atenolol, metoprolol, and nebivolol. Blocking beta-1-receptor action results in 
decreased heart contractility, heart rate, cardiac output, and norepinephrine/renin 
levels [307]. Therefore, beta-1-blockers are indicated for the management of 
hypertension (by decreasing cardiac output and renin levels [308]), heart failure (by 
reducing the adverse effects of norepinephrine on myocytes [309]), post-
myocardial infarction and chronic stable angina (by reducing oxygen demand as a 
result of decreased heart rate and contractility [310,311]). Selective beta-1-blockers 
are now considered the first-line agents for the management of chronic unstable 
angina [312].  
The most common side effects of selective beta-1-blockers including bisoprolol are 
hypotension, bradycardia, low exercise capacity, nausea, vomiting, dizziness, 
headache, fatigue, and dry mouth/eyes [313]. Another risky side effect, which 
could mostly affect diabetic patients on glucose-lowering agents, is masking of the 
symptoms of hypoglycemia such as tachycardia which could delay the response to 




The cases of toxicity from bisoprolol which have been documented to date presented 
mostly with bradycardia and/or hypotension [314]. The chance of this toxicity 
increases with the presence of other factors such as drug-drug and drug-gene 
interactions. As outlined before in chapter V, bisoprolol is mainly metabolized by 
CYP3A4, implying that CYP3A4 inhibitors could increase the risk of bisoprolol-
induced toxicity. Our initial (discovery) finding shows that bisoprolol users co-treated 
with atorvastatin (a CYP3A4 inhibitor) who carry the rs9516519 (T>G) variant in the 
ABCC4 transporter were at high risk to stop either of the two drugs during their 
combined use. In the replication cohort, I was not able to see the same association 
with the same phenotype. However, when I examined the hypothesis that the two 
potential risk factors (atorvastatin + rs9516519 (T>G) ABCC4 SNP) could increase 
bisoprolol-induced toxicity as indicated by greater systolic blood pressure (SBP) 
lowering, large drug-drug and drug-drug-gene interactions were observed. The most 
prominent effect seen was the drop in SBP by ~ 8 mmHg among bisoprolol-
atorvastatin users compared to bisoprolol-only users. This drop in SBP was even 
greater amongst carriers of the rs9516519 (T>G) ABCC4 variant allele. This variant 
is mostly distributed among Americans (18.30%) and Europeans (13.22%) [315]; 
with the percentage being ~14% in the UK (according to our results from chapter III) 
while it is rarely found among South Asians (2.8%), East Asians (0.40%), and 
Africans (0.30%) [315]. It could be the case that the reason for stopping one of the 
two drugs during their interaction for carriers of this variant allele is explained by 
increased bisoprolol-induced toxicity. A drop in SBP by >= 8 mmHg could be 
clinically significant and lead to the development of symptoms of hypotension such as 
dizziness, nausea, fainting, fatigue, loss of concentration, blurry vision, and 




who are prescribed bisoprolol for the management of other conditions, rather than 
hypertension, such as heart failure, myocardial infarction, or chronic stable angina.   
 
Our findings provide the first evidence for a potential harmful drug-drug interaction 
between bisoprolol and atorvastatin and also shows potentially novel genetic variant 
(rs9516519 (T>G)) and transporter (ABCC4) which seemed to affect this drug-drug 
interaction. Further clinical trials and/or in-vitro studies are required to confirm these 
observations. If these findings are confirmed, then the prescribing guidelines for 
bisoprolol could change in the future. For patients already on atorvastatin or those 
who will add atorvastatin, bisoprolol dose could be reduced, or the drug could be 
switched into an alternative beta-1 blocker not influenced by the CYP3A4 enzyme 
such as atenolol. If the patient carries the G allele at rs9516519 ABCC4 SNP, the 
recommendation will more likely be switching the drug as the risk of bisoprolol 
toxicity is expected to be higher for this subgroup of patients. As the distribution of 
this variant allele is higher among White Americans and White Europeans, the 







                              2.2 Associations consistent with previous studies' findings. 
 
For drug-drug-gene interactions, all of our findings were novel, so we cannot 
identify whether any of our results replicated previously reported findings. However, 
for the drug-gene interactions study, I was able to identify 19 results from both the 
combined and the UKBB-cross-sectional cohorts to be consistent with previously 
reported findings. I have discussed these findings in chapter III. In Table 13 below, I 
summarize these findings. 
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rs1057910 (A>C) (2C9*3) 
 
CYP2C9 
Increased likelihood for dose reduction > 
increased toxicity. 




















Decreased likelihood for stopping of the drug > 
increased efficacy or decreased side effects. 
Increased simvastatin lactone plasma 
concentration and decreased clearance 
> increased chance of increased 










Decreased likelihood for stopping of the drug > 
increased efficacy or decreased side effects. 














The A allele is linked with an    increased  
likelihood for 
stopping the drug > increased side effects or 
decreased efficacy. 
 















The C allele is linked with dose decrease > 
increased side effects 
The  C  allele is linked with decreased clearance 










Decreased likelihood for dose reduction > 
increased likelihood of increasing the dose. 
Decreased plasma concentration > low efficacy 













The A allele is linked with increased  
likelihood for 
stopping the drug > increased side effects or 
decreased efficacy. 
 
The A allele is linked with increased clearance 






rs10509681 (T>C) (2C8*3) 
 
CYP2C8 
Increased likelihood for stopping the drug > 
increased side effects or decreased efficacy. 










Increased likelihood for stopping the drug > 
increased side effects or decreased efficacy. 
 













The A allele is linked with decreased likelihood 
for stopping of the drug > increased efficacy or 
decreased side effects. 
 
 






rs1057910 (A>C) (2C9*3) 
 
CYP2C9 
      Decreased likelihood for dose reduction > 
Decreased side effects/efficacy 
 






rs1065852 (G>A) (2D6*10) 
 
CYP2D6 
Low distribution of the variant allele carriers > 
increased side effects or low efficacy 
Increased nortriptyline plasma level > 









Low distribution of the variant allele carriers > 
increased side effects or low efficacy 







rs4149056 (T>C) (1B1*5) 
 
SLCO1B1 
Low distribution of the variant allele carriers > 
increased side effects or low efficacy 
 














High distribution of the variant allele carriers > 
low side effects or high efficacy 
Decreased cardiovascular events/ increased 










Low distribution of the variant allele carriers > 
increased side effects or low efficacy 
 






rs28371725 (C>T) (2D6*41) 
 
CYP2D6 
High distribution of the variant allele carriers > 








rs10509681 (T>C) (2C8*3) 
 
CYP2C8 
Low distribution of the variant allele carriers > 
increased side effects or low efficacy 
 






rs1065852 (G>A) (2D6*10) 
 
CYP2D6 
Low distribution of the variant allele carriers > 
increased side effects or low efficacy 
 




Table 14: Summary of 11 drug-gene associations require further investigation in a larger cohort. 
 
                            2.3 Associations require further investigation in a larger cohort. 
 
I have found 11 novel DG/DDG associations from the UKBB cross-sectional 
prescribing data which were significant after Bonferroni correction. However, I was 
unable to check for the replicability of these findings as no ideal replication data was 
available to us. The ideal replication data should be another independent and larger 
cross-sectional prescribing data. In chapters III and IV, I have already discussed these 
findings. Here, I briefly outline these 11 findings in Table 14 below. 
 
 














Low distribution of the variant allele carriers 









Low distribution of the variant allele carriers 









Low distribution of the variant allele carriers 









High distribution of the variant allele carriers 
> low side effects or high efficacy 









High distribution of the variant allele carriers 









High distribution of the variant allele carriers 









High distribution of the variant allele carriers 









Low distribution of the variant allele carriers 














Low distribution of the variant allele carriers 









Low distribution of the variant allele carriers 









Low distribution of the variant allele carriers 





          3. Points of strength and weakness of our research 
 
 
I started this PhD project at the time when the UKBB prescribing data was available 
only as cross-sectional data in 2017. Therefore, the only way we found to define drug 
response phenotypes in this kind of data was by observing changes in the genotype 
distribution between drug/drug combination users and non-users. For our DGI study, 
the challenge of this approach lies in the fact that this phenotype could detect not only 
genetic variants affecting drug response but also variants which might be associated 
with diseases for which these drugs are prescribed for. To help minimize this risk, we 
excluded any drug-variant association where the variant was most likely associated 
with diseases but not drug response by utilizing the GeneAtlas database which 
provides millions of variants-traits associations using the UKBB cohort. In addition, 
DDGIs phenotypes cannot be accurately defined in a cross-sectional database due to 
uncertainty regarding the overlapping period between the two prescribed drugs and 
therefore the detected association might not necessarily reflect a DDGI, but could 
more simply reflect a DGI. To account for this issue, all DDGI findings in chapter IV 
were discussed considering DGI results from chapter III. So, for any DDGI, I also 
mention the results for each drug individually with the same variant, so we recognize 
whether our observation is a DDGI, DGI, or both. 
Having mentioned these limitations in the UKBB cross-sectional data, one should not 
ignore its great power in detecting previously unrecognized associations giving the 
huge cohort size. With around 500,000 participants, the UKBB cross-sectional data 
represents the world's largest genetic database available to date. 
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In contrast to the UKBB cross-sectional data, I have also utilized three Scottish 
cohorts with longitudinal prescribing which provide a relatively small cohort size, 
even after combined together, compared to the UKBB. However, the advantage of this 
cohort is that it enabled us to define more accurate drug response phenotypes such as 
drug-stop and dose-decrease among users of the same drug/drug combination. For 
DDGIs, the longitudinal data enabled us to identify the exact interaction period 
between each of the two drugs. However, for the DDGI analysis, the numbers of 
patients prescribed two drugs concurrently who have a particular genotype is usually 
very small, which limits the power for these studies in the Scottish cohorts. 
The points of strength of this project are that it covers for the first time a large variety 
of drug-gene and drug-drug-gene associations, utilized 4 different UK cohorts, and 
shows different methodologies for defining drug response phenotypes including both 
general and specific phenotypes in both cross-sectional and longitudinal prescribing 
data. Moreover, the majority of our findings from our DGI study were novel with 
almost all findings from our DDGI study to be novel giving the fact that this is the 
first work studying this topic comprehensively; however, clearly, further replication 
of all results is required before these results can be taken forward clinically. One other 
feature of this work is that it provides two user-friendly online applications to view all 
48,600 results I generated in this project for both DG and DDGI studies. 
We can gain considerable confidence in the findings we report because a total of 19 
results from all different phenotypes ('drug-stop', 'dose-decrease', 'genotype 
distribution changes') were validated or replicated previous findings in some way. 
For example, validating findings from previous studies including the association 
between CYP2C9*3/8*3 variants and increased risk of side effects/inefficacy from 
gliclazide/pioglitazone treatments. We have also validated the finding that loss-of- 
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function variants in ABC transporters family are linked with increased statin efficacy. 
What is more, our study has also validated some findings currently classified as 'level 
A evidence' (i.e., supported with strong evidence) from PharmGKB including the 
common associations between SLCO1B1*5 variant and increased simvastatin side 
effects/intolerance, CYP2C19*17 and increased clopidogrel efficacy/tolerance, and 
CYP2C19*2 and decreased clopidogrel efficacy/tolerance. In addition, unlike many 
other publications in pharmacogenomic, our work also shows the replication results of 
the top discovery findings by utilizing a larger and independent UK cohort: the 
UKBB primary care data (recently available on September 2019 on ~230,000 
participants). 
Out of 8 DG associations (excluding one that cannot be replicated due to genotyping 
issues), 6 associations (75%) were found directionally consistent in the replication 
cohort. Four of these associations were of more interest. The Quinine-rs4918758 
(CYP2C9) association was clearly replicated, doxazosin-rs9895420 (ABCC3) 
association was validated, and the amlodipine-rs868853 (ABCC4) and clopidogrel- 
rs12353214 (PTGS1) associations were directionally consistent with p-values close to 
but not passing the significance level. In addition, out of 3 DDG associations, one 
(bisoprolol-atorvastatin-rs9516519 (ABCC4)) was validated. 
The lack of replication beyond these findings is to be expected. In part, this is due to 
the large number of tests and high likelihood to find false positives. This is more 
likely to be seen with findings from the DDGIs study using the combined Scottish 
cohort. Sample sizes were generally quite small for most drug combinations to detect 
reliable statically significance associations. The first reduction in sample sizes was 
mostly driven by the fact that number of the combination users should be always 
lower than users of individual drugs. The second larger reduction has occurred  
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 mainly in the case groups where we were looking only for patients who developed 
rare events (e.g., drug-stop) and within a limited period of time (i.e., the interaction 
time). The situation was much better with the DGI study as we had relatively larger 
sample sizes. However, the drug-stop and dose-decrease phenotypes were not very 
common events so the number of cases quite limited. A greater power and more 
interpretable results could have been achieved by grouping all individuals with the 
similar metabolizer status as defined by all variants in the same gene rather than 
considering each variant individually as in our study. A greater power could have 
also been achieved by grouping drugs as classes according to their substrate 
specificities (e.g., all CYP2D6 substrates) rather than examining each drug 
individually as in our study. However, all of these two methods require a previous 
knowledge on either the variant function or whether the drug is a known substrate for 
the gene which counters one of the main targets of this project which is uncovering 
novel variants and/or novel drug targets.     
  The second main reason beyond lack of replication is the generic nature of our drug 
response phenotype that is inherently noisy and non-specific. For example, if the 
same adverse drug reaction has been observed from the same drug with carriers of 
the same risky allele, one physician may decide to stop the drug, the second might 
decide to decrease the dose, the third might keep the drug but provide the patient 
with a specific lifestyle changes advice to deal with this adverse event, the fourth 
might keep the drug but prescribe another drug to treat the side effect, and so forth. 
In short, the effect seen from the initial finding might be 'diluted' in the replication 
cohort because of this variability in the clinical decisions for the same clinical 
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Figure 19: Visual illustration explaining why flexible phenotypes cannot be always replicated. 
* Side effects resulting from a certain drug-variant interaction can be dealt with 
using many strategies (a, b, c, or d). If drug-stop phenotype for example was very 
common (significant) in the discovery cohort, the same phenotype can be very 
common (replicated), moderately common (close to replication), or not common 
(not replicated) in the replication cohort. 
 
 
scenario due to different patient groups, and clinical practice variation. Figure 19 








On the other hand, this variability is less likely to be seen with drug-specific 
phenotypes. For example, sulfonylurea-induced hypoglycemia can be defined as 
blood glucose levels < 4 mmol/l after treatment initiation. This provides accurate 
identification of all cases of interest as hypoglycemia definition is specifically defined 
depending on a well-known threshold among health care providers. If a certain variant 
was associated with this phenotype, then the same association should also be seen in 
the replication cohort if it was genuine. However, the disadvantage of drug-specific 
phenotypes is that they are difficult to be utilized to provide a rapid efficient 
screening of a large variety of DG/DDG associations unlike the 'generic' phenotypes 
we used in this project. We used these phenotypes as our target was studying a large 
number of drugs from different drug classes rather than only a specific drug or a 
specific drug class. The other advantage of 'generic' phenotypes such as 'drug-stop' 
and 'dose-decrease' is that they can provide a direct evidence for a potential change in 
the clinical practise, which is the ultimate goal of pharmacogenomics' studies. On the 
other hand, drug-specific phenotypes may not result in a change in clinical practice. 
For instance, if a certain variant was found to be associated with increased nicorandil-
induced reduction in systolic blood pressure, this provides an evidence for increased 
risk for hypotension-related ADRs but doesn't necessarily imply that this is also 
sufficiently clinically significant to result in stopping of or reducing the dose of the 
treatment.           
 












    4. Future directions 
 
 
Reaching the end of this project is only the beginning of many other exciting 
scientific journeys. Our findings have identified that ABCC4 transporter as a potential 
novel transporter for amlodipine and bisoprolol while ABCC3 could be a potential 
novel transporter for doxazosin. In chapter V, we discussed that quinine was 
identified as a CYP2C9 substrate even though CYP3A4 was the main metabolizing 
enzyme. However, we presented another study linking CYP2C9 genetic variability 
with the therapeutic efficacy of quinine derivatives chloroquine and primaquine 
providing more evidence on a potential correlation between CYP2C9 genetic variants 
and quinine efficacy/safety as well but further investigation is warranted here. 
Therefore, it could also be of interest to examine these potential correlations in 
future work by conducting a laboratory-based investigation. We are collaborating 
with Kathy Giacomini and colleagues at UCSF to follow up on some of our 
transporter related hits. They transiently transfect HEK293 Flp-In cells with the 
transporter and then looks at drug transport into the cell. Regarding metabolizing 
enzymes-related work, Ronald Wolf’s research team, based in Dundee, could help 
us to identify the degree of correlation between CYP2C9 and quinine metabolism. 
These in-vitro studies will help us to have a better understanding of the mechanisms 
by which our findings have occurred. If amlodipine and bisoprolol were ABCC4 
substrates, ABCC3 was a transporter for doxazosin, CYP2C9 contributed 
significantly to quinine metabolism, then our proposed pharmacokinetic mechanisms 
of interactions I explained in chapter V could be justifiable. However, drug 
transporters and metabolizing enzymes have many different physiological roles in 
the body and therefore if these drugs were not substrates for these 
transporters/enzymes, then there might be other unknown mechanisms of  
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interactions leading to our observed phenotypes. If we're able to confirm any of the 
above potential correlations from the laboratory work, then the next step would be to 
consider conducting genotype-based pharmacokinetic studies. It would be of interest 
to study the influence of different genotypes at rs4918758 CYP2C9, rs9895420 
ABCC3, and rs868853 ABCC4 SNPs on quinine, doxazosin, and amlodipine plasma 
concentrations respectively. If any interesting correlations were detected, then this 
could be followed by clinical trials in which the outcome to be assessed is dose 
reduction. Regarding clopidogrel- rs12353214 PTGS1 SNP association, we could 
assess the drug-stop phenotype, or bleeding time, or use population data to look at 
the effect on stroke recurrence, ACS or bleeding risk. 
A clinical trial to establish a clinically relevant drug-gene interaction could include a 
number of different study designs including, for example, an exposure-only design 
(EOD) [316] or an enrichment design (ED) [317]. The first study design focuses on 
the treatment group only. In our case, patients are treated with the drug of interest 
first (i.e., quinine, doxazosin, amlodipine, or clopidogrel), and then these patients are 
followed up. I then evaluate the outcome of interest (dose-decrease for quinine, 
doxazosin, or amlodipine and drug-stop for clopidogrel) when the genotype group is 
known ( (rs4918758 (quinine), rs9895420 (doxazosin), rs868853 (amlodipine), or 
rs12353214 (clopidogrel) ). 
The other design (ED) starts by knowing the patient genotypes and defining patient 
subgroups based upon carriage of the variant allele classified into carriers or non-
carriers of the variant allele. Then, both groups are treated with the drug of interest 
and followed up to evaluate the phenotype of interest (dose-decrease/drug-stop) in 
each group. A significant difference in the number of events between the two groups 





Regarding the bisoprolol-atorvastatin-rs9516519 ABCC4 SNP-drug-stop association, 
the drug-stop phenotype could be too rare and tricky to study clinically in DDGIs 
studies. However, I have validated this finding using an alternative phenotype (SBP 
drop) which can be investigated better clinically. Here, patients are stratified into two 
groups: carriers and non-carriers of the variant allele. Then, each group is treated (in 
random order) with bisoprolol alone and atorvastatin + bisoprolol. Then, I study 
whether there is any significant difference in SBP levels between the two groups 
during the bisoprolol-only period (DGI) and during atorvastatin + bisoprolol period 
(DDGI). 
The UKBB primary care data is a very rich resource combining both the large cohort 
size and the large variety of clinical phenotypes such as clinical measurements, direct 
drug-related adverse events, and indirect but could be drug-related adverse events. 
This data only became available towards the end of my PhD and is likely to soon 
incorporate the primary care data for all 500,000 participants making it the world's 
largest longitudinal data for pharmacogenetic studies. This will facilitate studying a 
large variety of drug response phenotypes in a large cohort leading to more 
previously undiscovered associations. In the future, I would like to use this database 
to study "drug-stop" and "dose-decrease" phenotypes again for all of my selected 
drugs and drug combinations. I would also like to take a more targeted drug-specific 
approach to look at drug-specific adverse events or drug efficacy using clinical 
measurements such as blood pressure change, HbA1c change or change in 
electrolytes.  
Scientific research will be an important part of my academic responsibilities in the 
university where I will work in Saudi Arabia. Therefore, UKBB primary care data 




I propose to work with includes patients from Saudi Arabia - Genetic and 
pharmacogenomic studies are ultra-rare in the Arabic region making studies on this 
particular ethnic group of great importance and of course relevant to the management 
of patients in Saudi Arabia. The Saudi Human Genome Program (SHGP) [318] is the 
largest genetic project in the middle east area aiming to collect genotype data for 
100,000 Saudi individuals to facilitate the discovery of genetic variants associated 
with rare diseases in Saudi individuals in addition to pharmacogenomic studies. The 
project started in 2013, and the number of participants to date (2020) reached 56,799 
individuals [319]. My future plan is to establish a collaborative research work 
between the incredible research team I worked with in the University of Dundee and 
the department of Clinical Pharmacy in the College of Pharmacy in Umm Al-Qura 
University where I will work to facilitate pharmacogenomic research on both the 




                     Publications and prizes 
 
1. I have been awarded the 1st prize award (see supplementary material 3) for 
 
the best poster presentation and research outcome among all other submissions 
for my work titled "Drug-Gene and Drug-Drug-Gene Interactions for the 
Most Commonly Used Drugs in the UK" during the Postgraduate Research 
Student Symposium 2019 which has been held in the University of Dundee. I 
have received an encouragement award of ~ £ 1000 from the Royal Embassy 
of Saudi Arabia in London upon this achievement. 
2. One review article has been published at the end of 2019. 
 
'' Malki M, Pearson E. Drug–drug–gene interactions and adverse drug 
 
reactions. The Pharmacogenomics Journal. 2019;20(3):355-366 ''. The paper 
 
has been highlighted by the journal as one of the best publications in The 
Pharmacogenomic Journal 2019 .I have received an encouragement award 
of ~ £ 1000 from the Royal Embassy of Saudi Arabia in London upon this 
paper publication. 
Regarding publishing our main findings from this project, we preferred not to 
publish our work until after we can support it with a replication study from an 
independent cohort. The replication cohort (the UKBB primary care data) 
wasn't available to us until after the end of my 3rd year in this 4-years PhD 
program. The last (4th year) started with working with this data, followed by 
the writing-up stage of my thesis. Therefore, I couldn’t find enough time to 
publish our main findings. However, two papers, one for DGIs and the other 
one for DDGIs for the most commonly used drugs in the UK, have already 
been written. We plan to publish the DGI paper in the near future.  
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                                 Supplementary material 2: 
 
The final 162 selected SNPs with their MAF and HWE results from all cohorts. 
*SNP groups: 1= 26 important SNPs, 2 = 76 independent SNPs, and 3 = 60 randomly selected SNPs among groups of correlated SNPs. 
 
 
         GoDARTs   GS   GoSHARE   Combined   UKBB  
No. rsid Position_build_37 SNP group * Major allele Minor allele * allele Gene Chromosome MAF HWE (p-value)  MAF HWE (p-value)  MAF HWE (p-value)  MAF HWE (p-value)  MAF HWE (p-value) 
1 rs1045642 87138645 1 A G *2/*13 ABCB1 7 0.46361993 0.301747799  0.458067093 0.714597532  0.464754953 0.203217862  0.460458956 0.440908535  0.45625 0.06113509 
2 rs1128503 87179601 1 G A NA ABCB1 7 0.44226689 0.078822311  0.452500998 0.682991294  0.449322211 0.151744141  0.449424367 0.257672978  0.4371464 0.06359866 
3 rs2032582 87160618 1 C A NA ABCB1 7 0.460066808 0.456101958  0.46083766 0.745763601  0.456517205 0.02989111  0.460092725 0.17082713  0.4561078 0.3049629 
4 rs1186746 87133993 2 T C NA ABCB1 7 0.259061513 0.343387799  0.127720647 0.176156577  0.121272158 0.782606731  0.124939978 0.457945631  0.1137491 0.07089484 
5 rs12720066 87169702 2 A C NA ABCB1 7 0.056235717 0.96149662  0.259210264 0.781268221  0.253180396 0.480632005  0.258226228 0.277776174  0.2720129 0.459068 
6 rs2032588 87179443 2 G A NA ABCB1 7 0.068757674 0.308036192  0.057657748 0.609020715  0.064859228 0.685035282  0.060099818 0.129446994  0.06216873 < 1*10-8 
7 rs3842 87133366 2 T C NA ABCB1 7 0.155827322 0.09014297  0.056908946 0.727020808  0.064025026 0.774576965  0.059252738 0.206786659  0.06076218 0.003384094 
8 rs4728709 87233602 2 G A NA ABCB1 7 0.061397633 0.490482721  0.249575679 0.810723151  0.257142857 0.78232084  0.249698395 0.642264407  0.2510837 0.09216039 
9 rs9282564 87229440 2 T C NA ABCB1 7 0.097764322 0.03821894  0.216728235 0.781621444  0.215015641 0.591835595  0.214976562 0.915007841  0.214707 0.7667071 
10 rs1186745 87133947 3 C A NA ABCB1 7 0.128333085 0.902763069  0.146440695 0.423916518  0.15265902 0.970630609  0.145362293 0.871344139  0.1492706 0.6086663 
11 rs2235013 87178626 3 C T NA ABCB1 7 0.47054229 0.488204875  0.117462061 0.936549577  0.118456726 0.799306212  0.118842693 0.317287328  0.1223943 0.9279406 
12 rs4148739 87161049 3 T C NA ABCB1 7 0.134887872 0.674554603  0.047898363 0.700544836  0.051616267 0.497310605  0.051523771 0.976466428  0.05285953 0.1522764 
13 rs152023 16085236 2 T C NA ABCC1 16 0.306932656 0.728744821  0.117561901 0.982463359  0.118039625 0.849683212  0.119032775 0.341922155  0.122257 0.816522 
14 rs16967126 16128418 2 T C NA ABCC1 16 0.08373393 0.755782298  0.127346246 0.149035713  0.131386861 0.052379586  0.127272997 0.231492416  0.1315234 0.849175 
15 rs17287570 16155103 2 A C NA ABCC1 16 0.191023567 0.904572321  0.248028155 0.725571509  0.238894682 0.15425162  0.24710734 0.589360208  0.2464634 0.3060833 
16 rs17501331 16089441 2 A G NA ABCC1 16 0.092577432 0.114325292  0.064621605 0.981327652  0.064650678 0.042635067  0.064913211 0.701081242  0.06276541 0.5430438 
17 rs2074087 16184232 2 G C NA ABCC1 16 0.13935991 0.045708425  0.123901757 0.47277556  0.125860271 0.956578786  0.125876185 0.088155977  0.1352321 0.9720862 
18 rs212090 16236004 2 A T NA ABCC1 16 0.448242521 0.50870511  0.210163738 0.65883872  0.215745568 0.707421751  0.21425569 0.565516127  0.2219529 < 1*10-8 
19 rs215095 16060394 2 A G NA ABCC1 16 0.116290811 0.916192172  0.456594449 0.844980188  0.449009385 0.402512745  0.452368073 0.286879544  0.4518098 < 1*10-8 
20 rs2889517 16181956 2 C T NA ABCC1 16 0.280029435 0.528310133  0.329248203 0.062754193  0.33096976 0.877420561  0.327639333 0.579722081  0.325659 < 1*10-8 
21 rs35621 16168608 2 C T NA ABCC1 16 0.132808135 0.969712542  0.100938498 0.660367074  0.102294056 0.709054389  0.099952333 0.845755591  0.09608641 6.54E-08 
22 rs3743527 16235681 2 C T NA ABCC1 16 0.196559504 0.682366402  0.200554113 0.747444158  0.202815433 0.76512132  0.202875112 0.535614905  0.2075959 < 1*10-8 
23 rs8187843 16101875 2 G A NA ABCC1 16 0.081941725 0.545553962  0.083191893 0.584717368  0.089259645 0.192375021  0.083814169 0.009833538  0.08851212 0.5950531 
24 rs11861115 16199670 3 G A NA ABCC1 16 0.24635405 0.007851622  0.064771366 0.946349511  0.062252346 0.782792169  0.064879513 0.553938188  0.07002605 0.8726684 
25 rs1967120 16108894_16108895 3 A G NA ABCC1 16 0.291950811 0.533475283  0.39057508 0.345814587  0.394786236 0.387759192  0.388478706 0.1419192  0.3891436 0.4411858 
26 rs212082 16227147 3 A G NA ABCC1 16 0.205325112 0.818787982  0.162365216 0.39204648  0.160896767 0.794246535  0.161047051 0.760200016  0.1500915 0.3749078 
27 rs215066 16079117 3 G A NA ABCC1 16 0.056142144 0.952080151  0.259784345 0.100673993  0.267049009 0.78806089  0.260717926 0.285316079  0.2581483 1.76E-07 
28 rs35596 16152940 3 T C NA ABCC1 16 0.2126378 0.13573572  0.064496805 0.248236476  0.063399374 0.759481522  0.061636801 0.413787494  0.06176809 0.1723977 
29 rs45511401 16173232 3 G T NA ABCC1 16 0.055733945 0.16282317  0.065869609 0.072949371  0.064754953 0.17887041  0.066471845 0.145063054  0.06066049 0.5065297 
30 rs4781712 16103232 3 G A NA ABCC1 16 0.448702101 0.48508198  0.15634984 0.596696035  0.149426486 0.451358371  0.155120616 0.465953225  0.1399296 0.08815652 
31 rs8058040 16107712 3 A G NA ABCC1 16 0.168973987 0.264512895  0.060203674 0.907936158  0.060896767 0.111014416  0.060569648 0.984877753  0.0644072 0.5916309 
32 rs2273697 101563815 2 G A NA ABCC2 10 0.197784086 0.440369379  0.102535942 0.88161535  0.098540146 0.856953662  0.100600304 0.230125499  0.109195 0.3056447 
33 rs717620 101542578 2 C T NA ABCC2 10 0.207726808 0.161407065  0.311177117 0.039921571  0.303023983 0.377740239  0.30865503 0.046128273  0.3153561 0.2548448 
34 rs7910642 101541579 2 G A NA ABCC2 10 0.107563025 0.973268313  0.085613019 0.139654975  0.086548488 0.653323267  0.085198267 0.140225746  0.08975572 0.1931096 
35 rs4148386 101548468 3 A G NA ABCC2 10 0.442324855 0.129130664  0.197533946 0.127175191  0.195307612 0.748719341  0.195566267 0.235417397  0.1982107 0.02506933 
36 rs8187707 101610533 3 C T NA ABCC2 10 0.058770556 0.095507915  0.111571486 0.07259935  0.087486966 0.684987702  0.103644469 0.367928484  0.1087784 < 1*10-8 
37 rs1051640 48768486 2 A G NA ABCC3 17 0.174780527 0.852401095  0.146415735 0.645960596  0.143899896 0.056472335  0.144166766 0.029936152  0.1448096 0.2241819 
38 rs4148416 48753423 2 C T NA ABCC3 17 0.060174968 0.940128442  0.441094249 0.186294547  0.439311783 0.99394779  0.442781323 0.196792225  0.4416392 0.1517074 
39 rs4793665 48712087 2 T C NA ABCC3 17 0.420598743 0.36962251  0.117811502 0.208097343  0.11282586 0.951319054  0.116681521 0.283380615  0.1177531 0.02568038 
40 rs9895420 48712038 3 T A NA ABCC3 17 0.090893231 0.266780672  0.286142173 0.247470752  0.28540146 0.822052068  0.284395473 0.264360884  0.288644 0.0245887 
41 rs17268122 95844494 2 G T NA ABCC4 13 0.223215283 0.55827223  0.13296226 0.636842513  0.133159541 0.48501968  0.132879274 0.492250561  0.1121012 0.07763722 
42 rs17268282 95925314 2 G T NA ABCC4 13 0.073071341 0.250930324  0.199880192 0.661813515  0.201876955 0.464304497  0.199229442 0.765589725  0.2088848 0.3073711 
43 rs2274407 95859035 2 C A NA ABCC4 13 0.064939837 0.099298759  0.076477636 0.348483565  0.077163712 0.068417009  0.077983847 0.065293998  0.07126842 0.9478854 
44 rs4773866 95929326 2 C T NA ABCC4 13 0.085462901 0.852078426  0.197758586 0.418684193  0.191553702 0.368869572  0.197067399 0.606488974  0.2006881 0.8779732 
45 rs7317112 95923523 2 A G NA ABCC4 13 0.26405499 0.980723634  0.205121805 0.881875446  0.20354536 0.66104501  0.205734729 0.429715107  0.2049396 0.06990433 
46 rs868853 95955076 2 T C NA ABCC4 13 0.076552882 0.532197411  0.107727636 0.269430207  0.110427529 0.234991542  0.108101687 0.732843725  0.1081523 0.6268031 
47 rs899494 95861804 2 G A NA ABCC4 13 0.145206399 0.123306562  0.173672125 0.046882079  0.172888425 0.486105404  0.17389164 0.253294714  0.1778635 0.4193322 
48 rs9556455 95697416 2 G A NA ABCC4 13 0.138228197 0.86770208  0.060927516 0.695680548  0.05620438 0.648311284  0.060130894 0.986077558  0.05424158 0.3159807 
49 rs9561778 95713715 2 G T NA ABCC4 13 0.21940999 0.282914366  0.419304113 0.373373191  0.432429614 0.724888401  0.421631573 0.187364123  0.4358378 0.9398552 
50 rs2274405 95858978 3 C T NA ABCC4 13 0.352284151 0.186668956  0.219698482 0.696026038  0.224504692 0.077730382  0.221259422 0.500748828  0.2233558 0.3216945 
51 rs3742106 95673791 3 A C NA ABCC4 13 0.402181208 0.906654535  0.07430611 0.146401961  0.075703858 0.533543229  0.074219677 0.045790725  0.07158207 0.2736217 
52 rs9516519 95672457 3 T G NA ABCC4 13 0.144551354 0.619655985  0.064247204 0.356586872  0.066840459 0.35989113  0.064685413 0.449838682  0.06602204 0.1649555 
53 rs3805111 183689989 2 G A NA ABCC5 3 0.063707426 0.971490999  0.084464856 0.486029018  0.079979145 0.122675688  0.084098132 0.217885996  0.08645253 0.9139518 
54 rs8180093 183642303 2 G A NA ABCC5 3 0.061990394 0.699205033  0.26936901 0.637786824  0.278519291 0.966970989  0.269365466 0.611301331  0.2743199 0.543975 
55 rs10937158 183708439 3 C T NA ABCC5 3 0.474935804 0.284712426  0.08206869 0.953391641  0.075495308 0.066630466  0.079641945 0.813279943  0.07843594 0.5459893 
56 rs2293001 183700211 3 C T NA ABCC5 3 0.347772554 0.147099256  0.142097644 0.600218174  0.146715328 0.537177681  0.143620495 0.514180448  0.1282055 0.08194285 
57 rs3749442 183660585 3 G A NA ABCC5 3 0.167206885 0.720507134  0.129642572 0.742862951  0.128467153 0.754695505  0.131704036 0.85655181  0.1338329 0.957173 
58 rs3792581 183695870 3 C A NA ABCC5 3 0.176726542 0.912600688  0.226837061 0.06194851  0.223044838 0.988130418  0.224180912 0.048284908  0.2191852 0.4976166 
59 rs2231142 89052323 1 G T NA ABCG2 4 0.121948348 0.861449106  0.064047524 0.971045716  0.068821689 0.852493133  0.064506557 0.906908681  0.06606492 0.6538555 
60 rs17731538 89055379 2 G A NA ABCG2 4 0.156237748 0.932176553  0.060927516 0.721020586  0.059541189 0.362908852  0.061083086 0.685132434  0.0646645 0.956648 
61 rs2199939 39911494 2 C T NA ABCG2 8 0.170652913 0.625413351  0.15235623 0.058556677  0.153701773 0.447351159  0.153853333 0.285797648  0.1671135 0.05905998 
62 rs2231135 89079994 2 A G NA ABCG2 4 0.055699045 0.815900339  0.162265375 0.957815882  0.16016684 0.781973304  0.164184218 0.677084712  0.1649755 0.8861808 
63 rs2231148 89028478 2 T A NA ABCG2 4 0.364139841 0.551347093  0.056384784 0.10482826  0.056934307 0.983030317  0.056281945 0.147154809  0.05713432 0.5932062 
64 rs2725264 89026109 2 T C NA ABCG2 4 0.060995774 0.093339184  0.360872604 0.821513952  0.368300313 0.746892559  0.362856886 0.739104704  0.3712469 0.3293736 
65 rs7699188 89096061 2 G A NA ABCG2 4 0.150295792 0.728743652  0.063248802 0.26262389  0.062877998 0.528303855  0.062512278 0.043978442  0.06158675 0.2160949 
66 rs17731799 89068455 3 G T NA ABCG2 4 0.479218153 0.641297461  0.143320687 0.486667414  0.152137643 0.397984176  0.146413102 0.694408402  0.1530467 0.6143459 
67 rs2622604 89078924 3 C T NA ABCG2 4 0.256063485 0.869677019  0.269219249 0.843446206  0.287799791 0.035975729  0.27102593 0.314538202  0.2757951 0.9799706 
68 rs2725256 89050998 3 A G NA ABCG2 4 0.383376217 0.051900661  0.194988019 0.894094242  0.189468196 0.206097655  0.194503307 0.820371154  0.2067039 0.01577387 
69 rs4148157 89020934 3 G A NA ABCG2 4 0.102210255 0.938677137  0.32435603 0.030500873  0.329092805 0.010151105  0.325760649 0.015913366  0.3225237 0.1726202 
70 rs12443580 55866337 2 T C NA CES1 16 0.26405208 0.809500229  0.055061901 0.109282461  0.062565172 0.241139977  0.056488527 0.098109196  0.05050589 0.02524929 
71 rs3815583 55867042 2 A C NA CES1 16 0.196593218 0.433577703  0.44513778 0.690535157  0.438164755 0.858391666  0.444461599 0.880480961  0.4485127 0.7292141 
72 rs2244613 55844609 3 T G NA CES1 16 0.189174107 0.968591568  0.185952476 0.321295193  0.196037539 0.723859859  0.187598248 0.207030135  0.185798 0.9430286 
73 rs2244614 55844617 3 A G NA CES1 16 0.400883838 0.917584771  0.422299321 0.155338835  0.420020855 0.984620397  0.423595607 0.587456235  0.4220394 0.002322937 
74 rs2606345 75017176 2 A C NA CYP1A1 15 0.326463853 0.841730261  0.201203075 0.140484163  0.206256517 0.306414988  0.203633259 0.543934763  0.2063229 0.01893043 
75 rs2472297 75027880 3 C T NA CYP1A1 15 0.277331443 0.961463521  0.088857827 0.578028944  0.09092805 0.49588861  0.089627572 0.521588815  0.08490263 0.1149129 
76 rs4646903 75011641 3 A G NA CYP1A1 15 0.102604401 0.234710407  0.447683706 0.1388589  0.442961418 0.387222336  0.444398229 0.029979333  0.4393946 0.4203743 
77 rs762551 75041917 1 A C *1F CYP1A2 15 0.258330067 0.059398042  0.365864617 0.970831094  0.373722628 0.209742982  0.368456236 0.906245777  0.374327 0.1281515 
78 rs11636419 75047600 2 A G NA CYP1A2 15 0.056704507 0.821731843  0.052840455 0.101693901  0.052033368 0.651210168  0.05137131 0.02160369  0.05761093 0.7937895 
79 rs2472299 75033400 3 G A NA CYP1A2 15 0.261323085 0.060128845  0.066843051 0.023247851  0.075078206 0.046722317  0.06795165 0.000152791  0.06801547 < 1*10-8 
80 rs1056836 38298203 2 C G NA CYP1B1 2 0.446308725 0.876055112  0.2657498 0.974380337  0.271845673 0.383288369  0.26707057 0.511971005  0.2611868 0.09634747 
81 rs1800440 38298139 2 T C NA CYP1B1 2 0.186954123 0.625017274  0.050344449 0.352092845  0.05318 0.7889  0.05056493 0.352739239  0.0565631 0.472139739 
82 rs10012 38302390 3 G C NA CYP1B1 2 0.273656575 0.712800255  0.129442891 0.792143121  0.134306569 0.16983355  0.129348148 0.801336959  0.1336075 0.2320686 
83 rs28399433 41356379 1 A C *9A/*9B/*13/*15 CYP2A6 19 0.063116824 0.020251284  0.09377496 0.577530639  0.098957247 0.674730048  0.09406882 0.811003189  0.1007263 0.1893324 
84 rs8192726 41354496 1 C A *9b CYP2A6 19 0.062029217 0.047022858  0.069064497 0.184232504  0.068821689 0.852493133  0.068304315 0.511604728  0.06958865 0.1777295 
85 rs56113850 41353107 2 C T NA CYP2A6 19 0.429158233 0.251934724  0.19521266 0.929721144  0.202711157 0.393661999  0.197456389 0.951314891  0.2088051 0.00839187 
86 rs8192725 41354712 3 G A *1B CYP2A6 19 0.247542857 0.144649505  0.122928315 0.801100018  0.116996872 0.126998361  0.118759298 0.020307186  0.1214999 0.7818508 
87 rs2279343 41515263 1 A G *4 CYP2B6 19 0.245391842 0.770206525  0.097144569 0.772525626  0.093847758 0.003284807  0.096950241 0.210490209  0.0941616 0.2769282 
88 rs1042389 41524153 2 T C NA CYP2B6 19 0.208183818 0.939143594  0.393245807 0.660646886  0.403441084 0.62420847  0.394083613 0.916160112  0.3951876 0.8570128 
89 rs2279342 41510127 2 A T NA CYP2B6 19 0.090602106 0.870423847  0.217302316 0.413899678  0.221584984 0.356150439  0.216033521 0.457989899  0.2354793 0.1675238 
90 rs2054675 41495755 3 T C NA CYP2B6 19 0.240561253 0.722355894  0.393645168 0.230238603  0.389051095 0.4887597  0.392100336 0.133281622  0.4063358 0.1101212 
91 rs2279344 41515483 3 A G NA CYP2B6 19 0.401451232 0.182526369  0.238942692 0.147380104  0.238373306 0.337727023  0.238517002 0.055272553  0.2415883 0.2749666 
92 rs4803419 41512792 3 C T NA CYP2B6 19 0.29914966 0.947185691  0.39858726 0.062744329  0.407194995 0.87300222  0.399965303 0.473470324  0.4015661 0.8360004 
93 rs7254579 41494891 3 T C NA CYP2B6 19 0.335237455 0.412772839  0.285493211 0.4084298  0.304588113 0.384485251  0.289351852 0.042903124  0.2930131 0.9883079 
94 rs12248560 96521657 1 C T *17 CYP2C19 10 0.211574953 0.721646969  0.072484026 0.279648298  0.079979145 0.081878646  0.07358412 0.242728155  0.07693872 0.7701147 
95 rs4244285 96541616 1 G A *2 CYP2C19 10 0.139307649 0.388993244  0.059804313 0.321906435  0.055787278 0.003648692  0.059994369 0.593012415  0.06345643 0.7760909 
96 rs3814637 96521045 3 C T NA CYP2C19 10 0.06532411 0.959318786  0.340854633 0.795103481  0.338894682 0.656065496  0.337302923 0.651698545  0.3377004 0.8104226 
97 rs7916649 96534584 3 G A NA CYP2C19 10 0.416228904 0.304800189  0.38266274 0.397032658  0.381751825 0.286609752  0.383478287 0.857800009  0.3710704 0.1530958 
98 rs10509681 96798749 1 T C *3 CYP2C8 10 0.121223219 0.07165618  0.412739617 0.639047691  0.417413973 0.257282675  0.411331512 0.895110578  0.4046622 0.5538406 
99 rs1058930 96818119 1 G C *4 CYP2C8 10 0.051251647 0.541177061  0.313623203 0.370752487  0.310531804 0.490354382  0.312334906 0.100506337  0.3188762 0.4150226 
100 rs11572080 96827030 1 C T NA CYP2C8 10 0.12246839 0.054787706  0.403878794 0.813477123  0.400625652 0.462293884  0.402021889 0.666633824  0.4082129 0.8496473 
101 rs17110453 96829529 1 A C *1C CYP2C8 10 0.124761477 0.082735361  0.09771865 0.287965976  0.096767466 0.35102783  0.096724097 0.085822523  0.09529492 0.3393734 
102 rs7909236 96829430 1 G T *1B CYP2C8 10 0.249302377 0.595223987  0.184754393 0.801750909  0.184567258 0.636955207  0.183663175 0.677403741  0.1888402 0.3611373 
103 rs193451 108310986 2 A G NA CYP2C8 7 0.438117145 0.168587074  0.146066294 0.031568704  0.146402503 0.068079356  0.142403051 0.343312188  0.1508659 2.56E-06 
104 rs1113129 96811045 3 G C NA CYP2C8 10 0.205330204 0.077090815  0.462060703 0.981852079  0.468717414 0.516651537  0.465157673 0.511991234  0.4874342 0.9759373 
105 rs1057910 96741053 1 A C *3 CYP2C9 10 0.065329535 0.670182216  0.127570887 0.028290836  0.135140772 0.018972266  0.130658558 0.016353069  0.1318848 0.1656866 
106 rs1799853 96702047 1 C T *2 CYP2C9 10 0.129086913 0.036191833  0.248627196 0.4751529  0.252346194 0.52740754  0.248507174 0.282398584  0.2322301 0.333007 
107 rs4918758 96697252 2 T C NA CYP2C9 10 0.370946022 0.603029874  0.288213858 0.195328151  0.288112617 0.415051974  0.28919328 0.095778716  0.2956853 0.3056005 
108 rs9332197 96740908 2 T C NA CYP2C9 10 0.047484011 0.156213  0.201852037 0.636701067  0.207612096 0.911540371  0.203522737 0.810814376  0.1992852 0.1556136 
109 rs7089580 96705223 3 A T NA CYP2C9 10 0.208836014 0.98971349  0.05486222 0.26195174  0.055891554 0.900029323  0.055341976 0.417971189  0.05406515 0.2786757 
110 rs1065852 42526694 1 G A *10 CYP2D6 22 0.222339058 0.179421402  0.215679912 0.715067908  0.214702815 0.972864547  0.214779705 0.625579889  0.2257315 0.9968395 
111 rs1135840 42522613 1 G C NA CYP2D6 22 0.444718021 0.003907004  0.058107029 0.0892396  0.054535975 0.61641805  0.056933262 0.485329745  0.05339373 0.9977362 
112 rs16947 42523943 1 G A *2 CYP2D6 22 0.32235023 0.000135292  0.449680511 0.22061876  0.447758081 0.414873087  0.449147001 0.75578823  0.4594282 0.5488002 
113 rs28371725 42523805 1 C T *41 CYP2D6 22 0.09677968 0.397679961  0.173597244 0.378338526  0.170072993 0.521455135  0.171878709 0.322018499  0.1741842 0.1095684 
114 rs3892097 42524947 1 C T *4 CYP2D6 22 0.207740368 0.178521614  0.437025759 0.362929348  0.437643379 0.058610191  0.438417727 0.535236964  0.4370312 0.7240854 
115 rs1080983 42528568 3 C T NA CYP2D6 22 0.321003352 0.000114991  0.057832468 0.647219432  0.062252346 0.97288391  0.058720047 0.185716996  0.05617497 0.5887881 
116 rs1080985 42528382 3 C G NA CYP2D6 22 0.221194961 0.051390526  0.095896565 0.475247247  0.103023983 0.702744696  0.095606538 0.882243595  0.1015472 0.4065006 
117 rs8192766 135339385 2 T G NA CYP2E1 10 0.066450022 0.017402258  0.349640575 0.720921109  0.351094891 0.671831655  0.350637982 0.768538585  0.3297941 0.1894587 
118 rs2242480 99361466 1 C T *1G CYP3A4 7 0.082084507 0.002193865  0.404328075 0.131022901  0.403023983 0.929716368  0.403582985 0.200671934  0.4058335 0.06744483 
119 rs2246709 99365719 2 A G NA CYP3A4 7 0.267556549 0.448833833  0.142072684 0.056508269  0.142127216 0.427304389  0.142763841 0.37055315  0.1425589 0.8156045 
120 rs35599367 99366316 2 G A NA CYP3A4 7 0.046788991 0.522293144  0.458566294 0.109539932  0.468925965 0.994212691  0.464484928 0.056436574  0.4465487 0.3475424 
121 rs3735451 99355975 3 T C NA CYP3A4 7 0.09637746 0.006376792  0.359999002 0.764973817  0.351824818 0.844956893  0.3555417 0.536334013  0.3722907 0.5819374 
122 rs2257401 99306685 3 G C NA CYP3A7 7 0.079437688 0.060867437  0.173397564 0.79478724  0.17080292 0.943711631  0.171336143 0.894707275  0.1723831 0.7975453 
123 rs10306135 125137695 2 A T NA PTGS1 9 0.127213458 0.49243238  0.181634385 0.302371944  0.179353493 0.983164805  0.179961436 0.420258453  0.1815367 0.0329312 
124 rs12353214 125161870 2 C T NA PTGS1 9 0.092031492 0.942952427  0.486621406 0.56759361  0.485922836 0.251740909  0.484650361 0.244659698  0.4682546 0.1597321 
125 rs1236913 125133479 2 C T NA PTGS1 9 0.066791394 0.774778531  0.251996805 0.206866123  0.248383733 0.6194861  0.2525611 0.2869569  0.2553499 0.2678104 
126 rs1330344 125131688 2 T C NA PTGS1 9 0.200013492 0.711145774  0.387604832 0.588475086  0.391240876 0.923106327  0.387104435 0.138788537  0.380708 0.2836147 
127 rs5788 125143792 2 C A NA PTGS1 9 0.110233555 0.003638534  0.108950679 0.840489904  0.099687174 0.530774337  0.105867499 0.674692807  0.09868632 0.1250888 
128 rs3842787 125133507 3 C T NA PTGS1 9 0.064431541 0.072131869  0.192566893 0.280461009  0.193743483 0.739810106  0.191601191 0.339197442  0.1773967 0.1006764 
129 rs12208357 160543148 1 C T NA SLC22A1 6 0.065971145 0.507203817  0.368235823 0.054451131  0.384254432 0.598356606  0.377866667 0.055405938  0.3762641 0.08530785 
130 rs461473 160543562 2 G A NA SLC22A1 6 0.097641099 0.473126673  0.277031749 0.145988056  0.284567258 0.149677542  0.278089362 0.122489528  0.2669111 0.1748926 
131 rs622342 160572866 2 A C NA SLC22A1 6 0.391997805 0.572424176  0.099740415 0.858510955  0.108446298 0.986257469  0.101723369 0.641872626  0.09975471 0.08244419 
132 rs683369 160551204 2 C G NA SLC22A1 6 0.210473684 0.507204141  0.259409944 0.77927162  0.252763295 0.433385923  0.259193856 0.316053619  0.2720386 0.6275928 
133 rs628031 160560845 3 G A NA SLC22A1 6 0.396829682 0.238705364  0.275284545 0.816719645  0.277163712 0.250225308  0.275238887 0.65345275  0.2772396 0.2230025 
134 rs11231809 64302950 2 T A NA SLC22A11 11 0.389775281 0.103918889  0.249375998 0.378094399  0.248905109 0.296108901  0.248768546 0.669364526  0.2572772 0.000666108 
135 rs316003 160645832 2 T C NA SLC22A2 6 0.237688442 0.465599156  0.235647963 0.557140022  0.243378519 0.901762196  0.238146936 0.825955764  0.239993 0.08311653 
136 rs316019 160670282 3 C A NA SLC22A2 6 0.103078615 0.195243945  0.415809704 0.638849444  0.395933264 0.252767103  0.409204424 0.922150258  0.4093866 0.8276689 
137 rs2076828 160872786 2 C G NA SLC22A3 6 0.399253145 0.28348065  0.290684904 0.785406361  0.303649635 0.260002658  0.294753776 0.457274567  0.2947823 0.2819627 
138 rs555754 160769423 3 G A NA SLC22A3 6 0.467919856 0.127463691  0.330770767 0.567255071  0.339207508 0.140253221  0.333125464 0.143682023  0.3252902 0.7645817 
139 rs1050152 131676320 3 C T NA SLC22A4 5 0.440009265 0.879877745  0.0626248 0.720956582  0.064233577 0.019198525  0.063616138 0.197164888  0.06325918 0.3767132 
140 rs2631372 131703578 2 G C NA SLC22A5 5 0.289641301 0.081985351  0.426093251 0.344708696  0.432533889 0.56824179  0.424229833 0.28757554  0.4277281 0.1504987 
141 rs4149170 62752289 2 C T NA SLC22A6 11 0.072735487 0.490464652  0.208915735 0.243680546  0.214911366 0.923329153  0.208808167 0.067687679  0.2139033 0.3589543 
142 rs11568563 21457434 2 T G NA SLCO1A2 12 0.062378168 0.026745087  0.213658147 0.862153546  0.211783107 0.403819045  0.211949909 0.936609169  0.2115962 0.9985906 
143 rs10841795 21487544 3 A G NA SLCO1A2 12 0.121358331 0.268796518  0.327600839 0.045028646  0.330031283 0.827400641  0.326172226 0.628157751  0.3246384 < 1*10-8 
144 rs4148978 21488675 3 C T NA SLCO1A2 12 0.315465533 0.197434782  0.226287939 0.346022696  0.226798749 0.991341866  0.22507485 0.836259157  0.2280778 < 1*10-8 
145 rs4148981 21487068 3 C T NA SLCO1A2 12 0.318014089 0.169501462  0.093350639 0.560257274  0.100625652 0.202093265  0.095247989 0.013940384  0.104979 0.6654468 
146 rs2306283 21329738 1 A G *1B SLCO1B1 12 0.381736252 0.463774366  0.077276358 0.75414184  0.084045881 0.103919807  0.078834174 0.153399731  0.08264701 0.966784 
147 rs4149056 21331549 1 T C *5 SLCO1B1 12 0.158961319 0.06127064  0.065944489 0.279982701  0.067674661 0.909082284  0.065758645 0.078475131  0.07035441 0.2179228 
148 rs4149032 21317791 2 C T NA SLCO1B1 12 0.329846775 0.985200024  0.39434405 0.068866719  0.402189781 0.426340069  0.396078067 0.704767191  0.4154233 0.05026729 
149 rs4149057 21331599 2 C T *18/*19 SLCO1B1 12 0.385931559 0.409869136  0.10153754 0.243049599  0.104588113 0.123125668  0.102366731 0.023750365  0.1034855 0.707992 
150 rs4149087 21392562 2 T G NA SLCO1B1 12 0.404636577 0.703323462  0.471046326 0.524969679  0.469760167 0.885080787  0.470057388 0.22417665  0.4668787 0.2891047 
151 rs11045818 21329761 3 G A *18 SLCO1B1 12 0.1467106 0.359287815  0.438698083 0.607482328  0.4111 0.09884  0.435682766 0.527501128  0.4318939 0.6622558 
152 rs11045872 21372344 3 A G NA SLCO1B1 12 0.171932567 0.046742552  0.123127995 0.400063009  0.122523462 0.729605688  0.122501965 0.140661612  0.1314976 0.3878525 
153 rs11045879 21382619 3 T C NA SLCO1B1 12 0.172230907 0.176456412  0.325404353 0.83522154  0.319499479 0.461657387  0.321779533 0.549002299  0.3194753 0.1498299 
154 rs34671512 21391976 3 A C *19/*20/*22/*35 SLCO1B1 12 0.052112934 0.42100996  0.327900359 0.852536019  0.322732013 0.689928031  0.32438409 0.447160605  0.3218547 0.1278852 
155 rs3829306 21292280 3 C T NA SLCO1B1 12 0.053631285 0.024728974  0.15218151 0.493984504  0.154014599 0.971346915  0.150979228 0.94072363  0.1614003 0.08323085 
156 rs4149036 21327740 3 C A NA SLCO1B1 12 0.19875672 0.494746734  0.178239816 0.803088302  0.178415016 0.62644209  0.17662592 0.153369025  0.1865074 0.4444142 
157 rs4149118 21011581 2 A G NA SLCO1B3 12 0.310250391 0.190322009  0.172124601 0.135768317  0.172471324 0.981097097  0.172269531 0.663904763  0.160436 0.2827952 
158 rs4149117 21011480 3 G T NA SLCO1B3 12 0.142053253 0.990872327  0.0545627 0.32653818  0.051407716 0.960979971  0.053371102 0.245016465  0.05200801 0.4780846 
159 rs7977213 20980800 3 C G NA SLCO1B3 12 0.451160433 0.754442221  0.058206869 0.637211762  0.055161627 0.794740312  0.056592575 0.111333608  0.05003541 0.9422934 
160 rs3794271 20860093 2 A G NA SLCO1C1 12 0.398702481 0.3067926  0.203649161 0.015067249  0.197184567 0.705484476  0.201469933 0.098974476  0.1937534 0.4129888 
161 rs12422149 74883577 2 G A NA SLCO2B1 11 0.095031729 0.313938256  0.140949481 0.01786053  0.138686131 0.686796695  0.140935082 0.044552316  0.1413373 0.7041944 
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